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 Despite decades of effort, the mechanistic underpinnings of many cancers remain unsolved 
It has increasingly become appreciated that cancers can be more readily classified by their 
transcriptional identities rather than by genomics alone. A fuller understanding of the mechanistic 
connections between the aberrant genomics leading to the transcriptional dysregulation of tumors 
is key to both improving our knowledge of cancer biology as well as developing more precise and 
effective therapeutics. This thesis explores the development and application of a network based 
multi-omic master regulator framework designed to elucidate these pathways. In Chapter 2 we 
apply this analysis across 20 tumor types from the Cancer Genome Atlas and in doing so identify 
407 key master regulators responsible for canalizing a high percentage of the driver genetics 
present across these samples. Further evaluation of these key regulators revealed a highly modular 
structure, indicating that the regulators work in coordinated groups to implement a variety of key 
cancer hallmarks. Genetic and pharmacological validation assays confirmed the predicted 
interactions and biological phenotypes. Chapter 3 focuses on the application of this analytical 
framework specifically on gastroesophageal tumors. Using a more fine-grained approach we find 
15 distinct subtypes across a cohort of these heterogenous tumors. These subtypes align well with 
previously identified features of these cancers but also reveal novel genomic associations and key 




Table of Contents 
List of Figures ............................................................................................................................ iv 
Acknowledgments ....................................................................................................................vii 
Chapter 1: Introduction ............................................................................................................... 1 
1.1 Dissecting the Complexity of Cancer to Inform Treatment ................................................ 3 
1.1.1 Oncogene Addiction Theory ....................................................................................... 3 
1.1.2 Precision Oncology..................................................................................................... 5 
1.2 The Sequencing Era of Cancer Genomics .......................................................................... 7 
1.2.1 TCGA Implications and Limitations ........................................................................... 7 
1.2.2 Cellular Homeostasis and Cancer ................................................................................ 9 
1.2.3 Network Models of Cancer ....................................................................................... 11 
1.2.4 Gene Regulatory Network Models ............................................................................ 13 
1.3 Master Regulators at the Center of Cell Identity .............................................................. 16 
1.3.1 Master Regulators ..................................................................................................... 16 
1.3.2 Expanding the MR Framework ................................................................................. 18 
1.3.3 Oncotecture Hypothesis ............................................................................................ 21 
1.4 Multi-omic Analyses of Cancer ....................................................................................... 22 
1.4.1 A Pancancer Multi-omic Master Regulator Analysis ................................................. 22 
1.4.2 Other Multi-omic Frameworks.................................................................................. 24 
Chapter 2: A Modular Master Regulator Landscape Controls Cancer Transcriptional Identity ... 27 
2.1 Summary ......................................................................................................................... 27 
ii 
 
2.2 Introduction ..................................................................................................................... 28 
2.3 Results ............................................................................................................................ 30 
2.3.1 Tumor Subtype identification ................................................................................... 32 
2.3.2 Tumor Checkpoint MRs ........................................................................................... 36 
2.3.3 Tumor Checkpoints are Hyperconnected and Modular .............................................. 40 
2.3.4 Tumor Checkpoint MRs are Enriched in Essential Proteins....................................... 44 
2.3.5 MRBs Improve Outcome Analysis ........................................................................... 45 
2.3.6 MRB:2 Canalizes Driver Mutations in Prostate Cancer ............................................. 46 
2.3.7 Pharmacological MRB Modulation ........................................................................... 50 
2.4 Discussion ....................................................................................................................... 52 
2.5 Methods .......................................................................................................................... 58 
2.5.1 Key Resources Table ................................................................................................ 58 
2.5.2 Resource Availability ............................................................................................... 60 
2.5.3 Experimental Model and Subject Details .................................................................. 61 
2.5.4 Methods.................................................................................................................... 62 
Chapter 3: Multi-omic Analyses of Gastroesophageal Cancer ................................................... 81 
3.1 Introduction ..................................................................................................................... 81 
3.1.1 Gastroesophageal Incidence and Treatment .............................................................. 81 
3.1.2 Molecular Classifications of Gastroesophageal Cancer ............................................. 84 
3.2 Results ............................................................................................................................ 87 
3.2.1 MOMA Regulator Ranking and Iterative Clustering ................................................. 87 
3.2.2 Tumor Checkpoint MRs ........................................................................................... 93 
iii 
 
3.2.3 Microsatellite Instable Subtypes: S6, S7 and S13 ...................................................... 98 
3.2.4 Genomically Stable Subtypes: S8 and S11 .............................................................. 105 
3.2.5 HER2+ Subtypes: S1 and S2 .................................................................................. 112 
3.2.6 Cell Line Matching to MOMA Inferred Subtypes ................................................... 127 
3.2.7 Validation in External Cohort ................................................................................. 130 
3.2.8 MOMA Identification of Global Regulators of Gastroesophageal Cancer ............... 133 
3.2.9 Using Precision Oncology Algorithms to Predict Novel Therapeutics ..................... 136 
3.3 Discussion ..................................................................................................................... 139 
Discussion .............................................................................................................................. 143 
4.1 General Conclusions...................................................................................................... 143 
4.2 Future Directions ........................................................................................................... 146 
References .............................................................................................................................. 148 
Appendix A: Supplement for “A modular master regulator landscape controls cancer 





List of Figures 
Main text figures: 
Figure 2.0 Graphical Abstract. .................................................................................................. 28 
Figure 2.1 Conceptual overview of the algorithm to find sample “checkpoints” and checkpoint 
blocks. ...................................................................................................................................... 31 
Figure 2.2 Subtypes inference by network-based integration of gene expression and mutational 
profile data. ............................................................................................................................... 34 
Figure 2.3 Genomic saturation analysis of candidate master regulators across all subtypes. ....... 38 
Figure 2.4 Genomic Alterations Dysregulating COAD Tumor Checkpoints. ............................. 41 
Figure 2.5 MRBs are recurrently activated in cancer and regulate established tumor hallmarks. 43 
Figure 2.6 MRB2 and its upstream alterations drive the most aggressive PRAD subtype ........... 47 
Figure 2.7 Functional validation of MRB:2 and 14 .................................................................... 49 
Figure 3.1 MOMA Methodology Overview .............................................................................. 90 
Figure 3.2 Results of Iterative Clustering .................................................................................. 93 
Figure 3.3 Survival Curves for the Final 15 Subtypes ................................................................ 94 
Figure 3.4 Genomic saturation analysis of candidate master regulators. ..................................... 95 
Figure 3.5 Relative Essentiality of cMRs................................................................................... 97 
Figure 3.6 VIPER Activity Scores across the STES cohort. ....................................................... 98 
Figure 3.7 Summary of MSI Subtypes. ...................................................................................... 99 
Figure 3.8 OncoPrint plots for MSI subtypes. .......................................................................... 101 
Figure 3.9 Reactome gene enrichments of MSI subtypes. ........................................................ 102 
Figure 3.10 Phenotypic features of MSI subtypes. ................................................................... 103 
Figure 3.11 Summary of GS Subtypes. .................................................................................... 106 
v 
 
Figure 3.12 OncoPrint plots for GS subtypes. .......................................................................... 107 
Figure 3.13 Target genes of S8 cMRs are enriched in immune pathways. ................................ 108 
Figure 3.14 Phenotypic features of GS subtypes. ..................................................................... 110 
Figure 3.15 Target genes of S11 cMRs are enriched in cellular junction pathways. ................. 111 
Figure 3.16 Summary of HER2+ Subtypes. ............................................................................. 113 
Figure 3.17 OncoPrint plots for HER2+ subtypes. ................................................................... 115 
Figure 3.18. Target genes of S1 cMRs pathway enrichment. ................................................... 117 
Figure 3.19 Phenotypic features of HER2+ subtypes. .............................................................. 118 
Figure 3.20 Target genes of S2 cMRs pathway enrichment. .................................................... 119 
Figure 3.21 Heatmap of VIPER activity across all cell lines show that dominant drivers of 
difference are cell line and time............................................................................................... 122 
Figure 3.22 Schematic of multi-step classifier and resulting top TRs. ...................................... 124 
Figure 3.23 Paired VIPER Analysis to select candidate MRs. ................................................. 126 
Figure 3.24 Top matching cell lines for S1 (A) and S8 (B). ..................................................... 129 
Figure 3.25 GSEA Enrichment of cMRs in Achilles scores for matching cell lines. ................. 130 
Figure 3.26 PCA plots of patient’s VIPER profiles from each cohort. ..................................... 131 
Figure 3.27 Subtype annotation plot of STES samples with ACRG labels applied. .................. 132 
Figure 3.28 Results of iterative clustering applied to ACRG Samples. ..................................... 133 
Figure 3.29 Clustering Results using TCGA reference VIPER activities. ................................ 134 







Figure S2.1 Detailed Conceptual Flowchart of MOMA. .......................................................... 164 
Figure S2.2 Functional validation of MOMA subtypes and survival segregation. .................... 165 
Figure S2.3 Checkpoint proteins are highly recurrent and downstream of driver genomic events
 ............................................................................................................................................... 167 
Figure S2.4 Recurrent MRs are predicted to be hyperconnected and modular. ......................... 168 
Figure S2.5 MR-Block (MRB) cluster analysis, Cancer Hallmark enrichment analysis, and 
Achilles’ essentiality analysis .................................................................................................. 169 
Figure S2.6 Survival stratification by MRB activity ................................................................ 171 








I would first and foremost like to thank my mentor, Dr. Andrea Califano, for taking a 
chance on me and giving me the space, time and support to become the scientist that I am today. I 
came to him with no background in the field but a lot of hard-headed enthusiasm and he somehow 
saw some glimmer of potential in me (albeit with some reasonable reservations), and for that I am 
extremely grateful.    
 I would also like to thank my committee members, Dr. Peter Sims, Dr. Saeed Tavazoie, 
and Dr. Timothy Wang for their advice and insight over the years. I would particularly like to 
extend my gratitude to Dr. Peter Sims who was hugely helpful during my transfer to the Systems 
Biology department, and helped me to find my way during the early steps of the process. I’d also 
like thank Dr. Adam Bass for his insights over the years through our collaboration on the 
gastroesophageal tumor project.  
 While I have gotten support from a number of people during my time in the Califano lab I 
would especially like to thank Evan Paull for his mentorship and support and allowing me to ask 
him and all questions as I figured out what the heck I was doing.  
 In addition to my scientific mentors, I also want to thank my parents for their unconditional 
love and support throughout my many harebrained decisions over the years, I truly could not have 
gotten here without them. I’d also like to thank the rest of my family and many friends who’ve 




Chapter 1: Introduction 
Cancer is a disease marked by uncontrollable growth of abnormal cells in the body. Over time, 
normal cells accrue genetic and epigenetic alterations, eventually leading to dysregulation of their 
physiologic behavioral patterns. These changes can come from a variety of sources, from pre-
existing variants that predispose individuals to developing a certain form of cancer, to defects 
introduced by the machinery responsible for cell replication that are not caught before the next cell 
division. Most often, however, they are driven by external carcinogenic sources in our 
environment—including viruses, chemicals, radiation, and pollutants—leading to deleterious 
modifications of our DNA that changes the way cells function and interact with their environment1. 
 According to the GLOBOCAN 2020 estimates from the International Agency for Research 
on Cancer, 19.3 million new cancer cases were diagnosed across the world in 2020 along with 
almost 10 million deaths2. By 2040 the global cancer burden is expected to reach 28.4 million 
cases, an almost 47% rise from 20203. In the United States alone it is estimated that 39.5% of 
people will be diagnosed with cancer at some point in their lifetime4. Since the 1990s mortality 
rates for cancer in the US have been decreasing, with the overall cancer death rate from 1991 to 
2016 dropping by a total of 27%5. While this is good evidence of improved early screening and 
treatments, there is still much we don’t understand about cancer and how to treat it in the most 
targeted and efficient manner. 
 The standards of care for most cancer patients fall into three main categories: surgery, 
radiation therapy and chemotherapy6,7. Some solid malignancies, especially those caught before 
they disseminate and progress to metastatic disease can be surgically removed, with no additional 
treatment requirements. Tumors that arise in surgically inaccessible places or that have already 
metastasized by the time of identification have traditionally required a combination of more 
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aggressive treatments, including radio and chemotherapy. These broad-spectrum cytotoxic 
approaches preferentially target cells that are rapidly dividing—thus being effective against fast-
growing cancer cells; yet, they also target healthy cells with high turnover rates, leading to 
significant side effects, such as hair loss (from loss of cells in hair follicles), nausea (from loss of 
cells along the intestine), neutropenia (from loss of white blood cells), and overall fatigue. Despite 
their pervasive use, a 2004 systematic review of survival rates of 22 major adult malignancies 
estimated that the overall contribution of chemotherapy to the 5-year survival rate was only 2.1% 
in the USA8. It’s also estimated that, on average, any specific class of cancer drug is ineffective in 
75% of treated patients9,10. Moreover, most tumors become chemoresistant after an initial response 
rendering further chemotherapy effectively useless. While in some forms of cancer, chemotherapy 
can be fully curative it is becoming increasingly clear that it may not be the best tool for most 
patients. 
 This introduction reviews the changing views of cancer biology over the years, as well as 
how the progression network biology and high throughput sequencing brought the field of 
precision oncology into a new era. It will then describe tools developed throughout the years in 
the Califano lab built to assess the role of master regulators as key controllers at the center of 
cancer cell architecture. Finally, it will then review the merging of these tools into a multi-omic 
framework for studying the mechanistic determinants of cancer as well as comparing it to other 




1.1 Dissecting the Complexity of Cancer to Inform Treatment 
1.1.1 Oncogene Addiction Theory 
Though the general properties of cancer evolution have been known for many years the exact 
number of mutational events necessary to induce tumorigenesis has remained elusive11,12. For a 
while the prevailing theory has been that, in most cancers, tumorigenesis can be explained based 
on two to eight “driver gene” mutations13. These genomic mutations (here collectively referring to 
single point mutations, short indels, large deletions and amplifications, and fusion events) confer 
selective advantage to the affected cells, allowing them to proliferate and progress into tumors.  
These types of genes typically fall into two categories: oncogenes and tumor suppressors. 
Proto-oncogenes are genes that are typically involved in cell cycle processes and regulate cell 
growth and division; thus, when mutated, they can produce cells with unconstrained proliferation 
patterns. Once these genes are mutated in a deleterious way they are considered oncogenes.  A 
common analogy is to compare them to the gas pedal of a car getting stuck in the accelerate 
position. Frequently recurrent oncogenes include, for instance, MYC, KRAS, and BRC-ABL, which 
have been found to be mutated across a number of different tumor types and validated extensively 
in lab studies14–16. Tumor suppressor genes on the other hand, are genes that typically monitor cells 
for abnormal genomic events, including mutations and chromosomal breaks, and facilitate cell 
death or senescence when appropriate in order to maintain healthy cells and tissues. When these 
genes are affected by loss of function mutations—most often via truncations or deletions—they 
can no longer exert their regulatory surveillance within the cells, thus allowing for unchecked cell 
growth and division and, more importantly, rapid accrual of additional mutational events. 
Conceptually, they represent the brakes of a car, which if removed leave the car with no ability to 
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slow itself down. The most recurrently mutated tumor suppressors include TP53, RB1 and PTEN, 
for instance, and many of these too have been extensively studied and validated17–19. 
 In certain tumor types, the activities of a few key driver genes have been shown to 
effectively explain this tumorigenic process. Work by Bert Vogelstein, a pioneer in the field of 
cancer genetics, illuminated this progression in colorectal cancer, thus laying the groundwork for 
this theory of somatic evolution of cancer. Across years of research his team revealed a three-step 
progression that was able to transform intestinal epithelial cells into a carcinoma with metastatic 
potential. First, early mutations in the APC tumor suppressor allow cells to begin to outcompete 
their neighbors, in order to form a small, slow growing adenoma, and to accrue additional 
mutations. A follow up mutation in KRAS then facilitates a second round of expansion driven by 
the cells that now have both mutations. Later mutations in genes like PIK3CA, SMAD4 and TP53 
promote the full development of a malignant carcinoma that can protrude out of the epithelial wall 
and metastasize throughout the body13,20.  
Prior to large sequencing efforts, a number of these driver genes were identified by 
studying familial cancers and cancer cell lines in the lab. However, as sequencing technology 
improved and early cohorts of tumors began to be sequenced, statistically significant patterns of 
mutational events started to emerge that illuminated key aspects of tumorigenesis. One example is 
the delineation of “mountain” vs “hill” genes. Mountain genes were those that had very high rates 
of mutation while hill genes were ones that occurred at comparably lower frequencies. In the initial 
studies of breast and colorectal cancer that outlined this mountain-hill gene dichotomy, only 5 
genes were found to be mountains while about 200 were identified as hills21,22. These publications 
were some of the first of their kind to use the results of full genomic sequencing to describe the 
so-called landscape of cancer in the hopes of identifying new genes to both understand 
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tumorigenesis and ideally stratify patients for care. Though at the time all 5 of the genes identified 
as mountains were previously known drivers, it opened up the possibility that perhaps with more 
samples and more data we’d be able to reveal novel gene drivers and untangle the complexity of 
pathways being altered by combinations of less frequent mutant genes. 
 
1.1.2 Precision Oncology 
The goal of precision medicine is to utilize patient specific biological information in order to select 
and prioritize targeted treatments. This aims to improve upon the standard of care in which location 
and stage more predominantly determine the course of treatments. Though it’s been known for a 
while that these methods of treatment lead to differential response, it’s only been with the 
technological advances in next generation sequencing (NGS) and other omics technologies that 
the scientific community has been able to start readily identifying the biology driving these 
differences along with concordant diagnostics. Early successes using mutational analyses and 
driven by the oncogene addiction theory of cancer, led to the discovery of a number of genes, such 
as BRCA1/2, TP53 and MLH1/MSH2/MSH6, that when mutated significantly increase cancer 
risk23.  This led to a number of genes/biomarkers being used in clinical settings as companion 
diagnostics to facilitate tumor characterization and to prioritize treatments. A meta-analysis of 346 
Phase 1 clinical trials from 2011-2013 showed that biomarker-based selection strategies were 
associated with both improved response rate and progression free survival, but also found that 
many of the studies in this time period didn’t make use of these strategies24. While this is 
promising, unfortunately using mutational profiles to inform biomarkers alone has not been shown 
to be effectively predictive across all tumor types or across a high percentage of patients. Indeed, 
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a study across 21 different cancers showed that most druggable driver mutations were only present 
in 2%-20% of patients per cancer type, showing the limits to this therapeutic avenue25. 
 In addition to oncogene targeting therapies, immunotherapies have arisen as another arm 
of the precision medicine field. They comprise a new class of biological therapeutics that exploit 
and empower the patient’s immune system to fight the cancer. The idea behind these therapies is 
that the body already produces a variety of cell types that are geared to destroy aberrant cancer 
cells upon detection but that tumors evolve strategies over time to evade them by random 
accumulation of mutation and creating an immunosuppressive environment26. By tapping into each 
individual’s immune system to promote more precise targeting of the tumors, these therapies are 
less globally deleterious to normal cells, though in some cases they can trigger serious and 
potentially lethal autoimmune reactions. Some of the foremost immunotherapy approaches include 
immunomodulatory antibodies, checkpoint inhibitors, vaccine immunotherapy and CAR T cell 
therapy27. Immunomodulatory antibodies work by targeting tumor-associated antigens specifically 
and triggering an antibody mediated immune response, or can be directly conjugated to cytotoxic 
drugs28. An extension of these are immune checkpoint inhibitors that target the receptor pathways 
used by cancer cells to facilitate evasion of anti-tumor T cells29. Cancer vaccines and CAR T-cell 
therapy work by stimulating T cells with tumor antigens directly, either in vivo or ex vivo 
respectively, in order to stimulate a tumor specific immune response30. While these therapies have 
been hugely effective in some cases, particularly in combination with traditional interventions and 
other biomarker therapies, this has only been the case in a minority of patients and in specific 
tumor types. This is in part due to the immune landscape heterogeneity across patients as well the 
complex mechanisms underpinning the interactions between cancers and the immune system28,31.  
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 While some of the above strategies have proven to be effective in a subset of cases and 
certainly moved the field forward, much work is still left to be done to realize the full the goal of 
precision medicine for cancer.  
 
1.2 The Sequencing Era of Cancer Genomics 
1.2.1 TCGA Implications and Limitations 
The Cancer Genome Atlas (TCGA) initiative started in 2006 with the ambitious objective of 
producing a comprehensive molecular characterization of virtually all the most frequent human 
malignancies, including systematic profiling and characterization of the genomic alterations 
underlying them. As sequencing costs decreased dramatically over the last 20 years, this objective 
became realistic on a massive scale. After successfully completing a pilot for three tumor types 
(lung, ovarian and glioblastoma) the project was renewed and went on to profile more than 11,000 
samples, across 33 tumor types, ultimately generating > 2.5 petabytes of data32. Multiple, 
complementary omics modalities were acquired from each tumor sample, including mutational, 
copy number, gene expression, methylation, microRNA and proteomics profiles, as well as clinical 
data about the patients from which the samples came, often with complementary technologies (e.g., 
gene expression microarrays and RNA-Seq). This data has resulted in numerous publications and 
uncovered a multitude of aspects of cancer biology that were previously too rare or disparate to be 
appreciated. 
Yet, for all of the questions it answered, the TCGA effort failed to live up to one of its big 
initial expectations: identifying and classifying all tumors based on “driver gene” mutations. 
Indeed, most efforts to stratify tumors based on genetic alterations have produced at best mixed 
results, despite significant focus by many leading labs and consortia and the development of 
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sophisticated bioinformatic tools and pipelines33–37. Work by Bailey et al. in 2018 systematically 
merged the results of these often-divergent algorithmic efforts to create a master list of 299 
“driver” genes that occurred with statistically significant frequency across multiple cohorts in the 
TCGA33. Yet, these mutations did not provide any consistent stratification of tumor samples across 
most malignancies. Indeed, for most tumors, overwhelming genetic heterogeneity prevented 
identification of genetically-distinct tumor subtypes or—with few notable exceptions accounting 
for only a small fraction of all tumors—subtypes presenting sensitivity to specific pharmacological 
agents. Instead, what has become increasingly clear is that the vast majority of tumors cannot be 
described just in terms of a few, highly penetrant genetic events that induce tumorigenesis in 
normal cells.  
Part of the reason for the limited success of these taxonomical efforts based on cancer 
genetics can be found in the huge amount of heterogeneity that exists both between tumors 
(intertumor heterogeneity) and within individual cells within the same tumor (intratumor 
heterogeneity). Indeed, the same mutation arising in different contexts can play dramatically 
different roles. Cell-intrinsic properties establish a preliminary baseline, restricting the mutated 
proteins to interactions within pathways that are biologically available38. BRAF mutants, as an 
example, are found in both colorectal cancer and melanoma cells but drugs targeting BRAF are 
more effective in melanoma as compared to colorectal patients. This is likely attributable to the 
upregulated feedback loop with EGFR that occurs in colorectal tumors but not in melanoma tumors 
which are derived from cells with lower basal EGFR expression38,39. 
An additional confounding element to the identification of driver mutants is that at the time 
of sequencing, all of a tumor’s variant genes are compiled into a uniform list, thus obscuring the 
critical element of time-dependent mutational order. Though a number of tools exist to reconstruct 
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mutational timelines from bulk sequencing data, this represents a huge resolution loss when it 
comes to mapping out a stepwise mutational progression as postulated by Vogelstein and others40. 
Moreover, it seems that this stepwise progression might be less prevalent than previously 
predicted. In colorectal cancer for instance, the poster child for this phenomenon, the frequency of 
tumors that have all three of the tumorigenic mutations (APC, KRAS and TP53) is lower than the 
frequencies of those that have none of these mutations41.  Moreover, in certain tissues seemingly 
normal cells have been found to harbor just as many “driver” mutants as cancerous cells which 
again seems to contradict the idea that the presence of these mutations alone promotes cancer 
development42. This also complicates the driver versus passenger idea of mutations given that 
normal cells can harbor “driver” mutations while they are seemingly non-functional or passengers. 
This suggests that many mutations with weak phenotypic effects on an individual basis, and thus 
previously identified as passenger events, may in fact cooperate to form a strong “field effect,” 
including private mutations that may exist only in an individual sample and cannot be identified 
as recurrent across a cohort.  Thus, in retrospective, the potentially myopic view of focusing only 
on mountain vs. hill genes, while completely ignoring non-recurrent/private events, may have 
limited our ability to elucidate more universal mechanisms involved in tumorigenesis and cancer 
progression.  
 
1.2.2 Cellular Homeostasis and Cancer 
Paradoxically, while cancer’s mutational landscapes are extremely heterogenous, transcriptional 
profiles are remarkably conserved across a large number of samples, thus producing only a limited 
number of distinct tumor subtypes43,44. Comparisons of transcriptional profiles of both normal and 
cancer tissue show that not only do the cancer samples differentiate from the normal tissue but that 
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the cancer samples themselves exhibit internal patterns of similarity, suggesting that they 
collectively settle into a stable state or set of states. The stability of these profiles seems to indicate 
that tumors rely on critical homeostatic-control machinery to maintain their transcriptional state, 
independent of the virtually infinite variety of genomic alteration patterns that are identified in a 
transcriptionally homogenous subtype.  
 Homeostasis is defined as the ability of a living system to preserve its steady-state 
operating conditions independent of the exogenous and endogenous perturbations that it is 
subjected to. For instance, cells are able to operate over a wide range of temperatures, even though 
individual biochemical reactions have much stricter temperature tolerances. Similarly, 
homeostatic regulation allows cells with millions of genetic differences at polymorphic sites to 
perform their function virtually unaffected. Indeed, this concept is important across all aspects of 
biology, particularly in development as cells progress from being early stem cells, which have 
infinite potential states, to increasingly differentiated cells that are both energetically and 
physiologically viable; a process called Waddington’s canalization45. It’s generally been thought 
that the disruption of cellular homeostasis is a key component of diseases, including cancer. While 
it is true that cancer cells are no longer in a state of “healthy,” i.e., physiologic homeostasis, their 
transcriptional profiles are as stably maintained as those of physiologic cells. This suggests the 
existence of a dysregulated form of homeostatic control mechanisms, that has been dubbed 
“dystasis.” Indeed, studies have shown that cells lines and xenografts derived from tumor biopsies 
maintain a relatively high-fidelity transcriptional state compared to that of the original specimen, 




1.2.3 Network Models of Cancer 
Reconstructing the networks of cells to understand both the mechanisms driving their homeostasis 
and conversely the dysregulation occurring in cancer cells is a key strategy with which to leverage 
these high-throughput sequencing datasets. If a global model of all the interactions in a cell could 
be mapped out then biologists would in theory be able to dissect the pathways that had been 
disrupted during tumor development and devise precise strategies to target them. Adopting this 
more holistic lens, and instead focusing on the cellular networks controlling the cancer cell’s 
transcriptional state as a way to study tumor phenotypes, introduces a far more compelling and 
uniform view of the biological landscape of human malignancies compared to considering only a 
handful of driver genes.   
 One way to build these networks is to use literature derived pathways that have been 
elucidated and constructed based on years of bench research. While these pathways can provide 
information that has been tested and validated a priori, these representations are both not 
comprehensive and lack context specificity. Moreover, these pathways, by their reductive linear 
nature, do not capture the complex, multivariate and dynamic systems that determine cell 
behavior48. Certainly, many important biological mechanisms have been elucidated and catalogued 
in databases like MSigDB, KEGG, Gene Ontology and others, and these are tools have proven to 
be invariably useful for looking for patterns in large datasets49–52. But they fall short in being able 
to generate truly novel network insights.  
 Another way to approach building these networks is inferring them directly from the data. 
The ability to do this is built on the assumption that interactions occurring in biological networks 
will generate statistical relationships in the observed data53. These biological interactions can be 
conceptualized by the “module-network” model: that genes are grouped into modules under the 
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same regulatory control in order to execute common functions54. While the increasing complexity 
of the network under investigation using statistical methodologies requires increasingly larger 
datasets to be sufficiently powerful, by pooling genes together the module-network framework 
increases the statistical ability to identify these structures55.   
 One method to probe cellular networks and modularity directly from the data is to use 
methods based on SigArSearch (significant area search) which frame the search for modules as an 
optimization problem56,57. These methods first score the nodes (molecules) and/or edges 
(interactions) in the system based on some molecular metric, typically gene expression levels, 
though other measures are used as well. Subsequently a scoring function is devised to capture and 
quantify each aggregate subnetwork as based on the scores and activity of the member nodes and 
edges. From this a search strategy is deployed to identify high scoring subnetworks that thus 
represent an active module56. While these methods can work effectively in smaller networks, they 
become very computationally difficult as the size increases. This leads to the need for various 
heuristics and constraints that can keep from finding the true maximally scoring modules and 
networks.  
 Another framework to assess module structure involves using network diffusion and 
propagation models to integrate together other non-gene expression data types to find recurrent 
occurrences across a priori networks. One such method, HotNet, considers genomic alterations as 
heat sources, and allows them to propagate through a network of protein-protein interactions and 
linkages using a heat diffusion model58. It then computes the intensity of the heat appearing the 
nodes to identify relevant sub-networks. This approach is based on the idea that functionally 
relevant genomic events will aggregate within modules and this will be reflected in the flow of the 
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heat through the diffusion network. TieDIE is an extension of this that incorporated transcriptional 
data as well59.  
 
1.2.4 Gene Regulatory Network Models 
Another way to frame the module-network problem is to look specifically for networks of genes 
under the control of transcription factors. Prioritizing the reconstruction cellular networks in this 
way aligns well with what we understand from developmental biology and control of cellular 
processes. In the context of normal cell differentiation, key transcription factors facilitate 
progression by coordinating expression of related sets of genes in order to implement the functions 
necessary for the various cell states along the cascade. Once a cell has settled into its terminal state, 
certain transcription factors remain active in order to maintain the state and respond to stimuli to 
preserve homeostasis. Moreover, scientists aiming to control these processes experimentally will 
promote sequential expression of various transcription factors in order to create more or less 
differentiated cells60–62. In this way, transcription factors and associated regulatory co-factors, 
serve as mechanistic control centers for the regulatory networks governing cells. Thus, it serves to 
reason that disruption of their typical activity is a key mechanistic component of tumors’ dystatic 
network logic. 
Early analyses based this framework were implemented in simple genomes like E. coli and 
yeast, but ARACNe (Algorithm for the Reconstruction of Accurate Cellular Networks) developed 
in the Califano lab in 2005, was the first to effectively reverse engineer a mammalian cellular 
network in a context specific fashion63.  In order to generate these networks, ARACNe first 
identifies statistically significant coregulation between pairs of genes, specifically TFs/coTFs and 
potential targets, via mutual information in their expression levels. It then makes use of the data 
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processing inequality theorem to eliminate second and third order (i.e., indirect) interactions and 
optimally prioritize for direct regulator-target pairs. In doing so ARACNe is able to trace the most 
direct connection between pairs of genes thus increasing specificity of the relationships identified 
and reducing false positives found that can arise from indirect associations. Interestingly, in this 
first deployment of ARACNe it was found that the network topology was dominated by a handful 
of highly connected nodes that represented the majority of the connections. ARACNe has since 
been extensively experimentally validated and shown to be useful for reconstructing networks in 
a number of different tissue contexts63–65. 
 A number of Bayesian based methodologies have also been employed in gene regulatory 
network inference as well. One such way to do this is to construct a Bayesian network to infer the 
influence of a particular transcription factor on any given gene66. Typically the nodes of the 
network are gene expression but other relevant experimental data and/or priors can be included as 
well67. These are then related to hidden variables that represent the influence of the relationship 
between the TF and target and then these hidden variables are then related to the observed 
quantities from the experiment, based on a joint probability model. The relative probability for 
each type of potential influence is then calculated and the highest one is selected. While these 
networks can be very effective for incorporating priors and handling uncertainty they are very 
computationally intensive, especially for highly complex networks, and fail to reliably predict 
feedback loop associations68. 
 Another popular method for inferring gene regulatory networks from gene expression data 
is GENIE3 as developed in the Aerts lab69. In contrast to the previous frameworks, GENIE3 
instead trains a series of random forest models to predict the expression of each gene in a dataset 
using the expression of the TFs as input. The models are then leveraged to derive weights for the 
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TFs with respect to their relevance for the prediction of expression for a particular target gene. 
GENIE3 also makes use of a regression element which allows for identification of non-linear 
relationships between regulator-target pairs. This approach has been shown to perform very well 
in DREAM (Dialogue on Reverse Engineering Assessment and Methods) challenges, particularly 
in E. coli and yeast networks, but it too is very computational expensive, particularly in complex 
systems.  
 A complementary approach that has been employed in later iterations of GENIE3, and by 
others, is the incorporation of cis-regulatory sequence analysis to refine predict TF-target 
associations. This is predicated on the fact that transcription factors typically exert their regulatory 
control via binding to the DNA in close proximity to their target genes. By incorporating this 
information, as the Aerts lab has done with later tools like iRegulon, RcisTarget, and more recently 
in their single cell algorithm SCENIC, they can refine their original predictions of TF-target pairs 
by only including interactions that also have the correct binding motif70,71. While this line of 
analysis can be useful, it is also limited by the sensitivity and range of the motif prediction 
algorithms and potential experimental artifacts from binding assays. It also filters out potentially 
crucial co-factors that may play an important regulatory role but do not bind to the DNA directly. 
The above methods represent a select set of some of the key tools and frameworks that 
have been developed over the years to interrogate and reconstruct the networks underpinning 
cellular architecture. Compared to many of these frameworks, ARACNe excels in its unsupervised 
nature, and its limited reliance on heuristics and a priori networks. Moreover, its focus on first 
order interactions between regulators and their target genes provides a mechanistic lens, rather 
than just an associative one, to interrogate the key drivers of both individual modules as well as 
overall cell state.  
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1.3 Master Regulators at the Center of Cell Identity 
1.3.1 Master Regulators 
Developmental biologists coined the term “Master regulator” to refer to gene products (usually 
transcription factors) that are necessary and sufficient to induce cellular morphogenesis and 
lineage differentiation as described previously43,72,73. Cancer biologists later adopted the term but 
in a looser fashion, instead applying it to genes that were sufficient to induce a particular tumor 
phenotype, but not necessary per se. This definition encapsulates canonical oncogenes and tumor 
suppressors that have been shown to transform normal cells into cancerous ones. But notably for 
a number of these, studies have found that cancer cells without those particular mutants can still 
exist in the same transcriptional space, implying that these Master Regulators are not actually 
necessary to achieving that state. For the purposes of this paper and work done in the Califano lab, 
we adopt a modified, yet stricter definition of Master Regulators, requiring these proteins to be 
both necessary and sufficient to implement a specific cancer transcriptional state, via their 
mechanistic targets43.The last part of this nomenclature is important both from a biological and 
statistical standpoint. Biologically, it creates a threshold that ensures selection of proteins that 
would be effective pharmacological targets because they are directly enacting the signature versus 
selecting proteins that might be important and physiologically adjacent but not critical. 
Statistically, prioritizing direct regulator-gene target interactions provides a stronger signal when 
reconstructing gene network topologies as described previously. For the purposes of this thesis I 
will use the term “transcriptional regulator (TR)” to signify any transcription factor (TF) or co-
transcription factor (co-TF) that regulates gene expression. Among these, “Master Regulator” 
(MR) proteins will refer to those that have been determined to mechanistically regulate the genes 
that are differentially expressed in a specific cancer phenotype.  
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There is an inherent difficulty in determining MRs from protein activity directly in part 
because massive scale proteomics are still too costly for the amount of information they reveal and 
for this reason are less ubiquitously used. They are also dependent on the availability of high-
quality, high affinity, high specificity reagents, rendering it difficult for them to be 
comprehensive74.  Though more readily attainable given technological improvements, gene 
expression and mutational profiles of TRs are also limited in their scope. For one, while direct 
mutations in TRs can change their activity, this is not always the case potentially due to buffering 
activity of the cell to defend against these alterations. Moreover, changes in regulatory patterning 
have been shown to occur in the absence of these mutations. This is similarly true when looking 
for changes in gene expression of TRs as readouts of perturbed activity. This is largely due to the 
biology of how proteins, specifically TRs work. While overall expression and translation of TRs 
is certainly important, once present in the cell the real-time activity of TRs is usually controlled 
by factors like post-translational modifications, i.e. phosphorylation or methylation, sub-cellular 
localization, epigenetic changes, and cofactor binding availability. These elements all 
mechanistically contribute to whether or not a TR is able to control expression of its target genes 
and are difficult if not impossible to ascertain directly from proteomics assays, mutation profiles 
and gene expression alone. 
Several tools have been developed over the years by the Califano lab to address these 
challenges via interrogation of regulatory networks, thus allowing direct elucidation of candidate 
MR proteins. Since the expression or post-translational state of a protein, in isolation, is unlikely 
to determine its role as a MR (as discussed above), these tools look at the targets of a TR, instead, 
as a readout of its activity. This is akin to using a highly multiplex gene reporter assay to measure 
the effect of a TR on the regulation of a specific transcriptional signature. This again hinges on the 
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idea that the main role of a TR is to facilitate the expression of a particular set of genes that then 
enact the various functions associated with the cell state of interest.  
The information in the regulator-target networks reverse engineered by ARACNe, as 
described in the previous section, can thusly be used to predict and quantify the relative activity of 
a given TR63. If a TR is actively regulating its targets by activating or repressing their expression, 
this pattern will be reflected in the gene expression data. For instance, the targets activated or 
repressed by a TR will be over or under-expressed if the TR becomes aberrantly activated in a 
tumor, respectively. Conversely, if a TR’s activity is unchanged, its targets will not be 
differentially expressed. VIPER (Virtual Inference of Protein activity by Enriched Regulon 
analysis) is the algorithm developed by the Califano lab to quantify this phenomenon75. This 
methodology has been extensively validated and used to reveal key MRs in a number of different 
contexts, both within the Califano lab and by others in the field65,76–78. 
 
1.3.2 Expanding the MR Framework 
1.3.2.1 CINDY 
Other tools have been developed over the years in the Califano lab that have aimed to build upon 
this MR analysis framework. The CINDy algorithm (Conditional Inference of Network Dynamics) 
was designed to infer regulatory dependencies between potential modulators upstream of TRs in 
order to identify which ones affect a TRs ability to regulate its downstream targets79. 
Understanding the upstream signaling cascades leading to TRs is important to better deconvoluting 
the pathways within the cell, while still focusing on the MRs. CINDy utilizes conditional mutual 
information between a candidate modulator, a TR and a target in order to infer the likelihood of a 
three-way interaction. Using this framework, it can determine if the mutual information between 
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the gene expression of a TR and expression of its target is affected by the expression of a particular 
modulator. This tool, and its predecessor MINDy (Modulator Inference of Network Dynamics) 
have successfully identified a number of both known and novel MR-modulator interactions 
including, EGRF-STAT1, HUWE1-MYC and CDK2-HMGA179–82. 
 
1.3.2.2 DIGGIT 
DIGGIT (Driver-gene Inference by Genetical-Genomic Information Theory) is another tool that 
tries to better inform MR biology by searching for genetic alterations that are associated with 
dysregulated MR activity83. Similar to eQTL (Expression Quantitative Trait Loci) analysis which 
aims to associate genomic variants with expression changes, DIGGIT performs aQTL (Activity 
Quantitative Trait Loci) analysis in order to quantitate the degree to which a particular genomic 
variant in a cohort corresponds with changes in activity of a TR. By prioritizing genomic 
alterations based on whether or not they correspond to activity changes of an TR, DIGGIT 
effectively differentiates likely driver genes from passengers based on a mechanistic framework 
rather than just a statistical one. This parses through the candidate genomic alterations in a way 
that captures potential drivers that are less frequent but may still have a small but important impact 
on specific MRs. It also builds on the idea that TRs are typically regulated post-translationally by 
other molecules that may develop mutations during tumor development and thus pass on aberrant 
signals to the TRs.   
The main step of the DIGGIT algorithm is determining aQTL significance. In the original 
iteration, this was done using mutual information, but the updated version uses aREA (Analytical 
Rank-based Enrichment Analysis), an analytical derivative of GSEA (Gene Set Enrichment 
Analysis) that is also the underpinning of the VIPER algorithm50,75. Samples are ranked by 
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differential activity of a specific TR (after performing VIPER analysis across a cohort) and aREA 
is then used to calculate the relative enrichment of samples harboring a specific genomic event and 
having dysregulated activity of the TR. This produces a statistical determination of how likely it 
is that genomic event of interest affects that TRs activity. The resulting aQTL predictions can be 
further refined by only considering those that are also predicted to be upstream modulators by 
CINDY. In this way it is able to leverage both gene expression information and genomics profiles 




An additional layer of information that can further bolster the ability to elucidate regulatory and 
signaling mechanisms is related to physical protein-protein interactions (PPIs). We know that 
proteins enact their various functions by physically interacting, stably or transiently, with their 
cognate binding partner molecules in the cell. This includes, for instance, transcription factors 
binding to DNA to promote transcription, kinases binding to their substrates to phosphorylate 
them, and motor proteins “walking” down actin filaments via structure-mediated interactions. 
Structural biologists have characterized many protein-protein interactions by resolving the 
structure of the interacting pair at the atomic level, for instance using X-ray crystallography. 
However, only a very small fraction of all actual interactions has been characterized in this fashion. 
To further expand the universe of high-likelihood PPIs, the PrePPI (Predicting Protein-Protein 
Interactions) algorithm was developed in collaboration with structural biologist Barry Honig’s lab. 
PrePPI uses a Bayesian framework to integrate information from structural homologs known to 
physically interact, as well as from additional non-structure-related evidence, to predict the 
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likelihood of interaction between any two candidate proteins84. When assaying two novel proteins 
that do not have interaction information, PrePPI will search for proteins that are structurally similar 
(and/or have structurally similar subunits) and determine if any of these structural neighbors are 
part of a complex that has been reported in protein structure databases. From this PrePPI calculates 
a similarity score between the novel proteins and their structural neighbors and how likely it is that 
aspects of the neighbor interaction(s) also exist between the novel proteins. If available, non-
structural evidence like co-expression or functional similarity is also incorporated into the final 
score via a Bayesian classifier. This algorithm has been able to generate over 300,000 high 
confidence interaction predictions, many of which have also been validated.  This information can 
thus provide valuable insight to the likelihood of potential interactions between candidate 
modulators and MRs. 
 
1.3.3 Oncotecture Hypothesis 
Focusing on these key regulatory factors as drivers and maintainers of cancer state is the 
cornerstone of the “Oncotecture Hypothesis”43.  This hypothesis posits that a handful of key master 
regulators (MRs), working in highly autoregulated modular structures dubbed “Tumor 
Checkpoints”, are responsible for implementing and maintaining the dystatic state of tumor cells. 
This is accomplished through their coordinated regulation of genes that implement well-
established cancer hallmark programs, such as proliferation, migration, immune evasion, and 
epithelial mesenchymal transformation (EMT). Furthermore, the Oncotecture hypothesis implies 
that Tumor Checkpoint proteins are likely to be downstream of relevant genomic alterations via a 
complex, non-linear field effect leading to their dysregulation. Given the finding that driver gene 
mutational profiles do not readily co-segregate with the transcriptional state of tumor subtypes, we 
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instead expect that different mutational patterns will induce the same transcriptional state, due to 
the integratory logic present in human cells. In this way these Tumor Checkpoint MRs are 
predicted to canalize the effects of various lower effect mutations and aberrant signals in order to 
implement a stable cancer cell state.  
 
1.4 Multi-omic Analyses of Cancer 
1.4.1 A Pancancer Multi-omic Master Regulator Analysis 
The ARACNe and VIPER algorithms represent the conceptual foundations of MR analyses. While 
they have been used to elucidate mechanisms of initiation and progression in several distinct 
disease contexts, a systematic pan-cancer analysis across a comprehensive repertoire of tumor 
samples had not been performed. Elucidating both commonalities and differences in MR proteins 
controlling the state of different tumor subtypes and elucidating novel MR-based subtypes was 
thus the objective of our recently published work as detailed in Chapter 2. The goals of that analysis 
were two-fold: one, to test the Oncotecture Hypothesis and to determine whether tumor 
checkpoints could be identified on a sample by sample basis, which would integrate the genetic 
alterations in that sample to implement its transcriptional state, and two, to assess whether, even 
within tumor checkpoints, MR proteins may form smaller, highly recurrent modular structures.  
MOMA (Multi-omic Master Regulator Analysis) was developed with the purpose of 
integrating both genetic and transcriptomic profiles toward the elucidation of tumor subtype-
specific master regulators, tumor checkpoints, and their upstream genetic determinants85. To 
accomplish this goal, we leveraged all five previously described algorithms (i.e., ARACNe, 
VIPER, CINDy, DIGGIT and PrePPI) in a biologically-motivated and statistically robust 
framework to infer tumor subtype-specific MR proteins and the genomic events leading to their 
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dysregulation. As discussed above, one of the key tenets of this analysis is that it focuses on the 
mechanisms underpinning the biological role that TRs play in the cell and how they are (a) 
mechanistically affected by mutations in their upstream modulators and (b) mechanistically 
regulate their downstream targets, in turn. 
In brief, the steps of MOMA are as follows: 1) VIPER activities of all TRs are calculated 
across a given cohort of samples using gene expression and ARACNe generated regulons, 2) 
Upstream modulators of each TR are inferred by CINDy 3) the effect of mutations in these 
modulators on the TR is predicted by the aQTL analysis component of the DIGGIT algorithm, 4) 
physical interactions between each TR and its upstream CINDy-inferred modulators are assessed 
by PrePPI  and, finally, 5) all these evidence sources are integrated to generate a single MOMA 
score assessing the likelihood that a specific TR may be a Master Regulator protein, thus allowing 
ranking all TRs from the one most likely to the one least likely to be a MR, as well as the genetic 
events contributing to their dysregulation. This unique lens differentiates it from other network 
based multi-omics analyses that rely mostly on correlation or co-expression of features but not 
their mechanistic association. 
As is discussed more thoroughly in the manuscript, we then used these MOMA scores to 
drive our clustering analyses across the samples in the TCGA and to determine the tumor 
checkpoint MRs of each subtype. In doing so we were able to identify 112 distinct tumor subtypes 
and to show that, in almost all of them, only a handful of MR proteins were necessary to account 
for the majority of functional genomic events in that sample. We were further able to identify key 
modules across the most frequent checkpoint MRs indicating that a number of them work in 
coordinated groups to implement various hallmark cancer pathways. In doing so we thus confirm 
both parts of the Oncotecture Hypothesis.  
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1.4.2 Other Multi-omic Frameworks 
A number of other tools have been developed across the field using multi-omic data to characterize 
and classify cancer biology. A few of these were mentioned in the previous section discussing 
network models of cancer, but to place MOMA in the broader context of this field a selection of 
key ones representing some of the major classes of methods will be covered here. 
 
1.4.2.1 Early Integration Methods 
One method for approaching multi-omic clustering and classification has been to merge all the 
omics together into one large matrix at the outset, as a form of “early integration,” followed by 
clustering using any number of classical methods86. This enables the use of previously vetted 
clustering algorithms but requires a number of different normalizations in order to deal with the 
many types of data being merged together, each with various underlying distributions.  One such 
method is iCluster, which posits that tumor subtypes can be modeled as unobserved latent variables 
that can simultaneously be estimated from any number of combined omic sources87. After merging 
these omics together, it optimizes the likelihood of the observed data using an Expectation-
Maximization algorithm along with a lasso-type regularization to shrink the coefficients of non-
informative features. K-means clustering is then performed on this lower dimension representation 
of the data to identify final clustering assignments. As this method involves the generation and 
manipulation of one huge matrix of features, feature selection is incredibly important in mitigating 
computational complexity. A notable use of this algorithm was in the recent pancancer analysis 





1.4.2.2 Late Integration Methods 
In contrast to early integration methods, late integration methods first perform clustering on single-
omics separately, followed by an integration of these different clustering solutions86. This allows 
for tailoring of clustering algorithms best suited to each omic type prior to merging them together. 
Additionally, this helps to keep from any one platform dominating the others as they are all treated 
separately and then weighted accordingly during the consensus clustering step. One notable 
drawback is that signals that may be weak in each omic separately will be lost by the time they are 
merged with the other omics solutions. COCA (cluster-of-cluster assignments) is one such 
example of this method that has also been applied across tumors in the TCGA44. After performing 
per omic clustering, each sample is then encoded as a binary vector indicating its belonging to 
each omic’s clustering solution, and all vectors for each omic are concatenated. Consensus 
clustering is then performed using these sample indicator matrices to identify the final clusters. 
The initial application of COCA across 12 tumors of the TCGA identified 11 new molecular based 
subtypes, but in the later work across the full set of 33 tumors iCluster (as described previously) 
was found to be more powerful at revealing patterns that may not be strong enough to be identified 
within each omic individually44,88 
 
1.4.2.3 Statistical Methods 
Statistical models for multi-omics clustering are based on modelling the probabilistic distributions 
of the underlying data. This can allow for the inclusion of biological knowledge or other priors 
when choosing the underlying probability functions and can allow for probabilistic assignment of 
samples to multiple clusters at a time86. iCluster is one such version of this method as it assumes 
the data comes from a low dimension representation that determines the membership for each 
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sample. Another popular framework is PARADIGM (Pathway Recognition Algorithm using Data 
Integration on Genomic Models), which utilizes factor graphs to integrate omics data with 
information about known signaling pathways and then uses this to drive clustering89. While this 
methodology can allow for flexible integration of a number of different omics it relies heavily on 
known interaction pathways thus limiting its ability to utilize novel connections in its clustering 
stage. 
 
1.4.2.4 Deep Learning Methods 
Deep learning methods make use of multi-layered neural networks to integrate together multiple 
sources of information and make predictions based on underlying relationships in the data. Deep 
learning is a new development in the field of machine learning that has shown to improve 
performance in a number of different contexts, particularly in image recognition and biomedical 
applications90,91. One recent method applied a deep learning tool for dimension reduction to 
Hepatocellular Carcinoma data from the TCGA92. In doing so they were able to stratify the patients 
into clusters corresponding to significantly different survival, though this was somewhat expected 
given it was a supervised analysis to find features that corresponded with survival. It is unclear 
how broadly applicable deep learning methods will be on biological multi-omic analyses as they 
usually require many samples and few features, which is opposite of current multi-omic datasets86. 
They also tend to require the tuning of a large number of parameters, which can lead to overfitting, 






Chapter 2: A Modular Master Regulator Landscape Controls 
Cancer Transcriptional Identity 
The following is adapted from: 
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A modular master regulator landscape controls cancer transcriptional identity. Cell, 184(2), 
334-351.e20.  
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Supplementary Figures and Tables can be found in Appendix A. 
 
2.1 Summary 
Despite considerable efforts, the mechanisms linking genomic alterations to the transcriptional 
identity of cancer cells remain elusive. Integrative genomic analysis, using a network-based 
approach, identified 407 Master Regulator (MR) proteins responsible for canalizing the genetics 
of individual samples from 20 TCGA cohorts into 112 transcriptionally-distinct tumor subtypes. 
MR proteins could be further organized into 24 pan-cancer modules (MRBs), each regulating key 
cancer hallmarks and predictive of patient outcome in multiple cohorts. Of all somatic alterations 
detected in each individual sample, >50% were predicted to induce aberrant MR activity, yielding 
insight into mechanisms linking tumor genetics and transcriptional identity and establishing non-
oncogene dependencies. Genetic and pharmacological validation assays confirmed the predicted 
effect of upstream mutations and MR activity on downstream cellular identity and phenotype. 
Thus, co- analysis of mutational and gene expression profiles identified elusive subtypes and 




Figure 2.0 Graphical Abstract.  
A high-level summary of the MOMA framework inputs and outputs.  
 
2.2 Introduction 
Our understanding of cancer as a complex system is constantly evolving: in particular, it is 
increasingly appreciated that the steady-state transcriptional identity of a cancer cell is tightly 
regulated—akin to homeostatic regulation in their physiologic counterparts—albeit via distinct 
and aberrant (i.e., dystatic) regulatory mechanisms43. These mechanisms play a key role in 
determining which transcriptional identities may be compatible with the specific set of somatic 
and germline variants harbored by each cell, as well as their likelihood to plastically reprogram 
across molecularly-distinct identities.  
While some mutations effectively restrict the transcriptional identity repertoire accessible 
to a cancer cell—for instance, activating mutations in ESR1, FOXA1, and GATA3 are observed 
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almost exclusively in the luminal subtype of breast cancer93—many are far less deterministic. In 
GBM, for instance, there is only weak association between mutational and transcriptional states94. 
Despite a number of insightful studies, the molecular logic that determines the cancer cell identity 
as a function of its mutational and exogenous signal landscape remains elusive and largely based 
on statistical associations. 
The Oncotecture hypothesis43—an earlier, cancer-specific equivalent of the Omnigene 
Hypothesis95—proposes the existence of tumor-specific Master Regulator (MR) modules (Tumor 
Checkpoints) responsible for integrating the effect of mutations and aberrant signals in upstream 
pathways thus determining a tumor’s transcriptional identity, see Califano and Alvarez, 2017 for 
a recent perspective. Thus, MR analysis may help elucidate mechanisms responsible for 
implementing and maintaining the transcriptional identity of cancer cells, as a function of their 
mutational landscape, and for plastically reprogramming across distinct identities.  
To study MR modularity and genetic drivers in 9,738 TCGA samples32, on a sample-by-
sample basis, we developed MOMA (Multi-Omics Master-Regulator Analysis). MOMA 
integrates gene expression and genomic alterations profiles to identify MR-proteins and MR-
modules representing the key effectors of a tumors mutational landscape and thus responsible for 
implementing the cancer cell identity. 
MOMA96 can be accessed on Bioconductor97, thus allowing analysis of virtually any cancer 
cohort of interest, for which patient-matched transcriptional and mutational profiles are available. 





The MOMA framework is shown in both a simplified (Figure 2.1A-C) and a detailed 
(Figure S2.1A-E) conceptual workflow. Briefly, gene expression profiles from 20 TCGA cohorts 
(Table S2.1) were first transformed to protein activity profiles using the VIPER algorithm75 (Step 
1, Figure S2.1B). Candidate MR proteins were then identified by Fisher’s integration of p-values 
for (a) their VIPER-measured activity, (b) functional genetic alterations in their upstream 
pathways, by DIGGIT analysis83, and (c) additional structure and literature-based evidence 
supporting direct protein-protein interactions between MRs and proteins harboring genetic 
alterations, via the PrePPI algorithm84 (Step 2,3, Figure S2.1C). The vector of integrated -Log10 p 
values (MOMA Scores) were used to weight each MR’s contribution in a tumor subtype clustering 
step (Step 4, Figure S2.1D). Finally, genomic saturation analysis upstream of top candidate MRs 
identified those most likely to control the subtype transcriptional identity (Step 5, Figure S2.1D). 
This was followed by identification and functional characterization of MR sub-modules recurring 
across multiple subtypes (MRBs) (Step 6, Figure S2.1E). See Methods for a detailed description 
of each step. 
Somatic genomic alterations considered by the analysis include single nucleotide 
variants/small indels (SNVs) and somatic copy number alterations (SCNAs) from the Broad 
TCGA Firehose pipeline, as well as fusion events (FUS) reported by PRADA99. 
VIPER has been extensively validated as an accurate methodology to measure a protein’s 
activity, based on the enrichment of its tissue-specific activated and repressed transcriptional 
targets (regulon) in over and under-expressed genes75—i.e., akin to a highly-multiplexed gene-





Figure 2.1 Conceptual overview of the algorithm to find sample “checkpoints” and checkpoint 
blocks. 
(A) Conceptual diagram illustrating the “bottleneck hypothesis”. Master regulator (MR) proteins 
(e.g., MR1 – MR12) integrate the effect of genomic alterations (small red spheres) and aberrant 
paracrine and endocrine signals (small blue sphere), in upstream pathway proteins (e.g., P1 – P5). 
Furthermore, they regulate the “downstream” transcriptional identity of the cell—shown as a 
gene expression signature with genes ranked from lowest (blue) to highest (red) expression—via 
their activated and repressed targets (red and blue edges, respectively). Passenger alterations 
(small black sphere) and alterations not affecting the cell’s transcriptional identity occur in 
proteins (e.g., P6) whose downstream effectors (e.g., P7) do not affect MR activity. MR proteins 
form tightly autoregulated, modular structures (Tumor Checkpoints) responsible for homeostatic 
control of the cancer cell’s transcriptional identity. (B) Tumor checkpoints comprise multiple sub-
modular structures, termed MR-Blocks (MRBs), which regulate specific tumor hallmarks and are 
recurrently detected across different subtypes. As an illustrative example a tumor checkpoint 
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transcription factors (TFs) and co-factors (co-TFs) in Gene Ontology52,100, we used the ARACNe 
algorithm63, see Methods for more on ARACNe and VIPER accuracy. 
For each candidate MR we first identified candidate upstream modulator proteins using the 
CINDy algorithm79 and then assessed whether the presence of genomic alterations in their 
encoding genes was associated with differential MR activity (activity quantitative trait locus 
analysis, aQTL). These two steps comprise the DIGGIT algorithm, which was highly effective in 
elucidating key driver mutations missed by prior analyses in GBM83. 
 
2.3.1 Tumor Subtype identification 
MOMA was used to analyze 9,738 primary samples, from 20 TCGA tumor cohorts (with n ≥ 100 
samples) (Table S2.1). Minimum cohort size reflected the need to generate accurate regulatory 
network models using the ARACNe algorithm63. To identify tumor subtypes representing distinct 
transcriptional tumor identities regulated by the same MR proteins, we performed partitioning 
around medioids clustering (PAM)101, based on protein activity profile similarity, with each 
protein weighted by its cohort-specific, integrated MOMA Score (see Methods). Proteins with 
more functional mutations in their upstream pathways were deemed more likely determinants of 
tumor subtype identity and provided greater weight to the clustering solution. Within each cohort, 
the optimal number of clusters was determined using a Cluster Reliability Score (CRS) (Figure 
2.2A). Using identical approaches, MR-based clustering outperformed expression-based 
clustering in all 20 cohorts (p < 2.2×10-16 in all but one cohort, SKCM, p ≤ 1.8×10-8), by 1-tail 
Wilcoxon rank sum test of sample Silhouette Scores (SS)102 (Figure 2.2B). Indeed, a majority of 
samples clustered by expression-based analysis had SS ≤ 0.25—a value generally used as a 







Figure 2.2 Subtypes inference by network-based integration of gene expression and 
mutational profile data.  
(A) Cohort subtypes identified by MOMA, ranked from the lowest (UCEC) to the highest (COAD) 
number of optimal subtypes (x-axis). Solution optimality is shown by size and color of the dots, 
with larger, redder dots representing higher average CRS. The selected solution is marked by a 
black cross (see STAR Methods for handling ties). Statistical significance of survival separation 
between the best and worst clusters, by Kaplan Meier analysis, is shown next to the blue bars that 
represent the -Log10 p. The dashed line represents p = 0.05. (B) Violin plots representing the 
Silhouette Score probability density (y-axis) for each of the 20 TCGA tissue types (x-axis) for the 
optimal clustering solution, as inferred by either MR-based (blue) or expression-based (red) 
cluster analysis. A dotted red line indicates the standard statistical significance threshold 
(SS = 0.25). (C) MR-based clustering heatmap for the TCGA kidney clear cell carcinoma cohort 
(KIRC). Rows represent Tumor Checkpoint MR proteins, while columns represent individual 
samples. Color scale is proportional to protein activity (red activated; blue inactivated).  (D) Cox-
proportional hazard analysis of patient survival in subtype S5 (red line) vs. S3 (green line) 




significance102. In contrast, the vast majority of samples clustered by MR-based analysis had 
SS ≥ 0.25 (Figure 2.2B). 
Solutions ranged from k = 2 to 8 clusters/cohort. Whenever multiple statistically-
equivalent solutions were identified, the one yielding the best survival stratification was selected 
(Table S2.1). The 5-cluster solution for Kidney Renal Clear Cell Carcinoma (KIRC) is shown as 
an illustrative example (Figure 2.2C), including differential outcome for Cluster 5 (worst) vs. 
Cluster 3 (best) (Figure 2.2D) (p = 1.1×10-16). Equivalent analyses for all cohorts can be accessed 
via the MOMA Web App, see also Figure S2.2A and Table S2.1. MOMA identified 112 subtypes, 
representing the stratification of cancer into transcriptional identities regulated by distinct Tumor 
Checkpoints (Figures 2.2A, S2.1D; Table S2.1, Table S2.2, and Table S2.6). 
MOMA identified subtypes and differential outcome in cohorts that had been previously 
challenging from a gene-expression analysis perspective. For example, except for the 
neuroendocrine subtype, expression-based stratification of prostate cancer outcome has been 
elusive, requiring additional metrics (e.g. Gleason Score) or assessment of spatial tumor 
heterogeneity from multiple biopsies103, which may not be available for all tumors. In contrast, 
MOMA identified transcriptional clusters presenting statistically significant outcome differences 
in 19 out of 20 cohorts (Figures 2A, S2A). Even in COAD a clear trend was detected 
(p = 0.07).  Considering the significant improvement in cluster statistics (Figure 2.2B), this 
suggests that MOMA significantly outperforms expression-based subtype analysis leading to a 
more granular subtype structure that improves outcome stratification. 
Despite its unsupervised nature, MR-based clustering recapitulated established molecular 
subtypes and outcome differences. In breast cancer, concordance with Luminal A, Luminal B and 
triple-negative subtypes was highly significant (p = 2.2×10-16 by χ2 test, Figure S2.2B). Similarly, 
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in GBM, MOMA subtypes recapitulated previously published subtypes (p = 2.2×10-16)104, with 
similar outcome stratification based on activity of established MR proteins, CEBPβ, CEBPδ, and 
STAT364 (Figure S2.2B, S2.2C). Best and worst survival were associated with proneural 
(p = 3.0×10-6, by Fisher’s Exact Test, FET) and mesenchymal (p = 1.3×10-3) tumors, consistent 
with prior literature64,83,104.  Virtually identical results emerged for FOXM1 and CENPF in prostate 
cancer, previously validated as synergistic Master Regulators of aggressive disease105. Prior 
analyses were performed by pre-selecting genes, for instance by differential expression in best vs. 
worst survival samples (supervised analysis), while MOMA is completely unsupervised. Notably, 
subtype S6 (poorest outcome), in PRAD, comprises only nine samples—since TCGA is restricted 
to primary samples at diagnosis—and was thus missed by prior studies. 
 
2.3.2 Tumor Checkpoint MRs 
A Tumor Checkpoint is defined as a module with the minimum MR repertoire necessary to 
implement a tumor’s transcriptional identity by canalizing genomic events in its upstream 
pathways. We thus used saturation analysis to refine the initial ranked-list of subtype-specific 
proteins produced by MOMA analysis to a small set of candidate MRs that optimally account for 
the subtype’s genetic landscape (see Methods). By “accounting for an alteration” we mean that it 
is either harbored by the MR or by the MR’s upstream modulators.  
If driver mutations occurred mostly upstream of Tumor Checkpoint MRs, saturation should 
be achieved rapidly, with only few MRs. In contrast, if mutations were randomly distributed, 
saturation should be very gradual. To test this hypothesis, we considered all previously described 
genomic events (SNV, SCNA and FUS). To avoid over counting, we consolidated same-amplicon 
SCNAs upstream of MRs into single regional events, and further refined these by selecting 
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genomic events identified by GISTIC 2.0106. We then plotted the fraction of all such events 
predicted to be in or upstream of the top N candidate MRs, on a sample by sample basis—averaged 
over all samples in the same subtype (Figure 2.3A)—and defined the Tumor Checkpoint as the 
MRs needed to achieve a predefined saturation threshold in each subtype (see Methods). Finally, 
we identified 407 recurrent MRs (Table S2.2) occurring in n ≥ 4 subtypes, a statistical threshold 
determined by a null hypothesis model (Figure S2.3A). Of these, 37 were highly recurrent, 
occurring in n ≥ 15 subtypes (Figure 2.3B). The H3/H4 histone chaperone ASF1B emerged as the 
most pleiotropic MR (n = 31 subtypes), followed by MYBL2 (n = 30), JUP (n = 29), TOP2A 
(n = 25) and TRIP13 (n = 25). 
Consistent with the Tumor Checkpoint hypothesis, we observed rapid genomic event 
saturation in all but 3 subtypes (ovarian cancer subtype S1, S3, and S4). For the vast majority, 
saturation was achieved with very few MRs, starting at n = 4 for THCA subtype S6. Overall, 
between 14 and 52 MRs (i.e., 0.6% to 2% of 2,506 transcriptional regulators, respectively) were 
sufficient to account for the first and third quantile of each sample’s mutational burden, with a 
median of 33 MRs (1.3% of regulatory proteins). Ovarian cancer was an outlier with 170, 140, and 
140 MRs needed to account for the mutations in subtypes S1, S3 and S4, respectively, likely due to 
the very large number of likely passenger structural events in this cohort. In contrast, when MRs 
were chosen at random from all transcriptional regulators, saturation increased very gradually with 
only 0.4% of the events found upstream of 100 randomly selected MRs (Figure 2.3A).  
At the saturation point, ~50% of all genomic events were accounted for, with a ratio of 
genomic events/MRs ranging from r = 0.02 (i.e., one event affecting 50 MRs) to r = 32 (i.e., 32 





Figure 2.3 Genomic saturation analysis of candidate master regulators across all subtypes.  
(A) Individual curves show the average fraction of functional genomic events in each sample 
identified upstream of the top n MOMA-inferred MR proteins for each subtype, as n increases 
from 1 to 100. Saturation curves produced by the null-hypothesis—i.e., n randomly selected MRs 
from 1,253 non-statistically significant regulatory proteins (i.e., the bottom half of all MOMA-
ranked proteins)—are shown in gray. Cohorts are sorted in decreasing order of the fraction of 
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(continued from previous page) are shown on an expanded y-axis scale (0-50%). (B) This panel shows 
the 37 most recurrently activated MR proteins, which canalize genetic alteration effects in n ≥ 15 
MOMA-inferred subtypes (black cells), based on saturation analysis. Rows represent MR proteins 
clustered by their subtype-specific activity, to highlight MRs co-activated in the same clusters 
(e.g. FOXM1 and CENPF), while MOMA-inferred subtypes are shown in the columns, grouped 
by tumor type. The recurrence rank of each MR, based on the number of subtypes in which it is 
aberrantly activated, is shown to the left of the matrix while the number of subtypes is shown on 
the right as a bar chart. 
 
Checkpoints as regulatory bottlenecks responsible for canalizing upstream mutations and suggests 
that <50% of all genomic events may be actual passengers. 
To further assess MOMA’s ability to differentiate between driver and passenger events, 
we assessed the differential enrichment of mutations upstream of MRs in either 
GISTIC2.0/CHASM-predicted driver events or all genomic events reported by the TCGA Firehose 
pipeline. When averaged across all MOMA-inferred subtypes of a specific TCGA cancer cohort, 
differential enrichment of the former was highly statistically significant across all but one tumor 
cohort (LAML), with p-values ranging from p = 10-7 to p = 10-156 and significant fold-ratio with 
respect to the latter (Figure S2.3B, S2.3C).  This suggests that low SNV and high fusion-event 
rates, may have contributed to the LAML discrepancy, since CHASM only assesses candidate 
SNVs. Even though a majority of inferred events were previously unreported, MOMA effectively 
recovered all but one (RQCD1) of the 200 high-confidence pancancer driver genes reported in 
(Bailey et al., 2018), as well as 82.3% of the high-confidence, tumor-specific driver genes, 
averaged across all subtypes (min:50%, max:100%, Table S2.3). 
In colon adenocarcinoma (COAD), for instance, 8 subtypes were identified, including 4 
enriched in MSIHigh samples (S2, S3, S7, and S8), two dominated by single nucleotide variants but 
not enriched in MSIHigh samples (S1 and S4), and two dominated by focal SCNA events (S5 and 
S6). The mutational landscape of these subtypes was highly distinct. For instance, the classic tumor 
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suppressor APC was frequently mutated in all subtypes (S2 = 39% to S5 = 93%) except S8.  
Similarly, taken together, mismatch repair genes (MSH2, MSH6, and MLH1) were mutated in 
~50% of S2 but not S3 samples, while BRCA2 was disproportionally mutated in S3 and several 
other genes were uniquely or disproportionally mutated in either subtype (Figures 2.4A, 2.4B). 
Finally, PI3K pathway mutations were frequent in S2 and S3, yet rarely mutated in other subtypes. 
In contrast S5 and S6 were dominated by focal SCNA events, with several genes mutated 
exclusively or disproportionately in S5, while virtually all S6 mutations were also detected in S5 
(Figure 2.4D). Similar mutational co-segregation differences were detected across virtually all 
cohort subtypes. 
Regional (i.e., non-focal) SCNAs have been largely ignored by previous analyses, due to 
their high gene content. However, MOMA is effective at removing regional SCNA genes that are 
unlikely to modulate MR activity, by DIGGIT analysis. When regional SCNAs were included, 
subtypes became highly homogeneous in terms of their mutational repertoire across patients. 
Consider, for instance, COAD subtype S5 where, except for APCMut/Del, already present in 98% of 
samples, the top 10 regional events increased in frequency from 12.5% to 84%, when 
focal and regional SCNAs were analyzed together (bold red, Figure 2.4E). 
 
2.3.3 Tumor Checkpoints are Hyperconnected and Modular 
Analysis of existing molecular interaction networks confirmed that Tumor Checkpoints represent 
hyperconnected modules, compared to equisized protein sets chosen at random from 2,506 
regulatory proteins, as a null model. Networks include HumanNet 2.0107 (p < 5.0×10-42, by 
Kolmogorov-Smirnov, Figure S2.4A), Multinet108 (p < 2.0×10-37, Figure S2.4B), and PrePPI84 




Figure 2.4 Genomic Alterations Dysregulating COAD Tumor Checkpoints.  
(A – D) OncoPrint plots109 showing genomic alterations in pathways upstream of subtypes S2/S3 
(MSIHigh) and S5/S6 (MSS) in COAD. Only focal SCNA events are shown. Horizontal histograms 
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(continued from previous page) histograms show the number of events detected in each sample. For 
SCNAs, each row corresponds to an independent cytoband, identified by a functionally 
established oncoprotein/tumor suppressor. Blue labels represent genetic alterations detected only 
in one subtype but not the other (i.e., S2 vs. S3 or S5 vs. S6), orange labels show alterations 
disproportionately represented across subtypes, while red ones show mismatch repair genes in 
S2. (E) OncoPrint plot of S5 alterations, including those in Regional (i.e., non-focal) SCNA, with 
most affected events shown with a red label. (F) Legend for genomic event types. (G – J) Genomic 
saturation curves for COAD subtypes S2, S3, S5, and S6. Vertical dashed line indicates the 
saturation threshold, see Figure 2.3A for detailed description. 
 
We then tested whether subtype-specific Tumor Checkpoints may be decomposed into finer-grain 
MR sub-modules—recurrent across multiple subtypes—representing pancancer core-regulatory 
structures. Clustering of 407 MRs identified by saturation and recurrence analysis yielded 24 
MR-Blocks (MRBs) as an optimal solution (Figure S2.5A), with each MR assigned to a single 
MRB (core-set). Since individual TFs may perform different functions, depending on interacting 
co-partners (e.g., MYC/MAX vs. MYC/MIZ-1), we used a “fuzzy” clustering algorithm to refine 
core-sets with additional non-unique MRs110 (Figures S2.5B, S2.5C ; Table S2.4). 
Each Tumor Checkpoint is thus deconstructed into a specific combination of activated or 
inactivated MRBs (Figure 2.5A), with MRB activity computed as the average activity of all of its 
MRs. Transcriptional targets of individual MRB MRs were enriched in Cancer Hallmarks49,111 and 
KEGG/Reactome categories51,112 (Figures 2.5B, S2.5D; Table S2.4). For instance, MRB:7 and 
24 regulate proliferation/DNA repair and inflammation/immune response programs, respectively, 
and are differentially active across subtypes (Figures 2.5A, 2.5B). Consistently, MRB activity 
effectively stratified outcome in multiple datasets, see METABRIC BRCA and TCGA SKCM, for 
instance (Figures 2.5C, 2.5D). Enrichment of Tumor Hallmarks, KEGG, and Reactome categories 
in genes altered upstream of each MRB was generic and sparser (Table S2.4), suggesting that 





Figure 2.5 MRBs are recurrently activated in cancer and regulate established tumor hallmarks. 
(A) Heatmap showing statistically significantly activated (ON) and inactivated (OFF) MRBs for 
each MOMA-inferred transcriptional subtype (p < 10-3), grouped by tumor type. Color saturation 
is proportional to statistical significance (Average protein activity of MRB MRs), see color-scale 
legend. Breast cancer (BRCA) and melanoma (SKCM) subtypes are marked to highlight 
differential activation of MRB:7 and 24, respectively, also highlighted. Horizontal histograms 
show total number of subtypes with significantly activated (red) and inactivated (blue) blocks, 
numerical values are also shown for clarity. (B) Enrichment of Tumor Hallmarks in MRB MRs 
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(continued from previous page) and their transcriptional targets (False Discovery Rate, FDR < 0.05, 
by Benjamini-Hochberg) identifies hallmarks significantly associated with each MRB. Order is 
based on co-clustering across both rows and columns to highlight related hallmarks and MRB co-
activation. Horizontal histograms summarize the total number of enriched hallmarks per block. 
(C) MRB:7 activity stratifies survival in the Metabric breast cancer cohort (p = 3.5×10-8; by Kaplan 
Meier). (D) MRB:24 activity significantly stratifies survival in the TCGA melanoma cohort (p < 
1.9×10-5). In contrast to MRB:7, higher activity of MRB:24 is associated with better outcome, 
consistent with its role as a marker of inflammation and immune sensing (Figure 2.5B). 
 
2.3.4 Tumor Checkpoint MRs are Enriched in Essential Proteins 
We further assessed whether the inferred Tumor Checkpoint MRs were enriched in essential 
proteins, based on Achilles Project data113, see Figure S2.5E for a conceptual workflow. 
Specifically, cell lines optimally matching MOMA-inferred subtypes were identified by protein 
activity analysis (see Methods). Essentiality was then assessed based on Achilles’ score in matched 
cell lines. Overall, MRs were highly enriched in essential genes (n = 141, p = 7.1×10-6; Figure 
S2.5F), based on 106 random selections of the same number of regulatory proteins for each 
subtype. 
We then tested MRB-specific essentiality. As expected, those most enriched for cell 
viability hallmarks, such as MRB:2, 3, and 7 (Figure 2.5B) were most enriched in essential MRs 
(50%, 43.8%, and 30.4%, respectively), including proteins such as E2F1, E2F2, E2F7, TOP2A, 
PTTG1, FOXM1, MYBL2, UHRF1, DNMT3B, ZNF695, TCF19, RBL1, and ZNF367. 
Interestingly, essentiality was also prominent in other MRBs, including 31% of MRs in MRB:6 
(ZNF436, HES1, HOXB7, TP63, TRIM29, GRHL1, PBX4, IKZF2, RARG, IRX5, HHEX, 
RUNX2, STAT5A, HDAC1, HOXC6) and 19% of those in MRB:14 (GRHL2, OVOL1, 
ZBTB7B), for instance. As expected, no essential MRS were found in immune-related MRBs 
(MRB:10, 19, 22, 23, and 24)—consistent with lack of immune function in cell lines. However, 
the role of many of these MRs in pancancer inflammation was previously reported114. This 
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suggests that MOMA can identify MRs that are relevant in a human tumor context but may be 
missed in viability assays in vitro. 
 
2.3.5 MRBs Improve Outcome Analysis 
To assess whether MRBs could stratify patient outcome, we used a sparse Lasso COX proportional 
hazards regression model115, with MRB activities as predictors. Of the 20 TCGA cohorts, 16 could 
be effectively stratified, often with highly-improved p-values compared to Tumor Checkpoint 
stratification (Figures S2.6A and S2.6B vs. S2.2A; Table S2.4). For instance, in melanoma we 
observed striking survival separation (p < 1.6×10-7), using a 6 MRB model—including MRB:10, 
controlling inflammatory/immune programs (Figure 2.5B). Tumor Checkpoint-based analysis 
was much less significant (p = 9.4×10-3). Similarly, in colorectal cancer, significant outcome 
separation was achieved using a 3 MRB model (p = 3.5×10-3)—with MRB:6 providing the 
greatest contribution—while Tumor Checkpoint stratification was not significant (Figure S2.2A). 
Finally, some MRBs provide complementary stratification. For instance, MRB:6—controlling 
EMT, KRAS signals, and immune evasion programs—effectively stratified HNSC, GBM, COAD, 
BRCA, and BLCA, but not UCEC, STAD, SKCM, SARC, LUAD, LIHC, while the opposite was 
true for MRB:3—controlling proliferation and DNA repair programs. 
To assess whether TCGA-inferred MRBs generalize to other cohorts, we analyzed the 
METABRIC breast cancer cohort, including metastatic samples, with long-term survival data93. 
Considering the 7 MRBs with highest differential activity in TCGA BRCA (MRB:2, 3, 7, 11, 14, 
16, and 21), all of them, but MRB:11, provided significant survival stratification in METABRIC, 




2.3.6 MRB:2 Canalizes Driver Mutations in Prostate Cancer 
To validate the effect of genetic alterations affecting MRB activity, we selected MRB:2, the most 
recurrently activated across all subtypes (40/112, Figure 2.5A). By regularized COX regression, 
MRB:2 produced some of the largest outcome regression coefficients across TCGA (Table S2.4), 
emerging as one of the most significant predictors of poor outcome (Figure S2.6A). 11 of its 14 
proteins had been previously reported as MRs of malignant prostate cancer (FOXM1 CENPF 
UHRF1 TIMELESS CENPK TRIP13 ASF1B E2F7 PTTG1 MYBL2 ASF1B TRIP13), including 
7 out of 8 in its core-set. FOXM1 and CENPF—the 6th and 13th most recurrent MRs (Figure 
2.3B)—were validated as synergistic MRs105. Yet, the mutations inducing MRB:2 aberrant activity 
were not previously elucidated. 
MOMA identified 7 molecularly-distinct prostate adenocarcinoma subtypes, with 
significant survival separation (Figure 2.6A), including S6 (worse) and S1, S3 and S5 (best survival) 
(p = 6×10-3), as confirmed by Gleason Score and biochemical recurrence analysis (Figures 2.6B, 
2.6C). Consistently, MRB:2 MRs are only activated in S6 samples (Figure 2.6A). In addition, the 
S6 vs. S1 differential expression signature (9 and 149 samples respectively) is enriched in tumor 
hallmarks associated with MRB:2 (Figure 2.6D). We ranked MOMA-inferred alterations 
upstream of MRB:2 based on their statistical significance across all TCGA cohorts and selected 
those with the strongest MRB:2 association (Figures 2.6E, 2.6F), most of which were not 
identified as drivers by MutSig2.CV116 and Mutation Assessor117 (Table S2.3). 
We selected 6 loss-of-function MRB:2-associated events for experimental validation, 
including TP53Mut (top pancancer SNV), PTENDel and PTENMut (top pancancer SCNA), 
MAP3K7Del (top PRAD-specific deletion), SORBS3Del (top integrated pancancer/PRAD-specific 




Figure 2.6 MRB2 and its upstream genetic alterations drive the most aggressive PRAD subtype  
(A) Heatmap showing MR-based clustering of the TCGA prostate cancer cohort (PRAD) into 7 
molecularly-distinct subtypes, as described in Figure 2.2C. (B) Gleason Score frequency 
stratification by subtype. (C) Biochemical recurrence status by subtype. (D) Enrichment of genes 
in MRB:2 hallmark categories in genes differentially expressed between S1 and S6 subtypes, sorted 
by Student’s t-test analysis. Genes in each hallmark are shown as black ticks and statistical 
significance is computed by GSEA analysis (p < 2.2×10-16, i.e., below minimum computable 
significance). (E) Genomic events significantly associated with MRB:2 activity. Samples (columns) 
are sorted by MRB:2 activity (bottom heatmap) and presence of a specific genomic event is shown 
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(continued from previous page) as vertical tick-marks. Functional SCNA events for genes that also 
harbor mutations in the cohort are marked with a brown square. Those involved in protein-
protein interactions with MR proteins, based on PrePPI analysis, are marked with a green square. 
Events are ranked based on their subtype frequency. The top integrated aQTL, CINDy and PrePPI 
association p-value (using Fisher’s method) for each event with an MRB:2 MR is shown on the 
right side. The five genes selected for experimental validation are highlighted in red. We also 
indicate the subtype designation per sample, as shown as tick marks above the heatmap. (F) 
Network diagram of MRB:2 proteins with edges representing a select set of DIGGIT-inferred 
alteration-MR interactions—including for deletions (blue), mutations (green), and amplification 




FOXM1) (Figure 2.6E). Of these only PTEN, a classic prostate cancer mutation, and TP53, a 
hallmark of advanced, castration-resistant disease, were previously reported. We validated their 
functional role in 22Rv1 AR-sensitive prostate cancer cells with low MRB:2 activity, thus ideally 
suited to detecting activity increase in loss-of-function assays. Two shRNA hairpins/target were 
used. Functional and tumorigenic effects were assessed both in vitro and in vivo (Figure 2.7A; 
Table S2.5). 
VIPER analysis following shRNA-mediated silencing of 4 of the 5 candidate genes vs. 
negative controls, revealed statistically significant activity increase of MRB:2 activity, based on 
its 8 core-set MRs (Figure 2.7B). TP53 silencing, while not significant at the MRB level, induced 
FOXM1, PTTG1, and UHRF1 activity increase.  Functionally, MAP3K7, SORB3, PTEN and 
TP53 showed significant increase in cell migration, as assessed by wound healing assays at the 
indicated time points relative to control cells infected with scramble shRNAs (Figures 2.7C, 2.7D, 
S2.7A) This was confirmed by Boyden chamber migration assays (Figures 2.7E, S2.7B). Finally, 
22Rv1 cells were engrafted in immune deficient mice, following target gene and negative control 
silencing. MAP3K7, TP53, and PTEN silencing produced significant growth increase compared 




Figure 2.7 Functional validation of MRB:2 and 14  
(A) Conceptual diagram of the functional validation assays. Androgen independent 22Rv1 
prostate cancer cells were infected with lentiviral non-targeting control vectors and vectors 
containing shRNA hairpins to silence genes harboring predicted, recurrent genomic events 
upstream of MRB:2. Stably silenced clones were then used to perform both in vitro and in in vivo 
assays.  (B) VIPER analysis of 8 MRB core-set proteins (rows) in each silencing condition 
(columns). Significance of overall MRB:2 differential activity is shown above. (C) Migration of 
22Rv1 cells was assessed in wound healing assays at 24 (control), 48, and 72 hours after scratching 
a confluent culture of control and silenced 22Rv1, in triplicate. (D) Quantification of the migration 
DMSO (T = 24h)DMSO (T = 0)
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(continued from previous page) assay. Bars indicate the migration percentage (gap area compared 
to T = 24h) ± standard error of the mean (SEM). P-values from the two hairpins were integrated 
by Fisher’s method (* p < 0.05, ** p < 0.001, by 1-tail Student’s t-test). (E) Quantification of Boyden 
chamber invasion assays in triplicate. Bars represent the proportion of invading cells ± SEM. P-
values from the two hairpins were integrated by Fisher’s method (** p < 0.001, 1-tail t-test). (F) 
Functional, in vivo validation of tumorigenic effects. Tumor growth curves, up to 35 days, are 
shown for mice engrafted with control and silenced 22Rv1 cells. In vivo assays where performed 
in triplicate; * p < 0.05 and ** p < 0.001, by 2-tail, two-way ANOVA. (G) Heatmap showing the 
effect of selected drug perturbations (columns) on the activity of MRB:14 MR proteins (rows) at 
24h. Drug names are followed by their EC20 concentration, based on dose response curves. The 
color bar on top of the heatmap indicates the significance of the average MRB:14 differential 
activity. (H) Modified migration assay of DU145 cells after drug treatment to activate MRB:14, 
assessed at 24h after drug treatment.  (I)  Average gap area (gap remaining) quantitation by 
integrating measurements of ≥ 3 images along the gap, after subtracting any residual gap area in 
DMSO-treated cells.  Percentage gap remaining is calculated with respect to images at 0h time. 
 
2.3.7 Pharmacological MRB Modulation 
We then asked whether MRB activity and associated function may be pharmacologically 
modulated. We focused on MRB:14, whose activity emerged as critical in establishing and 
maintaining hormonally-mediated luminal epithelial identity and cell adhesion (i.e., anti-
migratory) phenotypes. Several MRB:14 proteins (e.g., GRHL2 OVOL1 ZBTB7B) emerged as 
essential in MRB:14 active cell lines and in tissue-specific knockout mice studies118–120.  Others—
SDPEF GRHL2 JUP/g-catenin CDH1/E-cadherin ZBTB7B OVOL1 OVOL2 ATP8B1/FIC1 
PPP1R13L/iASPP—are established regulators of epithelial cell adhesion and anoikis, cellular 
apical-basal polarity, luminal epithelial structure maintenance, EMT, cell migration, and 
inflammation, as shown in prostate, breast, colon, and skin studies121,122. MOMA analysis 
recapitulated these roles in terms of hallmark enrichments, including androgen and estrogen 
response, EMT, apical surface and apical junction, and inflammatory response. 
Consistent with our analysis, SPDEF, GRHL2, γ-catenin, and CDH1 protein expression 
was lost or significantly reduced in AR-insensitive (DU145 and PC-3) vs. AR-sensitive (LNCaP) 
cell lines (Figure S2.7C). LNCaP cells treated with the AR antagonist enzalutamide or DMSO123 
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confirmed that MRB:14 genes have AR-dependent expression (Figure S2.7D). Furthermore, their 
role in luminal epithelial identity maintenance was supported by luminal and basal prostate 
epithelial cell analysis124 (Figure S2.7E). Indeed, MRB:14 activity effectively stratified luminal 
vs. basal samples in BRCA and BLCA TCGA cohorts, by PAM50 classification (Figure S2.7F), 
further supporting MRB:14’s role as a positive determinant of hormone-signal-mediated luminal 
state across tissues and loss of luminal identity when inactivated. 
VIPER analysis of patient-matched biopsies pre and post androgen deprivation therapy 
(ADT)125 showed pronounced MRB:14 MR activity suppression (Figure S2.7G).  Indeed, 
metastatic, post-ADT tumors are generally basal-like having undergone EMT, raising the question 
of whether prolonged ADT may induce loss of adhesion and metastatic progression126,127.  
Intermittent testosterone replacement therapy reduced appearance of aggressive tumors128,129, 
reflecting potential benefit of periodic, AR-mediated cell adhesion reinforcement. 
To test whether pharmacological activation of MRB:14 MRs may reduce the migratory, 
EMT-related potential of aggressive prostate cancer, we used the OncoTreat algorithm130 to 
prioritize 120 FDA-approved and 217 late-stage (phase-II and -III) experimental drugs, based on 
their overall ability to activate MRB:14 MRs, using RNASeq profiles of AR-resistant DU145 cells 
at 24h after treatment (see Methods).  Four MRB:14-activating drugs were inferred at 
physiologically-realistic concentrations (<10µM), including fedratinib, pevonedistat, ENMD-
2076 and lexibulin (Figure 2.7G), and their effect was assessed in wound healing assays.  All 4 
drugs but none of the negative controls significantly inhibited DU145 cell migration at 24h 
(Figures 2.7H, 2.7I). The latter—triapine, raltitrexed, and dorsomorphin—were randomly 




The repertoire of transcriptional identities accessible to a cancer cell, which ultimately determine 
its plasticity potential, is constrained by its mutational and paracrine/endocrine signal landscape, 
as well as its cell-of-origin epigenetics. Yet, the specific mechanisms by which these constraints 
are implemented are still poorly understood. We thus attempted to establish a more direct link 
between the proteins that regulate a tumor’s identity and the genomic alterations that induce their 
aberrant activity using an algorithm, MOMA, that integrates multiple omics data. 
The fine-grain subtype-structure emerging from the analysis revealed a highly modular and 
recurrent regulatory architecture, implemented by subtype-specific, combinatorial activation or 
inactivation of 24 Master Regulator modules (MRBs), each regulating specific tumor hallmarks.  
It also highlights highly-recurrent and distinct mutational patterns within each subtype that had 
been missed by gene expression-based clustering. This suggests a “mutational field effect”—a 
term borrowed from Ising Spin Fields in ferromagnetism131—where many “weak” events that 
would be unable to dysregulate MR proteins on an individual basis—such as those in regional 
SCNAs—may cooperate to create a “strong” effect, as discussed for COAD. Weak event 
cooperativity may have been previously missed because regional SCNA contains dozen to 
hundreds of potential contributing genes, most of which are efficiently removed by MOMA’s 
CINDy and aQTL analyses. 
While most samples lacked a driver event quorum by conventional analyses, MOMA 
inferred a large number of functionally-relevant events contributing to MR dysregulation in most 
samples, consistent with other complex diseases95. Despite the remarkable complexity of these 
mutational patterns, our study suggests that their effect is canalized by only 112 distinct regulatory 
modules (Tumor Checkpoints), each representing a combination of only 24 primary MRBs. 
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Consistent with the notion that transcriptional cell states have emerged as more accurate predictors 
of drug-sensitivity, compared to genetics132, this suggests that MR-based analyses may produce a 
more tractable landscape of potential therapeutic targets than could be achieved by genetic-based 
approaches, especially as great strides are being made to target transcriptional regulators using E3-
ligases, covalent binding molecules, or antisense agents.  To further support this observation, we 
show that MRB activity and associated phenotypes can be effectively modulated by drugs 
predicted to invert the activity of their MRs, suggesting that a relatively small repertoire of MRB-
targeting drugs could be developed to support precision combination therapy, as determined by 
MRB activity on an individual patient basis.  
Over the last 50 years, a number of cancer hallmarks, representing programs necessary for 
cancer cell survival and proliferation, have emerged26, thus spurring research aimed at identifying 
the specific proteins and protein-modules that comprise them. This has led to development of 
several methods to ‘decompose’ the 20,000+ dimensional gene-expression data space into 
orthogonal programs, either using 2-dimentional matrices133 or higher dimensional tensors134, thus 
creating a simplified representation of the underlying cellular states and shared oncogenic 
alterations133,135. These studies are encouraging and confirm that cancer hallmarks may be indeed 
implemented by coordinated activity of specific gene modules. However, current hallmark 
representations are basically tumor-independent gene sets that lack information on what regulates 
or dysregulates them. MRBs provide a complementary, subtype specific representation of the 
proteins that causally regulate cancer hallmark gene sets and, thus, a potential way to modulate 
them on an individual tumor basis, as confirmed by validation of OncoTreat-predicted drugs. 
MRB:2 was selected for experimental validation as the most recurrently activated across 
clustering solutions, mostly in poor outcome subtypes (Figures 2.5A, S2.5C). While 11 of its 14 
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proteins, which regulate cell growth, DNA repair, and mitotic programs (Table S2.4), were 
previously inferred as MRs of the most aggressive subtype of prostate cancer, including FOXM1 
and CENPF validated as synergistic MRs105, their concerted, pancancer role had been missed. 
Among them, TRIP13 also plays a critical role in chromosomal structure maintenance during 
meiosis136, facilitated by the DNA topoisomerase 2-alpha subunit TOP2A, a well-established 
therapeutic target137 enabling chromosomal condensation and chromatid separation. FOXM1, 
CENPF, MYBL2, and TRIP13 were implicated as part of a core “proliferation cluster,” associated 
with poor outcome, whose activity is dependent on p53 inactivation138. Indeed, TP53 mutations 
emerged as the most significant event upstream of MRB:2. Additional proliferation-related 
proteins, such as E2F2, E2F7, and TIMELESS, contribute to MRB:2’s strong association with 
proliferative hallmarks such as E2F Targets (p = 8.1×10-76), Mitotic Spindle (p = 2.6×10-2) and 
G2/M Checkpoint (p = 3.5×10-45), as well as MTORC1 (p = 1.7×10-5) and V1 and V2 MYC 
programs (p = 1.2×10-28 and 3.7×10-10, respectively). Finally, UHRF1, also a candidate 
therapeutic target, is overexpressed in many cancers139, where it regulates gene expression and 
peaks in G1 phase, continuing through G2 and M, while ASF1B—a core member of the histone 
chaperone proteins, responsible for providing a constant supply of histones at the site of 
nucleosome assembly and the most recurrent activated MR—is predictive of outcome in several 
tumors140. Thus, while the role of these proteins may have been individually established in some 
cancers, our study identifies them as a hyper-connected, synergistic core module activated in the 
most aggressive cancer subtypes, from melanoma and GBM, to colorectal, prostate, and ovarian 
cancer (Figure 2.5A).  
Activity of MRB:3 and MRB:7 was also associated with proliferation, yet via 
complementary MRs such as E2F1/2/7/8 and chromatin remodeling enzymes involved in mitotic 
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progression (SUV39H1), assembly (CHAF1B), and mini-chromosome maintenance 
(MCM2/3/6/7).  
At the other end of the functional spectrum, MRB:24—significantly associated with 
inflammatory response and immune related hallmarks, including via the immune-regulator MR 
STAT1 (Figure 2.5B)—was activated in 20 subtypes (Figure 2.5A) and highly predictive of 
outcome (e.g. in SKCM, Figure 2.5C). MRB:19 was also enriched in immune related hallmarks 
(Figure 2.5B) via alternative MRs, including CIITA, an MHC transactivator, whose inactivation 
abrogates HLA-DR presentation and promotes immune-evasion141, CD86, the canonical CTLA-4 
ligand involved in immune checkpoint activation, and additional proteins (e.g., NOTCH4, MITF, 
etc.) associated with an immune-evasive microenvironment114.  
Taken together, these data suggest that MRBs may provide complementary “molecular 
recipes” for implementing the same cancer hallmarks in different tumor contexts. 
Obviously, there are several limitations to the MOMA analyses, providing options for 
potential future improvements. Consistent with other high-throughput methods, both experimental 
and computational, it is reasonable to expect that MOMA will also produce false positive and 
negative predictions. Moreover, MOMA was not optimized on an individual cohort basis but rather 
to identify commonalities across different tumor subtypes. As such, it is not intended as a 
replacement but rather as a complement to existing analyses, specifically to identify proteins that 
canalize cancer alterations towards subtype implementation. For instance, TP53 mutations, are 
ubiquitous in ovarian cancer, thus providing minimal contribution to its subtypes and failing 
detection by MOMA. Similarly, the proposed clustering strategy may over- or under-stratify some 
cohorts, in order to avoid missing rare subtypes across most cohorts. For instance, S6, the most 
aggressive PRAD subtype (Figure 2.6A), would have been missed by a more conservative 
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clustering strategy. Yet, tuning the algorithm for rare subtypes may cause over-stratification of 
others. Indeed, while most subtypes are molecularly distinct, PAAD subtypes S3, S4, and S5 were 
quite similar, both in terms of MRs and upstream genetics. Conversely, under-stratification was 
evident in breast cancer, where MOMA identified only four subtypes, a basal-like one (S4), a 
Luminal-B one (S2), and two molecularly-distinct Luminal-A ones (S1 and S3). Forcing a more 
granular 8-cluster solution split the basal subtype into Claudinlow and Claudinhigh subtypes (Figures 
S2.2D, S2.2E), HER2 positive tumors, however, still failed to form a separate cluster and were 
enriched in either the Luminal B or Basal subtypes (Figure S2.2B), suggesting that, while HER2+ 
tumors may present a distinct oncogene dependency, due to their hallmark mutation, their 
transcriptional identity may be more consistent Basal (HR-negative) and Luminal B (HR-positive) 
tumors. 
Some key events may also be missed (false negatives) due to the highly conservative nature 
of the DIGGIT analysis. Indeed, BRAF mutations, which are frequent in SKCM, were significantly 
associated with differential MR activity by aQTL analysis. Yet, they were not identified as 
upstream MR modulators by CINDy, because activity of this protein is not effectively tracked by 
VIPER, and were thus missed by MOMA. Indeed, previous validation43,75 shows that ~20% of 
proteins harboring functional genetic alteration may be missed by VIPER analysis. We are 
currently developing approaches to further improve sensitivity, for instance by including DNA 
binding motifs, ATAC-Seq data, or other epigenetic data modalities. Similarly, as also reported, 
VIPER may invert the sign of differential activity due to autoregulatory loops. This does not 
compromise MR identification but may identify some activated MRs as inactivated and vice-versa. 
Further improvement to the algorithm may be possible by changing the integration logic or by 
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using mutational or perturbational data to better infer the activity of mutation harboring proteins, 
as shown in142. 
While the current version of MOMA identified a large repertoire of previously unreported 
mutations and subtypes, the algorithm may be tuned for improved stratification, on an individual 
tumor cohort basis, for instance by using the average of each cohort, rather than the average of 
TCGA, as a control, as shown in several prior studies, e.g., 64,143, thus further highlighting subtle 
subtype differences. 
To make MOMA broadly available to the research community, we deposited the related 
software in Bioconductor96, allowing its application to any cohort for which matched gene 
expression and mutational data is available. We also developed a public-access Web Application 
that allows biologists to easily query and visualize the ~2 million tumor-specific molecular 
interactions emerging from the analysis98. 
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2.5 Methods 
2.5.1 Key Resources Table 
Table 2.1: Key Resources Table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit Anti-GRHL2 Millipore Sigma Cat# HPA004820 
Rabbit Anti-SPDEF Proteintech Cat# 11467-1-AP 
Rabbit-Anti AR Cell Signaling Tech. Cat# 5153S 
Mouse Anti- -catenin (JUP) BD Biosciences Cat# 610253 
Mouse Anti-E-Cadherin (CDH1) BD Biosciences Cat# 610404 
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Chemicals, Peptides, and Recombinant Proteins 
Fedratinib Selleck Chemicals Cat# S2736 
Pevonedistat Selleck Chemicals Cat# S7109 
Lexibulin Selleck Chemicals Cat# S2195 
ENMD-2076 Selleck Chemicals Cat# S1181 
Triapine Selleck Chemicals Cat# S7470 
Dorsomorphin Selleck Chemicals Cat# S7306 
Raltitrexed Selleck Chemicals Cat# S1192 
Deposited Data 
TCGA Sample Data Broad Institute https://gdac.broadinstitute.org/ 
PRADA Gene Fusion Data The Jackson Laboratory https://www.tumorfusions.org/ 
Achilles shRNA Essentiality Data DepMap; Broad Institute https://depmap.org/portal/achilles/ 
METABRIC Breast Cancer Patient Data cBioPortal; Curtis et al., 2012 https://www.cbioportal.org/study/s
ummary?id=brca_metabric 
Pancancer Driver Genes  Bailey et al., 2018 https://doi.org/10.1016/j.cell.2018.
02.060 
Network of Cancer Genes (NCG) Repana et al., 2019 http://ncg.kcl.ac.uk/ 
Molecular Signatures Database (MSigDB) UC San Diego; Broad Institute https://www.gsea-
msigdb.org/gsea/msigdb/index.jsp 
Gene Ontology  Gene Ontology Consortium http://geneontology.org  
Enzalutamide-treated LNCaP cells Handle et al., 2019 GEO Accession# GSE130534 
Analysis of prostate cells and tumor biopsies Rajan et al., 2014 GEO Accession# GSE48403 
Analysis of prostate cells and tumor biopsies Zhang et al., 2016 GEO Accession# 
GSE067070 
Experimental Models: Cell Lines 
LNCap clone FGC ATCC Cat # ATCC® CRL-1740 
DU 145  ATCC Cat# ATCC® HTB-81 
22Rv1 ATCC Cat# ATCC® CRL-2505 
PC-3 ATCC Cat# ATCC® CRL-1435 
293 [HEK-293]  ATCC Cat# ATCC® CRL-1573 
Experimental Models: Organisms/Strains 
Immunodeficient Athymic Nude mice - 
Foxn1nu 
Envigo Model# Hsd:Athymic Nude-
Foxn1nu --069 
Oligonucleotides: shRNA Clones 
See Table S5 for clones    
Recombinant DNA 
pMD2.G Laboratory of Didier Trono 
via Addgene 
Addgene plasmid #12259 
psPAX2  Laboratory of Didier Trono 
via Addgene 
Addgene plasmid # 12260 
Software and Algorithms 
MOMA Web application This paper http://www.mr-graph.org/ 
MOMA Bioconductor Package This paper https://bioconductor.org/packages/
release/bioc/html/MOMA.html 
R for Statistical Programming R Core Team, 2020 https://www.R-project.org/  
Complex Heatmap Gu et al., 2016 https://doi.org/10.1093/bioinforma
tics/btw313  
Q-Value Estimation for FDR Storey et al., 2020 http://github.com/jdstorey/qvalue  
ggplot2: Graphics for Data Analysis Wickham et al., 2016 https://ggplot2.tidyverse.org  
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VIPER R package Alvarez et al., 2016 https://doi.org/10.18129/B9.bioc.v
iper  
mixtools R package Benaglia et al., 2009 https://www.jstatsoft.org/article/vi
ew/v032i06  
DEBrowser Kucukural et al., 2019 https://debrowser.umassmed.edu/ 
clusterProfiler R package Yu et al., 2012 http://yulab-
smu.top/clusterProfiler-book/  
MutSig2CV Lawrence et al., 2013 https://software.broadinstitute.org/
cancer/cga/mutsig  
Mutation Assessor Reva et al., 2011 http://mutationassessor.org/r3/  
CHASM Carter et al., 2009 https://wiki.chasmsoftware.org   
GISTIC 2.0 Mermel et al., 2011 https://doi.org/10.1186/gb-2011-
12-4-r41  
PrePPI  Zhang et al., 2012 https://honiglab.c2b2.columbia.ed
u/PrePPI/index.html  
HumanNet v2 Hwang et al., 2018 https://www.inetbio.org/humannet
/  




2.5.2 Resource Availability 
Primary Dataset Information 
Source data for the analyses done in the paper is available from the TCGA Firehose Repository 
(gdac.broadinstitute.org, 2016-01-28 release). Full description of data types per sample (RNA 
sequencing, SNV and SCNA) acquired from TCGA firehose available in Supplemental Table 1. 
All samples with RNA sequencing data available were used in the analysis. Cohorts with fewer 
than 100 samples were not used. Further information about sample acquisition and relevant clinical 
annotations are available on the TCGA website. Fusion data was acquired from the Tumor Fusions 






The results of the analysis can be interactively accessed on our MOMA web application 
(http://www.mr-graph.org/). Code used to analyze the data has been compiled into a Bioconductor 
R package, MOMA, that can be downloaded here 
(https://bioconductor.org/packages/release/bioc/html/MOMA.html).  
 
2.5.3 Experimental Model and Subject Details 
Animals 
The immunodeficient NCr nude Spontaneous mutant model (Envigo; Product model: Mutant mice 
- Hsd:Athymic Nude-Foxn1nu - 069) was used for the MRB:2 xenograft validation experiments.  
All experimental procedures were approved by the Ethical Committee on Animal Research at 
IDIBELL, and have been authorized by the responsible Department of the Catalan Autonomous 
Government (File Number: FUE-2016-00307059; Project Number: 9025, Project coordinator: 
Alvaro Aytés). The barrier facility at IDIBELL is an AAALAC-certified facility.  Maximum cage 
density was 5 mice/cage and cages were placed in ventilated racks with water ad libitum and chow 
replenished weekly as well as clean new bedding.  All animals used in this study were 6 weeks old 
male athymic Nude-Foxn1nu (Envigo). Mice were monitored daily for signs of distress throughout 
the course of the experiment. 
 
Cell lines 
All cell lines were acquired from ATCC, as authenticated by them.  Growth medium for cells is as 
follows: LNCaP cells and 22Rv1 cells were grown in RPMI-1640 medium (Gibco) supplemented 
with 10% Fetal Bovine Serum (FBS; Sigma-Aldrich) and antibiotics (penicillin/streptomycin, P/S; 
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= 100 units of penicillin and 100 µg of streptomycin per ml of medium); DU145 cells were grown 
in Eagle’s Minimal Essential Medium (Gibco) supplemented with 10 % FBS and P/S; PC3 cells 
were grown in Ham's F-12K (Kaighn's) Medium (Gibco) supplemented with 10 % FBS and P/S; 
HEK-293 were grown in DMEM supplemented with 10 % FBS and P/S.  All cell lines were grown 
at 5% CO2 and 37C. 
 
2.5.4 Methods 
Sequencing Data and Activity inference 
RNA-Seq raw gene counts were downloaded from the TCGA firehose web site 
(gdac.broadinstitute.org, 2016-01-28 release), transformed to Reads Per Kilobase of transcript, per 
Million mapped reads (RPKM), using the average transcript length for each gene and log2 
transformed. Transcriptome-wide expression signatures were computed by two non-parametric 
transformations. First, each column (tumor sample) was rank transformed and scaled between 0 
and 1. Then each row (gene) was rank transformed and scaled between 0 and 1. Finally, regulatory 
protein activity was measured by the VIPER algorithm75, using tissue-matched ARACNE 
regulons145,146 (See Figure S2.1B).  
Systematic experimental validation has confirmed that VIPER can accurately measure 
differential activity for >80% of transcriptional regulator proteins, when ≥ 40% of the genes in a 
regulon represent bona fide targets of the protein75. In addition, multiple studies have 
experimentally validated that >70% of ARACNe-inferred targets represent bona fide, physical 
transcriptional targets—e.g., by Chromatin Immunoprecipitation (ChIP) and RNAi-mediated 
silencing, followed by gene expression profiling63–65,75—thus fulfilling the VIPER requirements 
for accurate protein measurement. The results of the VIPER analysis are reported as a Normalized 
63 
 
Enrichment Scores (NES) values of a protein targets in differentially expressed genes with respect 
to the centroid of TCGA, as assessed by aREA (see below). This has been shown to accurately 
characterize differential protein activity. Positive NES values (shown as a red gradient) indicate 
increased protein activity while negative NES values (shown as a blue gradient) indicate decreased 
protein activity.  
 
Genomic events  
Candidate genomic event data were downloaded from the TCGA firehose (gdac.broadinstitute.org, 
2016-01-28 release). For mutations and small indels, we downloaded Mutation Annotation Files 
(MAF) and selected all events annotated as non-silent alterations. For SCNAs, we downloaded 
SNP6 copy number profiles and selected a threshold of +/-0.5 as the value that provides an optimal 
tradeoff between sensitivity and specificity in capturing copy number changes, as discussed in the 
literature147.  
To ensure that copy number changes are functionally relevant, we adopted the approach 
discussed in the DIGGIT manuscript83. Specifically, only SCNA genes whose correlation between 
copy number and expression was statistically significant across a cohort were considered as 
functional candidates (Figure S2.1B). For the Genomic Saturation analysis, GISTIC2.0 results 
were downloaded from Firehose to better account for proximal copy number alteration events and 
to differentiate between focal (score of +/-2) and regional (score of +/-1) events. When multiple 
functional events were identified within the same amplicon, they were consolidated into a single 
event vector, thus preventing overcounting (Region Consolidation). However, for completeness, 
the MOMA Web App reports the identity of all events in an amplicon that pass the CINDy and 
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aQTL analyses. Finally, gene-fusion calls were called by the PRADA algorithm, and downloaded 
from the Tumor Fusions Gene Data Portal (www.tumorfusions.org, 2017-10-01 release)99,144. 
 
aREA Analysis 
The analytic Rank-based Enrichment Analysis (aREA) was introduced in75 as an analytical 
methodology to assess gene set enrichment analysis statistics, producing results that are virtually 
identical to GSEA50 without the need for time-consuming sample or gene shuffling. 
 
DIGGIT Analysis  
We implemented a slightly improved version of the DIGGIT algorithm. The original DIGGIT 
combined (a) a MINDy analysis step82 to identify proteins representing candidate upstream 
modulators of a MR protein (b) an aQTL analysis step to identify genomic events in candidate 
upstream modulators associated with statistically significant differential MR activity, and (c) a 
conditional association analysis step to eliminate genomic events that were no longer significant 
given another genomic event. The analysis was improved as follows: (a) rather than using mutual 
information, aQTL statistical significance is assessed by aREA-based enrichment analysis of 
samples, ranked by differential activity of the specific MR, in samples harboring a specific SNV 
or SCNA events, (b) the MINDy algorithm was replaced by CINDy79, providing a more accurate 
implementation of the conditional mutual information foundation of the algorithm, and (c) the 
conditional association analysis step was eliminated because it produced too many statistical ties 
when applied to pancancer cohorts; note that aQTL analysis was performed only for events 
occurring in ≥ 4 samples since fewer events are highly unlikely to achieve statistical significance 
(Figure S2.1C Step 2). The individual steps are described in the following.  
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CINDy Score  
Step 1: Proteins were first ranked by their VIPER statistical significance, integrated across all 
cohort samples using the Stouffer’s method for p-value integration148. 
 
Step 2 For each statistically significant differentially active protein (i.e. candidate MR) the 
conditional mutual information 𝐶𝑀𝐼 = 𝐼[𝑀𝑅, {𝑇+}|𝑀], between the expression of the MR and of 
its regulon genes, given the expression of any gene harboring a somatic event, was computed. 
Thus, CINDy identified mutation-harboring genes encoding for proteins that affect the ability of a 
MR to regulate its targets (Figure S2.1B).  
 
Step 3: For each event type (i.e. SNV, amplified SCNA, or deleted SCNA) all statistically 
significant CINDy scores for a given MR were integrated using Stouffer’s method to produce three 
global CINDy scores 𝑆0123 = −Log89(𝑝0123), 𝑆0
=>? = −Log89(𝑝0
=>?), and 𝑆0@AB =
−Log89(𝑝0@AB). Fusion events were not analyzed in this fashion since ARACNe is not designed to 
identify targets of fusion proteins. Thus, for fusion events, only the aQTL analysis step was 
applied.   
 
aQTL Score  
Step 1: Proteins were ranked by their VIPER statistical significance, integrated across all cohort 
samples using Stouffer’s method. This could be further improved in the future by integrating across 




Step 2: For each statistically significant differentially active protein (i.e. candidate MR) and 
somatic event (SNV, SCNA, or FUS), the statistical significance of the aQTL event was assessed 
by computing the enrichment of all cohort samples, ranked by the MR’s differential activity, in 
samples harboring the event, using aREA.  
 
Step 3: For each event type, a global aQTL score (𝑆CDEF) was computed as the −𝐿𝑜𝑔89(𝑃CDEF), 
with 𝑃CDEF  representing the integration of all statistically significant MR-event aQTL p-values 
(p ≤ 0.05) per MR for that event type, using Stouffer’s method. This produced three global aQTL 
scores 𝑆CDEF123 , for SNVs, small indels, and fusion events, 𝑆CDEF@AB , for SCNA deletion, and 𝑆CDEF
=>?  for 
SCNA amplifications. If ≥ 100 CINDy-inferred MR modulators were identified in a given cohort 
(see CINDy Score), then only aQTLs for somatic events harbored by genes with a statistically 
significant CINDy p-value were integrated. Otherwise, the p-values of all statistically significant 
aQTLs were integrated independent of CINDy results. This is because fewer than 100 statistically 
significant CINDy modulators indicates that the dataset is too small for a properly powered CINDy 
analysis.  
 
PrePPI Score  
PrePPI84 is used to identify structure-based protein-protein interactions between proteins encoded 
by genes harboring a somatic event and each MR protein.  
 
Step 1: Proteins were first ranked by their VIPER statistical significance, integrated across all 




Step 2: High-confidence interactions in the PrePPI database 1.2.0 (likelihood > 0.5) were assigned 
an empirical p-value as follows: first they are ranked based on their likelihood scores; then p-
values were computed as the fraction of interactions with equal or better rank, normalized by the 
total number of PrePPI interactions in the database.  
 
Step 3: For each event type, a global PrePPI score (𝑆K) was computed as the −𝐿𝑜𝑔89(𝑃KLMKKN), 
with 𝑃KLMKKN generated by integrating the individual p-values of all statistically significant PrePPI 
interactions (p ≤ 0.05) for that event type, using Fisher’s method (Jerby-Arnon et al., 2014). This 
produced three global PrePPI scores 𝑆KLMKKN123 , 𝑆KLMKKN@AB , and 𝑆KLMKKN
=>? . 
 
Integrated rankings and MOMA Scores  
Step 1: For each candidate MR, the p-values corresponding to same-type events (e.g., all SCNA 
deletions) as assessed by aQTL, PrePPI, and CINDy, were integrated using Stouffer’s method. For 
fusion events, CINDy and PrePPI scores cannot be computed and are thus not integrated. For the 
aQTL analysis, fusion events were considered equivalent to SNVs. This produced 9 integrated p-
values for each statistically significant, candidate MR protein: 𝑝CDEFOPQ ,	𝑝CDEF
STU , 𝑝CDEFVMW , 𝑝KLMKKNOPQ , 
𝑝KLMKKN
STU , 𝑝KLMKKNVMW , 𝑝0NPVXOPQ , 𝑝0NPVX
STU , and 𝑝0NPVXVMW .  
 
Step 2: After ranking all proteins in a cohort based on their VIPER score, we used Stouffer’s 
method to integrate the 9 p-values for each statistically significant protein (i.e., candidate MR) 
with its VIPER p-value, thus creating a global MOMA p-value (𝑝Y(𝑀𝑅)). The latter representing 
the probability that a protein may be a bona fide MR by chance. A global MOMA score was then 
computed as 𝑆Y(𝑀𝑅) = −Log89Z𝑝Y(𝑀𝑅)[ squared (Figure S2.1C).  
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Cluster Reliability Score (CRS)  
The CRS was introduced in130 as a statistically sound way to assess the fit of each sample within 
a cluster. For each sample, a distance vector V1, representing its distance from all other samples in 
the same cluster and a vector V2, representing its distance from all other samples in the cohort are 
computed. The sample distance matrix was computed by taking the weighted VIPER scores for 
each sample (VIPER activity values multiplied by each MR’s MOMA Score) and calculating the 
pairwise Pearson correlations. The normalized enrichment score of V2 distances, ranked from the 
largest to the smallest one, in V1 distances, is then assessed using aREA. This produces a p-value 
that represents the tightness and separation of the cluster being considered in relation to all other 
samples. A cluster-wide reliability score for each cluster is assessed as the average cluster 
reliability (NES) of each sample in the cluster, scaled between 0 and 1. Finally, the reliability of 
the entire clustering solution (global cluster reliability score) is assessed as the average of the 
cluster-wide reliability score of all clusters in the solution. 
 
Activity-based Clustering  
Each tissue-specific VIPER activity matrix was clustered using k-medoids clustering, with k 
ranging from 2 to 10 clusters, using a distance matrix defined by the weighted Pearson correlation 
between VIPER-inferred protein activity vectors. Weights were defined as the square of the 
integrated MOMA scores (𝑆Y\ (𝑀𝑅+)), thus increasing the contribution of high-scoring MRs 
(Figure S2.1D). Cluster Reliability Scores (CRS) were calculated for each sample and for each k 
value and the optimal number of clusters was determined as the first local maximum for the Global 
Cluster Reliability Score. We used a Kolmogorov–Smirnov test between the CRS of the samples 
from the optimal k-cluster solution (i.e. the one with the highest global reliability score) and the 
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CRS of the samples from every other k-cluster solution to identify solutions that were statistically 
indistinguishable. Among those, we selected the one producing the best survival separation, as 
described in Survival analysis. 
 
Silhouette Scores  
Silhouette Scores were computed as described in102. They were used purely for visualization 
purposes, since they are well-established as metrics to assess cluster reliability.  
 
Expression-based Clustering 
Similar to Protein Activity-based clustering, each tissue-specific gene expression matrix was 
clustered using k-medoids clustering with k set as the same value chosen for the tissue-specific 
VIPER activity clustering. Distance between samples was defined using Pearson correlation 
between gene expression profiles. Cluster Reliability Scores and Silhouette scores were computed 
as described in above.   
 
Survival analysis   
Clinical data was downloaded from the Broad Institute GDAC website (gdac.broadinstitute.org). 
We used the ‘survival’ R/CRAN package version 2.41-3 to fit a Cox proportional hazards model 
to each sample grouping defined by the initial clustering. We then defined the “best” survival 
clusters as the one with the lowest proportion of observed to expected death events, and the “worst” 
survival as the highest observed/expected ratio. We then fit a second Cox model exclusively to 
samples from those two clusters and calculated the significance of survival differences between 





Saturation curves were generated by ascertaining the number of functional somatic events 
upstream of the N most statistically significant candidate MR proteins, ranked by their global 
MOMA score. To assess an appropriate saturation threshold, we first assessed how many 
functional somatic events 𝑁^_8,\`a were upstream of the first half (1,253) of all regulatory proteins 
in that subtype, thus conservatively excluding proteins with a non-statistically significant VIPER 
activity. The saturation threshold then was set at 85% of that number 𝑁9 = 0.85 × 𝑁^_8,\`a. We 
then assessed how many of the N proteins with the highest VIPER activity were needed to identify 
𝑁9 somatic events in their upstream pathways. For all subtypes—except for 3 Ovarian cancer 
subtypes (S1, S3 and S4)—saturation increased so rapidly and significantly, compared to an 
identical number of randomly selected regulatory proteins (null hypothesis), that increases in event 
number for N > 100 MRs were not statistically significant. To avoid contaminating functional 
genomic events with passenger ones, by using non-significant MRs to assess saturation, we thus 
selected a more conservative saturation threshold 𝑁8 = 0.85 × 𝑁^_899. We used 𝑁8 for all 
subtypes except for the three ovarian cancer subtypes for which we used 𝑁9. 
 
Genomic Plots  
To visually represent genomic events upstream of MR proteins in each sample, as identified by 
saturation analysis, we used cBioPortal OncoPrint149, with ComplexHeatmap109. To avoid clutter, 
we restricted visualization to events previously reported as oncogenes and tumor suppressors33,150. 
However, all events can be downloaded from the MOMA Web App. For amplified or deleted 
SCNAs, we determined whether an oncogene or tumor suppressor had been identified by MOMA 
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as functional in that region, before region consolidation (see Genomic Events). For regions with a 
single oncogene/tumor-suppressor its name is used as representative of the SCNA. When two were 
detected, their names separated by a semicolon were used. When three or more were detected, the 
SCNA locus is used followed by “-multi.” Due to size constraints for figure representation, a 
maximum of 50 most frequent events is shown. However, complete driver event lists are available 
on the MOMA Web App. The option to generate OncoPrint plots with all genes is prioritized for 
the next version of the application. 
 
Driver Mutation Enrichment  
To assess the statistical significance of somatic event enrichment, upstream of checkpoint MRs, 
we performed a sample-specific analysis in each cohort. For each sample we identified activated 
MRs and their upstream somatic events using the same methodology described in the Saturation 
Analysis section. Then, for each sample, we computed the ratio of all validated CHASM151 and 
GISTIC2.0106  putative driver events vs. the total number of events (Figure S2.3C). To assess the 
cohort-level significance, we compared the number of samples with a ratio > 1 against a one-tailed 
binomial null distribution (p = 0.5). This showed that every cohort but one (LAML) showed 
significant enrichment in putative driver genes (Figure S2.3B). 
 
MRB Analysis 
The 407 MRs identified by saturation analysis that were also statistically significant in ≥ 4 
subtypes (recurrence analysis) were clustered based on their VIPER-inferred activity, using a 
Euclidean distance metric and partitioning around medoids (PAM) for k = 2 to 100 clusters 
(Figure S2.1E). To compute the Euclidean distance, each MR was associated with a 112-
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dimensional vector representing its VIPER-inferred activity in each subtype. A Cluster Fitness 
score was defined as the Average Cluster Reliability Score for all MRs in a cluster. The analysis 
identified k = 24 as the optimal clustering solution (Figure S2.5A).  Each “core-set” cluster 
identified by this analysis was then expanded by the m MRs with the best average Euclidean 
distance to those in the core-set, for m = 0, … 100. For each m additional MRs in each MRB, the 
trace of the covariance matrix of the Tumor Hallmark enrichment across the 24 MRBs was 
calculated to assess the total variance of the solution. This variance showed optimal increase for 
m = 6 (Figure S2.5B). These optimization steps to ensured uniqueness, specificity, and robustness 
of the MRB solution. 
 
Jaccard concordance index 
Each MRB is represented as a 112-dimensional vector representing its statistically significant 
activation (1), inactivation (-1) or neutral (0). The Jaccard concordance index between two MRBs 
is the scalar product of their associated vectors, such that co-activation or co-inactivation of the 
MRB in the same subtype increases the score by 1 while non-concordant activity in a subtype does 
not increase the score.   
 
MRB Enrichment Analysis 
Cancer Hallmarks include 50 gene-sets defined by the Broad Institute and refined/simplified by 
others49,111. To calculate downstream enrichment, we pooled genes from the regulons of each MR 
in each MR block that had a highly significantly likelihood of being a physical target (p < 0.05) 
and that were identified in at least 2 different tissues.  We then assessed enrichment using the 
hypergeometric distribution between MR targets and each Hallmark’s gene set. The same 
73 
 
approach was used to compute enrichment in KEGG and Reactome gene sets. Significance was 
assessed by Benjamini-Hochberg False Discovery Rate (FDR) to account for multiple hypothesis 
testing. Only significant enrichments (FDR < 0.05) are shown. To calculate enrichment of genomic 
events upstream of MR blocks, we selected the top 100 most significant predicted upstream 
genomic events, for both SNVs and functional SCNA genes, in subtypes with significant MRB 
activity (p < 10-3). The hypergeometric overlap between these gene sets and the Hallmark, KEGG 
and Reactome gene sets was performed as described above. A fixed event number was chosen to 
avoid biasing the statistical analysis for MRBs with a greater number of upstream events. All 
enrichment analyses were done using the enricher function from the R clusterProfiler package152. 
 
Achilles Essentiality 
Achilles shRNA DEMETER knockout scores were downloaded from The Broad Institute for all 
cell lines in CCLE for all TFs and co-TFs analyzed by MOMA.  To identify a natural threshold to 
assess essentiality, Achilles dependency scores were re-normalized by fitting a bimodal normal 
mixture models using the R package ‘mixtools’ 153.  The normal probability density with the most 
positive (i.e., least essential) mean was set as the null-hypothesis (essentiality null hypothesis 
probability density) to assess essentiality as a z-score.  This allows setting an appropriate null 
hypothesis to assess essentiality on a gene by gene basis.  
For each of the 112 MOMA subtypes, we matched the MR activity vector, weighted by the 
cohort-specific MOMA score of each MR, to the protein activity profile of each CCLE cell line, 
using the ‘viperSimilarity’ algorithm included in the VIPER algorithm75, thus identifying the cell 
lines that best recapitulates subtype-specific MRs as possible dependencies. We then assessed the 
essentiality of each MR in cell lines that were significant matches (p < 0.01; Bonferroni correction) 
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vs. those providing clear non-matches (p = 1) using a non-parametric rank-based Mann-Whitney-
Wilcox test based on the null hypothesis probability density defined in the previous paragraph; 
significant FDRs after multiple hypothesis correction (Benjamini-Hochberg FDR < 0.05) were 
considered essential subtype-specific MRs. Essentiality was then stratified for each MR across the 
subtypes where that MR was statistically significantly active. To calculate statistical significance 
of the enrichment of essential genes, a null model was built by taking 106 random selections of 
MRs equivalent to the number of MRs in each tumor checkpoint and then counting the number of 
essential MRs across all subtypes. These permutations were then fitted to a normal distribution 
(Figure S2.5F). 
 
METABRIC Breast cancer analysis  
ARACNE was run with 100 bootstrap iterations and a mutual information significance threshold 
of p = 10-8, separately for candidate TF and coTF regulators, using METABRIC gene expression 
profile data. For each sample, protein activity was inferred using VIPER. Survival analysis was 
performed by first calculating the mean VIPER activity across checkpoint proteins and binning 
samples into “high” and “low” quantiles, for each checkpoint. Clinical data was downloaded from 
the cBioPortal. We used the ‘survival’ R/CRAN package version 2.41-3 to fit a Cox proportional 
hazards model to each sample grouping, using the last known follow-up date, and testing for 
significant survival differences with that model.  
 
MRB:2 Analysis 
For each of the candidate Master Regulator proteins in MRB:2 we computed the rankings based 
on the integrated p-value of each MR-event in prostate cancer, as well as the cross-pancancer 
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rankings for the same interactions. For each MR and each somatic event, p-values were generated 
as discussed in the DIGGIT methods section. A joint rank from these two lists was then created 
using an additive mean and the top 20 interactions were retained for each MR. These Interactions 
were visualized as a network graph (Figure 2.6F) with the Cytoscape software 
package154.  Network edges between MRB:2 proteins and mutation events identified in Figure 
2.6F were included in the sample/event plot (Figure 2.6E). Events with significant copy number 
associations were also included if they contained one or more samples with a mutation in that same 
protein. Additionally, for interactions with only copy number events (deletion, amplification) we 
computed the aREA association score with the average activity of MRB:2, and selected the top 10 
most significant deleted and amplified genes, respectively, to include on the plots. 
 
MRB:2 Validation 
Lentiviral-mediated gene silencing 
Silencing of SORBS3, BCAR1, MAP3K7, PTEN, Tp53 was achieved by lentiviral delivery of 
validated shRNAs. Two target-specific shRNAs in the pLKO.1 lentiviral vector were co-
transfected in HEK-293 cells together with the pMD2.G and psPAX2 envelope and packaging 
plasmids in 1% FBS. pMD2.G and psPAX2 were gifts from the laboratory of Didier Trono 
(Addgene plasmid # 12259; http://n2t.net/addgene:12259; RRID:Addgene_12259 and Addgene 
plasmid # 12260; http://n2t.net/addgene:12260; RRID:Addgene_12260) Supernatants were 
recovered at 24 and 48 hours and were later concentrated using the Lenti-X concentrator reagent 
(Takara #631231).  The 22Rv1 human prostate cancer cell line was spin-infected at multiplicities 
of infection (MOI) of approximately 1 in the presence of 8 µg/mL polybrene (hexadimethrine 
bromide), then incubated with virus for approximately 18 hours in a 37°C, 5% CO2 incubator. At 
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48h post-infection, cells were selected with 2 µg/mL puromycin and at 96h post-transduction 
medium was changed to fresh complete medium. Efficiency of gene silencing was assessed by 
qPCR using primers for each of the targets and comparing target expression against cells 
transduced with the MISSION® Non-Target shRNA Control Transduction Particles. 
 
Perturbation dataset VIPER analysis 
To assess the effect of selected gene silencing on MRB:2 MRs, we generated a signature for count 
data from each experimental condition, using the control condition as a reference, and performing 
a t test, using 100 permutations of the samples (columns) as a null model. This signature and null 
model were inputted to the ‘msviper’ function in the VIPER Bioconductor package, along with 
the TCGA Prostate cancer regulon. A second null model was constructed by re-running this same 
analysis on 100 permutations of the column labels, and a t-test was performed between the VIPER 
scores from each condition and this null, to assess the overall ability in reverting the signature for 
checkpoint 2 proteins.  
 
Wound Healing Assays  
Control and silenced cells where seeded at high concentration in 6 well plates in triplicate using a 
silicone insert. At day 1 the silicone insert was removed and cell migration into the gap was 
monitored at 24h, 48h and 72h hours. The percent of migrating cells was quantified, relative to 
non-targeting controls, by measuring the cell-free area with ImageJ software.  A Mann–Whitney 
U test was used to calculate the significance (P value) of the difference between the control (n=3 




Matrigel invasion assays  
5 × 104 cells were seeded in the BD FluoroBlok inserts (BD Biosciences) in FBS-free media. 
Inserts were placed in 24-well plates containing RPMI supplemented with 10% FBS as 
chemoattractant. Invasion was monitored using a bottom-reading fluorescence plate reader and 
invading cells detected using calcein AM fluorescent labeling. The fluorescence signal was 
quantified with ImageJ, and a Mann–Whitney U test was used to calculate the significance 
(p-value) of the difference between the control (n=3 replicates) and gene-silenced cells (n= 6 
replicates; 3 for shRNA shRNA#1 and 3 for shRNA#2). 
 
Xenograft assays  
IDIBELL´s Institutional Animal Care and Use Committee (IACUC) had approved all animal 
procedures. For analyses in vivo, 5 × 106 22Rv1 cells expressing the control or target shRNA 
lentivirus were mixed with Matrigel (1:1 vol/vol) and injected into the right flank of 
immunodeficient nude mice (Envigo, Nude-Foxn1nu); tumor growth was monitored with calipers 
until one of the experimental groups reached the maximum 1.5 cm3 tumor volume. One-way 
analysis of variance (ANOVA) was used to calculate statistical significance (p-value) of the 
difference between control and silenced groups. 
 
MRB:14 Validation 
Analysis of Enzalutamide-treated LNCaP cells   
Gene counts for this dataset were downloaded from Gene Expression Ominibus, (GEO), accession 




MRB:14 Drug Prioritization  
We used a dataset of protein activity profiles of drug response, as inferred from a screening of 120 
FDA-approved drugs and 217 late-stage experimental compounds (in Phase 2 and 3 trials) in the 
DU145 prostate cancer cell line. Profiles were generated at 24h following perturbation with the 
compound’s IC20 concentration determined at 48h by 7-point dose response curves. This 
concentration was selected to represent the highest sub-lethal concentration that would help 
elucidate the compound mechanism of action without significantly triggering additional cell 
response mechanisms, e.g., associated with drug stress response or cell death, that would confound 
the analysis.  
The aREA function from the R VIPER package 1.20.0 was used to compute a Normalized 
Enrichment Score (NES) for each drug, based on the enrichment of differentially activated 
proteins, as inferred by VIPER, in MRB:14 MRs. NES values were converted to p-values and 
corrected for multiple hypothesis testing, using the Bonferroni method. Finally, -Log10 p was used 
as a score to prioritize drugs and statistically significant drugs, with scores greater than two, were 
considered as potential candidates to elicit MRB:14 activation. 
 
Analysis of prostate cells and tumor biopsies 
Gene expression data (counts) from two studies124,125 were collected.  Both studies were analyzed 
in the same way as follows.  Counts downloaded from the GEO portal (GEO accession GSE48403, 
and GSE067070) were normalized using the variance stabilizing transformation function available 
from the DESeq2 package 1.26.0 in R. The metaVIPER approach156, available from the R VIPER 
package, was then used to generate two interactomes from the TCGA PRAD cohort (this 
manuscript) and the 2015 SU2C metastatic Castration Resistant Prostate Cancer (mCRPC) 
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cohort157. Regulons were pruned to the top 100 targets with the highest likelihood using the 
pruneRegulon function of the VIPER package.  Gene expression signatures for each individual 
sample were computed using the method ttest available from the viper function. Enrichment 
analysis on VIPER-inferred protein activity signatures was computed and resultant NES scores 
used.  Clustering of labeled samples due to similar activation profiles of MRB:14 on patient 
samples was performed using the hierarchical clustering algorithm available from the 
ComplexHeatmap package. 
 
BRCA and BLCA enrichment in MRB:14 activity  
Data for PAM50 annotation and luminal/basal subtyping from two studies on TCGA BRCA158 and 
BLCA159 were downloaded.  Protein activity profiles for the TCGA BRCA and BLCA cohorts 
were computed and enrichment scores for MRB:2 and MRB:14 derived.  MRB:2, which is a 
proliferation-associated block (described above), was used as a control.  Patients were sorted based 
on activity NES scores to show correlation between high MRB:14 activity and luminal subtypes 
as determined by published PAM50 classifiers. 
 
Additional reagents 
Small molecule compounds were purchased from Selleck Chemicals (Houston, TX).  Culture 
inserts for migration studies were from iBidi (Gräfelfing, Germany, #80209). 
 
Western Blotting  
Cell pellets were lysed in buffer composed as follows: 50mM Tris-HCl, pH 7.5; 250 mM NaCl; 
50 mM NaF; 10 mM Na-pyrophosphate; 2.5mM EDTA; 2.5 mM EGTA; 2 mM sodium 
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orthovanadate; 2% CHAPS; 0.5% Triton-X100; Phosphatase cocktail 3 from Sigma at 1:15 
dilution; Protease cocktail (Pierce) 1:15 dilution. After SDS-PAGE separation of equal amounts 
(~30 ug) of protein lysate from each sample, proteins were transferred to PVDF membranes and 
then probed with antibodies using standard procedures. Primary antibodies were as follows: AR 
(Cell Signaling Technology, # 5153S); GRHL2 (Millipore Sigma, #HPA004820); SPDEF 
(Proteintech, #11467-1-AP); g-catenin/JUP (BD Biosciences, #610253); CDH1 (BD Biosciences, 
#610404), diluted 1:1000 each. 
 
 
Wound Healing Assays   
These assays were performed using manufactured cell culture inserts with a defined cell-free gap 
(iBidi) in 6-well plates. DU145 cells were plated in the inserts at 4 × 105 cells per ml (70 uL per 
channel).  At 24 hrs after plating cells images of the gap were taken (T = 0) and medium was 
replaced with medium containing the drugs, or DMSO as vehicle control.  All drugs were tested 
at their EC50 concentration, 7.2 µM, 1.2 µM, 44 nM, and 8.77 µM for fedratinib, pevonedistat, 
lexibulin, and ENMD-2076, respectively. Negative control drugs were also tested at their EC50 
concentration, 1.65 µM, 3.5 µM, and 28nM for triapine, dorsomorphin, and raltitrexed, 
respectively.  After 24 hrs (T = 24), additional images (n ≥ 3) were taken along the full length of 
the gap for each treatment.  Images were analyzed using the MRI Wound Healing Tool macro 
(http://dev.mri.cnrs.fr/projects/imagej-macros/wiki/Wound_Healing_Tool) installed in ImageJ.  
Total gap area was calculated per image and averaged across images for a given sample and 





Chapter 3: Multi-omic Analyses of Gastroesophageal Cancer  
3.1 Introduction 
3.1.1 Gastroesophageal Incidence and Treatment 
Globally an estimated 1.5 million new cases of gastric and esophageal cancer have been diagnosed 
in 2018, making them collectively one of the most commonly diagnosed malignancies in the 
world3,160. As of now, available treatment options are minimal and recurrence is very common, 
thus contributing to dismal outcome for these tumors, with close to 1.3 million deaths in 20183,160. 
In particular, targeted therapy options are limited and immune checkpoint inhibitors have so far 
proven only partially effective. Until the mid 1990s, gastric adenocarcinoma was the leading cause 
of cancer-related death in the world. However, incidence of this disease has declined over the past 
several decades, primarily due to decreases in H. pylori infection prevalence in more developed 
countries as well as improvements in food preservation and preparation and early screening in 
Asian countries161. Obesity, age, alcohol consumption, acid-reflux disease and smoking have been 
associated with increased risk of both gastric and esophageal cancer incidence. As a result, aging 
populations, with increased prevalence of metabolic syndrome, are beginning to shift this trend162.  
  Histologically, esophageal cancer is divided into two subtypes, adenocarcinomas and 
squamous cell carcinomas160. Adenocarcinomas are tumors that arise from mucus producing cells 
while squamous cell carcinomas are derived from squamous cells as their name implies. Squamous 
cell carcinomas are presently the most common subtype of esophageal carcinomas, making up 
84% of cases globally, but in high-income countries in Northern Europe, North America and 
Oceania, adenocarcinomas dominate and are on the rise in other countries as well160. On the other 
hand, gastric cancers almost exclusively comprise adenocarcinomas (90-95%), with stromal 
tumors (GIST), neuroendocrine tumors (NETs) and lymphomas making up the bulk of the 
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remaining 5-10%163. Gastric adenocarcinomas are then usually divided into two histological 
subtypes based on Lauren’s criteria: intestinal and diffuse164. Intestinal type adenocarcinomas are 
typically well differentiated and cohesive structures that frequently become ulcers. Diffuse type 
usually presents without cell cohesion and instead results in thickening of the stomach wall but 
doesn’t form a discrete mass165. Gastric cancer can also be classified anatomically as based on 
proximity to the esophagus. Those that occur in the proximal areas of the stomach including the 
cardia, fundus and body are collectively classified as cardia tumors while those occurring in the 
distal areas including the antrum and pylorus are considered non-cardia160,163. Though research 
and epidemiology suggest that there may be different etiologies driving these subtypes they do 
share a number of similar features and as of yet no good differentiated treatments exist as based 
histology alone. 
 The recent changes in incidence for gastroesophageal cancers are predicated primarily on 
environmental shifts and geographic differences as clinical treatment has made little to no 
improvement over the intervening years. Complete surgical resection of all components of the 
tumor, known as radical gastrectomy, is the only current cure for gastric cancer but is not 
appropriate or doable in all cases166. Esophagectomy, meaning the complete or partial removal of 
the esophagus, is similarly the current standard of treatment for patients with esophageal 
carcinomas but these procedures are incredibly invasive with high incidence of morbidity, 
mortality and overall reduction in patients’ quality of life167. Increasingly, multimodal adjuvant 
chemotherapy regimens are being incorporated into treatment but meta-analyses of the clinical 
trials show mixed results in terms of improved survival168–170. One meta-analysis in particular 
found that significant differences exist in the effect of chemotherapy on cancers between Asian 
and European patients, suggesting that ethnic and environmental variables may play a role, though 
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this is confounded by cultural differences in clinical care171. Historically, different combinations 
of 5-fluorouracil and its derivatives, cisplatin or other platinum agents, and radiation have 
generally been used as adjuvant therapies as they increase survival as compared to surgery alone 
by about 15%171–174. Notably this improvement in survival is mostly found in Asian cohorts but 
not in Western clinical trials175. More recently, addition of docetaxel, a taxane, was found to be 
effective for perioperative chemotherapy, so now the reference regimen for resectable tumors is 
FLOT, a combination of 5-fluorouracil, folinic acid, oxaliplatin and docetaxel, but long-term 
addition of docetaxel can lead to more toxicities168,175.  
Heterogeneity in response to conventional therapies in addition to advancement in 
personalized treatments of other tumors has led to several attempts to differentiate treatment for 
gastroesophageal cancer patients on a molecular basis, for instance using genetics. Trastuzumab, 
a human epidermal growth factor 2 (HER2) antibody, has been used in cases where patients have 
a large number of HER2 amplifications (HER2+) and clinical trials have shown statistically 
significant but marginal increases in survival compared to chemotherapy alone172,176,177. Based on 
the results of these clinical trials Trastuzumab has been approved to be added to chemotherapy 
adjuvant care in HER2+ gastric cancer cases but these only occur in about 15-20% of patients, and 
is seemingly only effective in patients with a very high large number of HER2 copies168. Currently, 
several clinical trials are also underway to test the use of two anti-PD-1 antibody treatments, 
nivolumab and pembrolizumab across both gastric and esophageal cancers. For most of these trials 
they are being tested for efficacy as a second or third line of treatment after failure of earlier 
treatments but preliminary results are promising. Unfortunately, however, it is estimated that 
≤ 25% of patients will respond to immune checkpoint inhibitors, thus limiting their overall 
use167,175,178. A number of other clinical trials for specific targets—including EGFR, MET, 
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PI3K/mTOR and PARP inhibitors—have yielded disappointingly negative results175,179–185. While 
some of these trials show some promise for further treatment tailoring, the biggest challenge to 
moving forward with patient specific care is the lack of specific molecular targets due to the highly 
heterogeneous molecular signatures underpinning these tumors. 
 
3.1.2 Molecular Classifications of Gastroesophageal Cancer 
Over the past decade, increasing access to gene expression profiling technologies has helped 
multiple groups investigate the distinct molecular signatures characterizing gastric cancers in large 
patient cohorts. Work by researchers at the National University of Singapore, using gene 
expression patterns across 248 Singaporean and 70 Australian patients, identified three gastric 
adenocarcinomas subtypes, including proliferative, metabolic and mesenchymal186.  The results of 
this study showed promise as different subtypes presented differential response to specific 
treatments, when tested on matched cancer cell lines. A prospective clinical trial sponsored by this 
group is currently ongoing to investigate the feasibility of genomic-guided treatment based on 
these proposed subtypes187. In a seminal paper released by The Cancer Genome Atlas research 
group in 2014, molecular analyses integrating data from RNAseq, protein, mutation, and copy 
number profiles delineated four different subtypes, including Epstein Barr Virus (EBV) positive, 
Microsatellite Instability (MSI), Chromosomal Instability (CIN), and Genome Stable (GS)188. A 
later study that included a pan-analysis of all the cancers in the gastrointestinal tract (esophagus, 
stomach, intestines, and colon) revealed a fifth subtype of Hypermutated samples with Single 
Nucleotide Variants (HM-SNV)189. Subsequent studies by other researchers showed that these 
groups were associated with different prognoses and responses to adjuvant chemotherapy, when 
the classification was applied to an independent cohort with additional post-resection follow up 
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data190. Moreover, retrospective meta-analysis of 1,552 patients, accrued by four clinical trials, 
showed that microsatellite instability status could be used as an effective predictor of good 
prognosis, both in terms of overall and progression-free survival175,191. Notably, patients with 
microsatellite instability had significantly longer overall survival following surgery, with no 
adjuvant chemotherapy, while patients with microsatellite stable tumors had the opposite response. 
Work done by the Asian Cancer Research Group (ACRG) in South Korea over the last several 
years led to identification of four different subtypes, including mesenchymal-like, microsatellite 
unstable, TP53 active, and TP53 inactive192–194. Their subtypes also showed significant, albeit 
slight differences in prognosis and recurrence for the molecular subtypes identified by their 
analysis. Because of the open data availability, most of the groups applied their classification 
schemas to the other cohorts and were able to recapitulate them, with some level of overlap. This 
suggests that, despite the high molecular heterogeneity of gastric cancer, there are molecularly 
distinct subpopulations. However, lack of consensus and harmonization across these different 
classification schemas suggests that the optimal molecular classification of this disease may still 
be elusive. Moreover, all of these classification attempts are based almost entirely on gene 
expression data. Indeed, despite including data from mutational profiles and copy number variants, 
the causal biological determinants of the identified subtypes are still undefined, thus stymying 
development of targeted therapeutic interventions. 
Other than our analyses in the first MOMA paper, no prior work has investigated the master 
regulator drivers of gastroesophageal cancer. In that analysis, only gastric adenocarcinoma 
samples could be considered because the esophageal adenocarcinoma cohort in TCGA was too 
small to produce statistically sound results. Thus, the pancancer version of MOMA only captured 
the broadest features of the gastric tumor type, failing to reveal a fine-grain genetic and 
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transcriptional picture of this disease.  For this more in-depth analysis, samples from both cohorts 
were combined, since recent studies have revealed a high degree of similarity between the two189.  
In the work below, I apply an improved version of the MOMA framework in combination 
with an iterative clustering methodology to the merged gastroesophageal adenocarcinoma cohort 
of samples from the TCGA. My results identify 15 molecularly-distinct subtypes that more 
effectively capture the genetic and transcriptional heterogeneity of this disease, illuminate critical 
combinatorial biological processes upstream of key MRs, and harmonize across other published 
datasets. I propose that this novel, molecular-level taxonomy of gastroesophageal cancer, when 
combined with the elucidation of novel MR-based dependencies and with the subtype-specific 
drug predictions by the Califano lab’s CLIA certified algorithms OncoTarget and OncoTreat130 
algorithms, will help to increase the application of precision medicine approaches in individuals 





3.2.1 MOMA Regulator Ranking and Iterative Clustering 
The analyses of this work build off of our previous MOMA framework but include a number of 
key improvements85. All raw data was acquired from the TCGA FireBrowse data repository and 
processed in the same manner described in the MOMA paper. Briefly, gene expression profiles 
from 462 STES (stomach and esophageal adenocarcinoma) patients were first transformed to 
protein activity using the VIPER algorithm using an interactome built on the same samples63,75. 
For the main set of analyses, I generated an internal signature for the VIPER transformation, i.e. I 
designed the analysis to accentuate differences between the STES samples themselves versus 
comparing them to all the samples across the TCGA as was done in the first version the analysis. 
This has been shown in previous VIPER analysis to better highlight subtle subtype 
differences64,143. I then identified global candidate MR proteins as described previously, by 
Fisher’s integration of p-values for (a) their VIPER-measured activity, (b) functional genetic 
alterations in their upstream pathways, by DIGGIT analysis83, and (c) additional structure and 
literature-based evidence supporting direct protein-protein interactions between TRs and proteins 
harboring genetic alterations, via the PrePPI algorithm84,85. The vector of integrated -Log10 p 
values (Global MOMA Scores) were then used as weights for each TR during the clustering step. 
This was done with the intention of giving more weight to TRs that had more supporting evidence 
that they would be drivers as based on calculated associations with candidate genomic events. 
For this analysis I also implemented an adapted version of the iterClust framework to 
interrogate the more granular subtypes present in the STES cohort195. Large differences may exist 
in a cohort of samples that can mask more subtle but significant variations when traditional single 
pass clustering methods are applied. Repeated clustering within initially identified groups can thus 
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be informative towards revealing these differences once stronger features of division are already 
accounted for. The workflow proceeded in the following manner: 
Input: STES VIPER matrix weighted by the Global MOMA Scores for each TR as 
calculated across the cohort 
1. Iteration n start 
2. Generate clustering solutions for the samples of interest using PAM (partitioning 
around mediods) clustering for k of 2-9. The distance between each sample was 
calculated using pairwise Pearson correlation. 
3. Select the best clustering solution as based on the highest average silhouette score 
across all samples.  
4. Remove samples determined to be outliers (having a silhouette score < 0.10) in 
order to promote finding true, high quality clusters. 
5. Repeat steps 2-4 within each cluster as determined by the n-1 iteration until all 
clusters have stabilized and are determined to be homogenous. 
6. For every sample that was determined to be an outlier across the analysis, test its 
similarity to each of the resulting clusters. If its new silhouette score for one of the 
clusters is above 0.10 then it is added back in to that cluster. 
While this was the overall method for the clustering analysis, certain parameters were used to 
ensure high quality homogeneity and stability of clusters throughout the process. Specifically, for 
Step 3 when determining the “best” clustering solution for all iterations, a new clustering solution 
was only selected if the average silhouette scores of the samples was higher than 0.20 to ensure 
high quality clusters. Additionally, if any clustering solution resulted in clusters that all had fewer 
than 10 samples it was not selected as I reasoned that having small clusters would artificially inflate 
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the resulting average silhouette scores as there would not be sufficient samples to draw 
comparisons from. Lastly, after retesting outlier samples in Step 6, all samples that did not have 
an individual silhouette score of > 0.10 for any of the clusters were determined to be full outliers 
and not added back in.  
 Using this method resulted in 15 stable clusters across 221 samples before outlier re-
clustering and 362 after 141 were added back in. Though this resulted in 100 samples from the 
cohort being removed as outliers, this could be because they are too unique to have a sufficient 
number of samples similar to them. Analyses of the outliers showed no specific clinical enrichment 
of any features as compared to the rest of the samples, suggesting it was not a specific feature 
collectively driving their difference from the rest of the samples. In order to assess the quality of 
the clustering, I used the sample labels from the recent PanGI analysis from the TCGA, as 
described previously189. Briefly, they are Epstein Barr Virus Positive (EBV), Microsatellite 
Instable (MSI), Hyper-mutated Single Nucleotide Variant (HM-SNV), Chromosome Instable 
(CIN), and Genomically Stable (GS). While these are not a pure gold standard, they delineate key 
biological patterns throughout the cohort and I wanted to determine if my unsupervised clustering 
methodology, which was agnostic to these labels, recaptured this biology. In addition to these 5 
labels, I also labelled samples as based on the degree of their HER2 amplification as this was also 
a biological phenotype of interest. Currently, Trastuzumab therapy for HER2+ gastroesophageal 
tumors is the only biomarker driven treatment, but there is a clear heterogeneity in patient response 







Figure 3.1 MOMA Methodology Overview 
(A) General schematic for the integrated MOMA methodology and the bottleneck hypothesis. See 
Figure 2.1A for full description. (B) A schematic for the iterative clustering, showing the influence 
of certain features at different iterations. 
 
One of the benefits of the step wise progression of this type of clustering is that I could track the 
driving differences for each iteration, similar to hierarchical clustering. As seen in Figure 3.2, 
each iteration promoted increased separation of the labels of interest. Iteration 1 split the cohort 










and MSI samples. C2 on the other hand contained almost all of the GS and EBV labelled 
samples (Figure 3.2A). The second iteration split C1 into two clusters, C1.1 and C1.2, in this 
case separating into clusters dominated by CIN and a mix of CIN and MSI respectively. C2 was 
divided into 3 clusters, C2.1, C2.2 and C2.3, effectively putting all of the GS samples in C2.1 
and all of the MSI samples in C2.2 (Figure 3.2B). Two more rounds of subsequent clustering led 
to a stabilization of 15 clusters with significant stratification of a number of different TCGA 
labels across them. (For simplicity final subtype clusters will henceforth be referred to using S 
and their final cluster number, from 1-15 and not using the nomenclature including their parent 
cluster, ie C1.1.1.1 will instead be S1). See Figure 3.2 for final subtype delineations and Table 
3.1 for specific enrichment statistics. 
 
Table 3.1 Final Subtype Summary Statistics 






CIN HM-SNV MSI GS EBV 
1 1.1.1.1 67 0.36 2.8E-08 1 1 1 1 
2 1.1.1.2 28 0.12 0.0087 1 1 1 1 
3 1.1.2.0 15 0.06 0.018 1 1 1 1 
4 1.2.1.1 32 0.32 1 1 1 1 1 
5 1.2.1.2 11 0.13 1 1 1 1 1 
6 1.2.2.1 18 0.14 1 1 2.9E-04 1 1 
7 1.2.2.2 11 0.32 1 1 6.0E-04 1 1 
8 2.1.1.2 41 0.20 1 1 1 9.8E-08 1 
9 2.1.1.3 33 0.23 1 1 1 1 9.9E-04 
10 2.1.2.0 12 0.03 1 1 1 1 1 
11 2.1.3.1 44 0.23 1 1 1 0.0031 1 
12 2.2.2.0 10 0.25 1 1 1 1 0.0021 
13 2.2.3.0 14 0.37 1 1 1.0E-08 1 1 
14 2.3.1.0 16 0.14 1 1 0.018 1 0.16 







without outliers with outliers
**** * *










Figure 3.2 Results of Iterative Clustering 
(figure on previous page). (A-E) TSNE plots of samples colored by their cluster assignment for that 
iteration. Bars across the top show TCGA classification labels, tumor tissue location and HER2 
amplification respectively. (F) Silhouette scores for the final clustering solution both without 
outliers and with them added back in. (G) Color legend for panels A-E. **** p < 0.00001;  *** p < 
0.0001 ;  **  p < 0.001; * p < 0.05 
 
In addition to being enriched in a number of previously identified biological labels, the resulting 
subtypes also had a number of notable differences in survival. Comparison of survival across all 
15 clusters at once did not reveal significant differences (p = 0.21 by Kaplan-Meier) (Figure 3.3A) 
in part because of the number of subtypes and because this cohort has been notoriously hard to 
stratify based on survival due to limited outcome data. Looking at specific subtype pairs does 
illuminate some significant differences. Specifically, comparing S6, the subtype with the best 
survival, to the two subtypes with the worst survival, S3 and S12, results in significant survival 
separation (p = 0.001 and p = 0.0098). Additionally, comparing S6 to the two subtypes enriched 
in GS samples, S8 and S11 also revealed significant separation (p = 0.047) which is concordant 
with the fact that patients who have GS tumors tend to have the worst outcomes.  
 
3.2.2 Tumor Checkpoint MRs 
As defined in the original MOMA paper, a Tumor Checkpoint is a module with the minimum MRs 
necessary to implement a tumor’s transcriptional identity by canalizing genomic events in its 
upstream pathways. In order to calculate this, we used saturation analysis as previously described 
to refine the ranked list of regulators (based on their MOMA scores) to the subset necessary to 
optimally account for each subtype’s genetic landscape. In the first version of MOMA the same 
Global MOMA ranking was used across every subtype, thus minimizing the effect a small number 




Figure 3.3 Survival Curves for the Final 15 Subtypes 
 
this, I improved upon the original framework by re-ranking the candidate TRs on a subtype by 
subtype basis to generate a Subtype Specific MOMA ranking to use for the saturation analysis. 
This was done by taking the resulting subtypes from the clustering analysis and repeating the 
integrated ranking methodology, but only considering genomic events that were over represented 
in that subtype as compared to the cohort as a whole. Subtype specific events were considered to 
be over represented only if they occurred in more than 2 samples in that subtype and if they had a 
p > 0.50 after doing a proportions test and using FDR for multiple hypothesis correction. Using 
this methodology to re-rank TRs prior to the saturation calculation in combination with the 
iterative clustering improved the quality of the tumor checkpoint analysis by increasing the overall 
saturation percentages captured across the cohort (Figure 3.4). In the first version of the analysis, 
the saturation percentages for the 3 clusters ranged from 4.0% - 21.4% (average = 13.7%). In the 




improvement. In this way, the analysis more accurately captured the different upstream biology of 
each more granular subtype versus focusing only the largest signals across the whole cohort. 
 
 
Figure 3.4 Genomic saturation analysis of candidate master regulators. 
As described in Figure 2.3, Individual curves show the average fraction of functional genomic 
events in each sample identified upstream of the top n MOMA-inferred MR proteins for each 
subtype, as n increases from 1 to 100. Saturation curves produced by the null-hypothesis—i.e., n 
randomly selected MRs from 1,253 non-statistically significant regulatory proteins (i.e., the 
bottom half of all MOMA-ranked proteins)—are shown in gray. Vertical dashed line indicates the 
saturation threshold. (A) The results from the first MOMA analysis vs (B) the results of the 
present analysis. 
 
To further validate the biological quality of these predicted checkpoint MRs (cMRs) I then 
tested to see if they were enriched in essential genes as based on the Achilles Project data113. I used 
a workflow similar to the one detailed in the original MOMA analysis but with updated Achilles 
results from their Quarter 1 2021 release, see Figure S2.5 (in Appendix A). Briefly, I took the 
VIPER protein activity profiles for each sample and used Stouffer’s Integration for each TR across 
each subtype to generate a single integrated VIPER profile to represent each subtype. Gene 
expression profiles from all available cell lines from the CCLE were then transformed into VIPER 






protein activity profiles and viperSimilarity was used to calculate similarity scores between each 
of the 15 integrated subtype profiles and each cell line. The top and bottom 25 TRs were used for 
the similarity scoring as this has been shown to optimally find matches based on relevant biological 
signal and not artifacts from cell lines or other models. Cell lines were considered a match if their 
similarity score was p < 0.01 and non-matches for the null model were selected as those with a p 
= 1, after Bonferroni correction. Relative essentiality in the matching cell lines as compared to the 
null cell lines was computed by comparing the essentiality rank of the cMR of interest in the cell 
line matches as compared to the rank of the MR in the non-matching cell lines, using a non-
parametric rank-based Mann-Whitney-Wilcox test. In total 39 cMRs were determined to be 
significantly relatively essential subtype-specific MRs after multiple hypothesis correction 
(Benjamini-Hochberg FDR < 0.05), and this total amount of essential MRs was significant with a 
p = 6.7x10-5 after fitting a null distribution to 104 random selections of the same number of TRs 
for each checkpoint. Essential MRs are highlighted in Figure 3.5B and bolded in Table 3.2. 
Figure 3.6A shows the full plot of all the VIPER activities for the cMRs for each of the 15 
resulting subtypes. From this global perspective a number of patterns emerge. Almost all of the 
cMRs from subtypes 1-7 are highly active in these subtypes but have middling to low activity in 
subtypes 8-15. The converse is true of the cMRs for subtypes 8-11. This is consistent with the 
division of samples in the first iteration of clustering. Amongst these larger differences in VIPER 
activities, more granular ones can be seen at this level and will be discussed more in the following 
sections. As an initial accounting for the biology and quality of these subtypes I used the labels 
from the TCGA analysis to look for enrichments. In particular, as can be seen in Table 3.1, MSI 
samples were primarily enriched in subtypes S6, S7 and S13. Additionally, GS samples were  
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Table 3.2 Checkpoint MRs for each subtype 
subtype Checkpoint MRs 
1 CDKN2A DNMT3B RNF2 TAF4 NONO SETDB1 COPS5 YY1 CHAF1B HDAC2 MED20 TAF2 TONSL ETV4 POGK ACTR5 TARDBP TCFL5 TGS1 
ZFP64 GTF2IRD1 CDC5L MORC2 TRIM28 SUMO1 KAT2A BAZ1B HLTF PLAGL2 NELFCD ING5 TP53 TRIM27 MCM8 ZC3H8 SUDS3 SRSF10 
ZBTB9 KDM1A PRMT5 RBBP7 BMP7 MAPK15 ZNF556 SUPT5H OTX1 YEATS4 PROX1 RUVBL1 TFDP1 TOP2A PPP1R10 
2 DNMT3B HLTF NR5A1 ARID3A PLAGL2 NR6A1 ZNF556 ZNF765 CHD7 DNMT3A TAF2 AHCTF1 ZNF544 SCML2 ASXL1 ZNF749 TBX4 ADNP 
CAND1 SUPT16H MCM8 ING5 HOXC13 ZNF217 ZBED4 ZNF572 BMP7 ZNF551 ZNF697 SMARCC1 GZF1 ZNF473 ZNF480 ERCC3 HOXD12 
DLX4 BMI1 NFXL1 CDC5L AGO2 HCFC1 CTNNB1 ZSCAN22 CHD4 ZNF133 POU4F3 TARBP1 
3 NR5A1 HOXC13 HOXC12 ANKRD1 ZNF280A SOHLH1 ZNF114 ALX1 MTA3 SSX4 ESX1 SSX5 TGIF2LX PCGF2 SSX1 MNAT1 
4 SETDB1 PLAGL2 MYC TAF4 RNF6 COPS5 RNF2 TAF2 NONO NR6A1 RNF4 CDC5L MCM8 HOXA11 CDK8 TRIM27 CHD7 TAF5L EMX1 CAND1 
OVOL1 EAF1 YY1 SMARCC1 SATB2 TGS1 LRPPRC PRMT5 CHAMP1 TARDBP HOXA10 ING5 CDH1 DDX1 NFX1 ZBED4 SFMBT1 TFB2M 
CNOT7 TARBP1 SUDS3 ADNP CTBP2 KDM1A ZDHHC13 ZDHHC23 NFXL1 RBBP4 ZNF3 RB1 SUPT16H TADA1 CTCF ZIC5 NOLC1 XRN2 
GTF2H3 ZC3H8 NELFCD ACAD8 ACTR5 KDM4C ZNF664 SLC30A9 FOXD4 KLF5 GMCL1 ZNF343 
5 ERN2 CASZ1 PPARA ATP8B1 ARX RFX6 FOXA1 TRAK1 RORC CASK LPIN2 ZNF710 FEV ZNF774 NPAS2 
6 COPS5 EMX1 ELP3 GTF2E2 C1QBP SUMO1 ASH2L SNW1 MLX MYC TRIM27 TP53 HDAC2 HOXA10 HOXA11 XRCC6 ERN2 SIRT7 PPP1R8 
7 MYC ELP3 CDC5L GTF2E2 SNW1 C1QBP CNOT7 EMX1 RBBP4 XRCC6 PRMT5 TGS1 ATF1 ZFAND1 
8 TRAK2 CREBL2 GATA1 ZNF536 STAT3 SAP30L ZMAT3 AFF3 NFIB SMAD2 ZNF671 ZSWIM6 SMARCA2 KLF11 ADH1A IGF1 ZEB2 STAT5B 
ZNF727 FOXO1 ELK3 FOXN3 CD86 ZIK1 SPI1 KAT2B ZNF483 SETD7 CREBRF ESRRB ABCG1 ELP2 EBF2 HCFC2 VAV1 ESR1 NFKB1 ZNF660 
SOX8 IKZF1 ZBTB38 TFEC ZNF486 GDF7 L3MBTL4 FOXP3 ZNF438 ZNF132 DBX2 SMAD1 NSD3 ZNF24 ZNF561 MNDA 
9 STAT1 MOV10 RELB ICAM1 IRF1 MAX ZNF683 CD86 BATF IFNG FOXP3 TNFRSF4 SNAI3 IRF2 TBX21 TRAFD1 CXXC1 NR1H3 MEF2B ETV7 
SPI1 BORCS8-MEF2B STAT5A BATF3 BATF2 FOXB1 PML ZBED2 VAV1 IRF5 RFX5 BTG1 GATA3 CIITA IL10 SLC11A1 NFKB2 HCLS1 KEAP1 
RUNX3 EOMES IKZF3 AKNA LITAF TFEC NFKB1 MNDA GFI1 TOX2 WNT1 IKZF1 MED9 SBNO2 LYL1 SP140 SAP30 PRDM1 SP100 CEBPE 
IRF4 TRIM22 PARP14 ZBTB32 OLIG2 
10 SOX21 KLF4 EYA2 RORC PTH NKX6-2 LRRFIP1 RNF141 
11 PURA TERF2IP HEXIM1 ZNF394 TCEAL1 ZFP36L1 SCX PHF1 TCEAL8 ZNF34 CAVIN1 TCEAL4 HOXA3 GTF2A1L HOXA2 PHF20 HOXA5 HOXB2 
HABP4 TCEAL3 DNAJB6 TCEAL6 HOXB4 PBXIP1 HOXA4 EID2B SIX2 MEIS2 TEAD3 ZNF358 PNRC1 SMAD1 ISL2 EID1 SIRT4 TCEAL2 APP 
RBPMS SCMH1 NPAS4 ZCWPW2 FOXP1 TSC22D1 RFX2 MEAF6 PRRX1 CAMK2A EMX2 ZNF615 ZFHX3 THRB MKX HAND2 DLX1 LMO1 
ZSCAN31 BARX1 KLF10 ID4 PIAS3 PKNOX2 NFYB MXD4 SMARCD3 TCEAL7 SOX2 PRDM8 MEIS1 MMP14 TSHZ1 MAEL GLI2 
12 STAT1 IRF1 MOV10 IFNG RFX5 TRAFD1 CD86 RBBP4 ICAM1 ZNF683 ZNF317 
13 GTF2E2 ELP3 SNW1 PRDX3 C1QBP XRCC6 SMAD2 ZFAND1 NRBF2 RCHY1 RBBP4 RB1 CNOT7 ING3 EAF1 ZIC5 
14 C1QBP TAF9 TRIM28 PCBD1 ELOB GTF2A2 PPP1R8 TSFM NEDD8 SAP18 APEX1 EDF1 PHB2 MED28 UBE2I TFB1M PA2G4 ELOF1 PRDX3 
RFXANK ENO1 ZNHIT1 PDLIM1 RUVBL2 PHF5A SRSF2 ZNF511 MRPL12 HNRNPAB SLIRP SUV39H1 HMGB1 ABT1 MCM5 MLX 
15 GLMP CERS2 PRPF6 ELK1 ATF6B CTBP1 FOXP4 DEDD MED8 SIRT2 MED29 ZBTB45 PREB VPS25 CREB3 ZSWIM3 TAF6 ZSWIM1 SMAD6 
SNAPC5 MESP1 RXRB FIZ1 ZNF768 THRA MAF1 ERF ZNF784 KAT8 SCYL1 LRCH4 IRF2BP1 CRTC2 HDAC11 ZNF444 MESP2 ZFPM1 RELA 
USP21 NFYC CREB3L4 
 
 
Figure 3.5 Relative Essentiality of cMRs.  
(A) Total count of subtype cMRs found to be relatively essential (blue line) compared with the 
probability density generated by 104 random selections of the same number of cMRs and fitted to 
a normal distribution to assess statistical significance. (B) Subtype specific relatively essential 
MRs. 
Subtype Essential cMRs
1 CHAF1B     GTF2IRD1         TP53
2 TBX4         MCM8
3
4 COPS5        CDC5L        TAF5L        KDM1A          RB1        TADA1         
KLF5
5 FOXA1        CASK
6 ASH2L        TP53      HOXA10
7
8
9 IRF2       TRAFD1        NR1H3         SPI1          PML         IL10        
RUNX3        NFKB1         GFI1      IKZF1         MED9        SAP30        
PRDM1         IRF4
10









highly enriched in both subtypes S8 and S11. Moreover, almost all of the highest HER2+ samples 
were disbursed between subtypes 1-4, with S1 and S2 having the most significant enrichment. All 
of these suggest that my new MOMA based classification is both identifying previously identified 
biological features as well as revealing novel ones. 
 
 
Figure 3.6 VIPER Activity Scores across the STES cohort.  
(A) MR-based clustering heatmap for the STES samples. Rows represent checkpoint MRs while 
columns represent individual samples. Color scale is proportional to protein activity (red 
activated; blue inactivated). Top annotations are the same as Figure 3.2G, and the same 
throughout.  
 
3.2.3 Microsatellite Instable Subtypes: S6, S7 and S13  
The first set of subtypes of interest in this analysis were those enriched in MSI samples: S6, S7 
and S13 (p = 2.9x10-4, p = 6.0x10-4and p = 1.0 x10-8 respectively).  MSI is a well characterized 
phenotype and these samples clustering consistently together served as a good positive control that 








Figure 3.7 Summary of MSI Subtypes.  
(A) Survival curves for all 3 MSI enriched subtypes. (B) Survival of MSI samples across all three 
subtypes vs the non-MSI samples. (C-E) Saturation curves as described in Figure 3.4. (F) Heatmap 






















































































the methodology was effectively capturing known subtypes189,194. While across these three there 
were no significant differences in survival, S6 was the best surviving subtype out of all 15, which 
is consistent with the literature and clinical findings showing that MSI high patients tend to fair 
better overall175,191. Additionally, analysis of non-MSI samples across these clusters did not reveal 
significant survival differences from the MSI samples. 
Saturation of upstream genomic events occurred at 76.3%, 80% and 78.4% total events 
respectively for each subtype (Figure 3.7C-E). These were some of the highest rates of saturation 
across the analysis, likely because of the overall high frequency of genomic changes. All three of 
the subtypes had high incidence of amplifications across chromosome 8, though for S13 predicted 
driver events were identified only on the q arm. Interestingly all of the non-MSI samples in S6, 
including a GS sample, had many of the same amplifications. A number of genomic events 
appeared as drivers at a high frequency across all three subtypes, most of them related to chromatin 
remodeling (Figure 3.8). These included ARID1A (39%-86%), NBN (64-72%), and members of 
the KMT2 and CHD gene families. Though KMT2D and KMT2C were present across all three 
subtypes, KMT2A and KMT2B were not found to be drivers in S7. CHD4 was a driver in S6 and 
S13 but not in S7 while mutations in CHD7 appeared in S7 and S13. Overall S13 had the highest 
overall frequency of different point mutations across the three subtypes. Absent across the drivers 
of all the subtypes were either of the canonical MSI related genes, MLH1 and MSH2. This is likely 
due to the fact that in cancers of the upper gastrointestinal tract these genes are more often affected 
via epigenetic silencing and not mutation189. 
Gene set enrichment of Reactome Pathways present across the upstream drivers showed a 
high degree of similarity between S6 and S13. In particular both had significant enrichment in 




Figure 3.8 OncoPrint plots for MSI subtypes.  
OncoPrint plots showing predicted driver events per sample upstream of the cMRs for (A) S6, (B) 
S7 and (C) S13. Horizontal histograms and percent numbers show the fraction of samples 


































































































































































































































































































































































































































Figure 3.9 Reactome gene enrichments of MSI subtypes.  
Gene set enrichment of upstream drivers, top 100 MRs and top cMR targets respectively. Color 
of each dot corresponds to its p value (red being more significant) and the size corresponds to the 
gene ratio for each gene set. 
upstream MRs targets
Subtype 6 Subtype 7 Subtype 13 Subtype 6 Subtype 7 Subtype 13 Subtype 6 Subtype 7 Subtype 13
Signaling by MET
Assembly of collagen fibrils and other multimeric
structures
Muscle contraction
MET promotes cell motility
Laminin interactions
MET activates PTK2 signaling
Semaphorin interactions
Extracellular matrix organization
Degradation of the extracellular matrix
NRAGE signals death through JNK
O−glycosylation of TSR domain−containing proteins




Diseases associated with O−glycosylation of
proteins
Interaction between L1 and Ankyrins
Metabolism of non−coding RNA
snRNP Assembly
Cell Cycle Checkpoints
tRNA processing in the nucleus
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rRNA processing
NEP/NS2 Interacts with the Cellular Export
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mRNA Splicing
Rev−mediated nuclear export of HIV RNA
mRNA Splicing − Major Pathway
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Synthesis of DNA
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G1/S Transition
S Phase
NR1H3 & NR1H2 regulate gene expression linked to
cholesterol transport and efflux
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Signaling by Nuclear Receptors
Nuclear Receptor transcription pathway
NOTCH1 Intracellular Domain Regulates
Transcription
PKMTs methylate histone lysines
Notch−HLH transcription pathway
RNA Polymerase II Pre−transcription Events
RNA polymerase II transcribes snRNA genes
Regulation of PTEN gene transcription
PPARA activates gene expression
SUMOylation
SUMO E3 ligases SUMOylate target proteins
Regulation of lipid metabolism by Peroxisome
proliferator−activated receptor alpha (PPARalpha)

















L1 and Ankyrins, all pathways related to cell membrane structure and connectivity to the ECM, 
processes particularly important to cancer progression and morphogenesis (Figure 3.9). While 
genomic events upstream of S7 were not enriched in these processes, it had significant enrichments 
for Laminin interactions, MET promotes cell motility and Assembly of collagen fibrils and other 
multimeric structures, processes also related cell structure and interactions with the ECM but via 
different mechanisms. This convergence of phenotype via different pathways suggests that while 
these subtypes are similar they may have progressed to this point by different genomic alteration 
cascades.  Notably both S6 and S7 were enriched in samples that were significantly more stem 
cell-like (p = 0.0024 and p = 0.00047 respectively by Students T-test) (Figure 3.10)135,189. 
Additionally, S6, the more stem cell-like of the two, had significantly fewer leukocytes, an 
association that’s been shown across a number of cancers (p = 2.8x10-5 by Student’s T-test)196. 
 
Figure 3.10 Phenotypic features of MSI subtypes.  
(A) Box plots of relative stemness between each subtype vs all others. (B) Box plots of leukocyte 


























Analysis of the cMRs for these subtypes also showed a fair amount of similarity. Four 
cMRs occurred across all three subtypes, GTF2E2, ELP3, SNW1, XRCC6, and C1QBP (Figure 
3.7F). The first two are components of the RNA polymerase complex, mediating initiation and 
elongation respectively, while SNW1 can serve as a transcription coactivator at certain Pol II 
promoters. XRCC6 is a helicase that is involved in DNA non-homologous end joining, particularly 
after double stranded breaks. C1QBP is a multifunctional protein that is involved in a number of 
processes including inflammation, ribosome biogenesis, regulation of apoptosis and mRNA 
splicing. Though an analysis of activity of all three sets of cMRs across all the subtypes showed 
broadly high activity across all three, certain cMRs had high specificity to their associated subtype. 
In particular, S6 cMRs TRIM27 and SIRT7 were specifically high only those samples, while 
SMAD2 and RB1, cMRs in S13 were highest in those samples with moderately elevated activity 
in S7. A broader analysis of the top 200 most significantly dysregulated TRs across each subtype 
(after Stouffer integration of sample specific regulator scores) showed similarity between S7 and 
S13, but not S6 (Figure 3.9). Top dysregulated TRs from S7 and S13 had significant enrichment 
in Chromatin modifying enzymes, SUMOylation, and gene expression pathways mediated by 
PPARalpha and PTEN. For S6 the only pathways that appeared as highly enriched across the 
dysregulated MRs were Notch-HLH transcription pathway and Nuclear receptor transcription 
pathway, both of which were also significantly enriched in S7 and S13.  
To further characterize these subtypes, I analyzed the top inferred downstream targets of 
each of the cMRs (p < 0.05) (Figure 3.9). Gene set enrichment across these again showed largely 
similar patterns of biology mostly related to cell cycle checkpoints, DNA replication and synthesis, 
and RNA processing. Interestingly, a number of the pathways enriched across all three were virus 
related, including HIV infection, Rev-mediated nuclear export of HIV RNA, Interactions of Rev 
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with host cellular proteins and NEP/NS2 interactions with Cellular Export Machinery. Further 
inspection showed that the cMRs shared across these subtypes (SNW1, C1QBP, GTF2E2 and 
XRCC6) were the main regulators of the target genes in these enrichments. This phenotype could 
be a result of the fact that MSI tumors are constantly making mutant proteins that can become neo-
antigens and may appear viral, thus triggering the same pathways.  
 
3.2.4 Genomically Stable Subtypes: S8 and S11 
Another set of subtypes of interest in this analysis were the genomically stable enriched subtypes, 
S8 and S11 (p = 9.8x10-8 and p = 0.0031 respectively). As with the MSI subtypes, finding that 
most of the GS samples clustered together was a good positive control for the efficacy of the 
methodology. These subtypes have been historically hard to categorize because of their limited 
number of mutational events and are also often the most lethal. This was consistent in my analysis 
as well, with S8 and S11 being two of the worst subtypes in terms of overall survival. Notably, 
though the subtypes are mostly GS samples, an analysis of the GS samples vs the others revealed 
no significant differences in survival, indicating a similarity in outcomes for these patients as well.  
 Saturation of upstream genomic events occurred at 21.3% and 14.3% total events 
respectively for each subtype (Figure 3.11D-E). While these values were on the lower end of the 
saturation range this is to be expected as many of these samples have few mutations overall and 
some may have been to infrequent to be statistically significant (Figure 3.12). S8 was dominated 
by CDH1, HECTD4, and FCRL3 mutations as well as CLDN18-ARHGAP26 fusions, all in a 
largely mutually exclusive manner. Additionally, most of the patients with either HECTD4 or 
FCRL3 mutations also had amplifications in ARFGAP1, UBE2C, POFUT1 and PIGU, all of 




Figure 3.11 Summary of GS Subtypes.  
(A) Survival of 2 GS subtypes vs the best surviving subtype. (B-C) Survival of GS samples across 
all both subtypes vs the non-GS samples. (D-E) Saturation curves as described in Figure 3.4. (F) 
Heatmap of VIPER activities of the checkpoint MRs as described in Figure 3.6. 
  














potentially in combination with these amplifications is likely enough to implement the downstream 
cMRs. S11 has a higher number of CIN samples along with the GS samples and its driver events 
included a number of the same amplified genes along chromosome 20. These samples did not have 
the corresponding mutations seen in S8 but a few have mutations in CDH1, CPQ and OR10K1.  
 
Figure 3.12 OncoPrint plots for GS subtypes.  
OncoPrint plots showing predicted driver events per sample upstream of the cMRs for (A) S8 and 
(B) S11. Horizontal histograms and percent numbers show the fraction of samples harboring the 
specific event type. Vertical histograms show the number of events detected in each sample. 
 
More interesting than the upstream events, given their sparsity, were the cMRs and their 
downstream targets. Gene set enrichment analysis of the top most highly predicted targets (p < 
0.05) for S8 cMRs showed a striking pattern of immune enrichment including Reactome pathways 
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell, Costimulation by 





Figure 3.13 Target genes of S8 cMRs are enriched in immune pathways.  
(A) Network plot of genes in immune related pathways downstream of S8 cMRs. Nodes are the 
Reactome pathways as labelled. (B) Top 20 most significant Reactome pathways. See Figure 3.9 







A number of these targets are under the control of several immune related cMRs, specifically, 
FOXP3, a driver of regulatory T-cells, SPI1, a transcription involved in macrophage and lymphoid 
development, CD86 which is involved in T-cell co-activation and stimulation, and IKZF1 another 
regulator involved in lymphoid development. The enrichment of these regulators is strongly 
suggestive of FOXP3+ T-reg infiltration in these samples, a previously identified phenotype in a 
subset of gastroesophageal tumors197. T-regs are known to suppress other effector immune cells 
and can thus facilitate an immune evasive tumor microenvironment. This is further verified by the 
fact that this cohort of tumors has a higher percentage of leukocytes but a lower infiltration of M1 
macrophages as compared to the rest of the samples (p = 3.5x10-8 and p = 6.7x10-5 respectively by 
Student’s T-test) (Figure 3.14). T-regs have also been implicated as part of the pathogenesis of 
gastric cancer in patients infected with H. pylori that leads to persistent gastritis. Unfortunately for 
this cohort at the time of analysis too few patients were sampled for H. pylori to assess for 
enrichment in this subgroup. Another notable feature of this subtype is that the samples were less 
stem-like and more differentiated as compared to the rest of the cohort (Figure 3.14) (p = 9.0x10-
20, by Student’s T-test)135,189 . 
 Comparatively in S11, the top downstream targets of its cMRs were predominately 
enriched for pathways related to cellular junctions including, Extracellular matrix organization and 
proteoglycans, Muscle contraction, Collagen formation and Integrin cell surface interactions. 
Subsetting to look just at the cMRs that were predicted to be dependencies in cell lines most similar 
to this subtype (ZFP36L1, SCX, TCEAL3, EMX2, SMARCD3 and TCEAL7) reveals an even 
further refinement of similar pathways in the corresponding targets including Muscle contraction, 
Neuronal system, Nitric oxide stimulates guanylate cyclase and Smooth muscle contraction 




Figure 3.14 Phenotypic features of GS subtypes.  
(A) Box plots of leukocyte fraction between each subtype vs all others. (B) Box plots of relative 
stemness. (C) Box plots of M1 Macrophages. All as reported in 189. ns: p > 0.05, *: p <= 0.05 , **: p 
<= 0.01, ***: p <= 0.001, ****: p <= 0.0001. 
 
pathways before but this suggests that dysregulation of these MRs potentially co-opts these 
pathways. This is also further evidence that this subtype is predominantly differentiated tumors, 
and analysis of purity of these samples did not indicate that they were significantly less pure than 
the rest of the cohort. Similar to S8 this subtype had increased leukocytes and decreased stemness 
as compared to the rest of the cohort (p = 3.2x10-3 and p < 1x10-16 respectively by Kolmogorov– 
Smirnov test) but did not have significantly fewer macrophages or other immune cell types (Figure 
3.14).   
An analysis of the VIPER scores for both subtypes’ cMRs showed that while the exact 
cMRs for each subtype are different, their collective activities across both subtypes are high 
(Figure 3.11). This could indicate that these subtypes have broadly similar biology but that their 








































Figure 3.15 Target genes of S11 cMRs are enriched in cellular junction pathways.  
(A) Network plot of genes in cellular junction pathways downstream of S11 cMRs. Nodes are the 
Reactome pathways as labelled. (B) Top 10 most significant Reactome pathways. See Figure 3.9 







3.2.5 HER2+ Subtypes: S1 and S2 
The other phenotype of interest was HER2 amplification. As mentioned previously, HER2 
positivity is the only current biomarker used to select for specialized treatment for gastric cancer 
patients, but its overall efficacy is variable and limited. To try and better understand the 
heterogeneity present in HER2+ samples I did further analysis of the two subtypes statistically 
enriched for those samples, S1 and S2 (p = 0.00012 and 0.048 respectively by Kolmogorov–
Smirnov test on GISTIC HER2 amplification scores). In addition to being enriched in HER2+ 
samples, S1 and S2 were also enriched in CIN type samples (p = 2.7x10-8 and 0.009 by Fisher’s 
exact test). Comparing the subtypes to one another did not reveal significant difference in survival, 
nor was there a difference between the samples that were HER2+ in each subtype versus those that 
were not (Figure 3.16A-C). 
Saturation for these subtypes occurred at 46% and 42% (Figure 3.16). Both subtypes were 
dominated by amplifications and deletions, as is to be expected because of the abundance of CIN 
samples, but the MOMA analysis was able to prioritize genes that are more likely to be the key 
drivers within a large region. As was done in the first MOMA analysis, copy number variant 
alterations were first filtered for whether or not they were “functional,” as in whether or not the 
variant corresponded to an actual difference in expression. Then during the saturation calculation, 
proximal events within the same cytoband sub-region were combined in order to avoid double 
counting genomic alterations that were likely part of the same large event. Finally, to select genes 
most likely to be the true drivers, the gene within each region that both had the highest DIGGIT 
aQTL score with the cMRs identified for that subtype and was also predicted to be a CINDY 
modulator was determined most likely to be the true driver83. Interestingly for S1 of the 32 samples 




Figure 3.16 Summary of HER2+ Subtypes.  
(A) Survival of 2 HER2+ subtypes. (B-C) Survival of HER2+ samples across all both subtypes vs 
the non-HER2+ samples. (D-E) Saturation curves as described in Figure 3.4. (F) Heatmap of 
VIPER activities of the checkpoint MRs as described in Figure 3.6. 
 
pathway (as identified by the Reactome “Signaling by ERBB2(HER2)” gene set). As can be seen 
















amplifications in PLCG1, SRC, AKT2 and AKT1, as well as a few with deletions in RHOA 
(Figure 3.17A). This is good evidence that these samples without HER2 amplification are still 
achieving the same biological phenotype via a different genomic event in the same pathway. In 
S2, this is similarly the case with many of the non-HER2 samples having amplifications in PLCG1 
(Figure 3.17B). Gene set enrichment analysis across the other genomic events showed that both 
S1 and S2 had significant enrichment in events related to regulation of TP53 which is aligned with 
the fact that 52% and 54% of samples in these subtypes respectively have TP53 mutations. Other 
highly enriched pathways for genomic events of S1 included SUMOylation and pathways related 
to apoptosis (Death Receptor Signaling, Activation of BH3-only proteins, Activation of BAD and 
translocation to the mitochondria) likely indicative of aberrancies related to TP53 and other genes 
leading to loss of effective regulation of cell death pathways. S2 did not have the same enrichments 
but upon closer inspection many of the samples across S2 did have some of the same genomic 
events driving these enrichments in S1, they were just not predicted to be drivers for S2’s cMRs. 
Gene set enrichment analysis of the top most significantly predicted downstream targets of 
the cMRs of S1 showed that the most enriched Reactome pathways were those related to cell cycle, 
DNA replication and repair, and metabolism of proteins and RNA. Specifically, some of the most 
notable were: Cell Cycle Checkpoints, DNA Replication, Extension of Telomeres, Transcriptional 
Regulation by TP53, Metabolism of non-coding RNA, and SUMOylation (Figure 3.18). The first 
three were somewhat predictable as they are related to tumor proliferation, and Transcriptional 
regulation by TP53 again aligned with the fact that TP53 is both mutated in 52% of samples and 
is a cMR for this subtype. The fact that SUMOylation appeared again, in addition to enrichment 
in the upstream targets, was interesting as this is a relatively understudied component to 




Figure 3.17 OncoPrint plots for HER2+ subtypes.  
OncoPrint plots showing predicted driver events per sample upstream of the cMRs for (A) S1 and 
(B) S2. Horizontal histograms and percent numbers show the fraction of samples harboring the 
specific event type. Vertical histograms show the number of events detected in each sample. 





SUMOylation is a process of post-translational modification similar to ubiquitination that serves 
an important role in cellular response to stress and has been found to be broadly dysregulated in a 
number of cancers. The specific cMRs that came up in this pathway were SUMO1, one of the key 
components of SUMOylation activity in the cell, as well as CDKN2A, DNMT3B, RNF2, HDAC2, 
TRIM28, TP53, TRIM27, and TOP2A. Though its role in cancer is not fully elucidated, 
SUMOylation has been implicated in a number of different cancer pathways including genotoxic 
stress, inflammatory signaling, hypoxia, and pluripotency acquisition198. A broader analysis of the 
top 200 most dysregulated TRs overall also showed enrichment for immune related pathways, 
Signaling by Interleukins and Interferon gamma signaling. These enrichments were driven by 
down regulated TRs which could correspond with the fact that these samples had significantly 
fewer leukocytes and M1 macrophages as compared to the whole cohort (p = 3.9x10-14 and p = 
6.0x10-3 respectively by Student’s T-test) (Figure 3.19). 
Interestingly, one of the most significant pathways from the same gene set enrichment 
analysis applied to the downstream targets of S2 was also SUMOylation (Figure 3.20). A post-
hoc analysis showed that this similarity in enrichment is largely due to any entirely different set of 
cMRs and their corresponding targets. The S2 cMRs associated with SUMOylation are NR5A1, 
DNMT3A, BMI1, and DNMT3B, the last of which is the only one to occur in both checkpoints. 
This suggests a possible convergence being achieved by different sets of cMRs and transcriptional 
processes, and moreover that this is occurring across both HER2 amplified samples and 
transcriptionally similar tumors as well. Other top Reactome gene sets were M Phase, DNA Repair, 





Figure 3.18 Target genes of S1 cMRs pathway enrichment.  
(A) Network plot of genes downstream of S1 cMRs. Nodes are the Reactome pathways as 









Figure 3.19 Phenotypic features of HER2+ subtypes.  
(A) Violin plots of leukocyte fraction between each subtype vs all others. (B) Violin plots of 
relative stemness. (C) Violin plots of M1 Macrophages. (D) Violin plots of resting NK cells. All as 
reported in 189. ns: p > 0.05, *: p <= 0.05 , **: p <= 0.01, ***: p <= 0.001, ****: p <= 0.0001. 
 
3.2.5.1 HER2 & Drug Resistance 
Trastuzumab is a monoclonal antibody that targets HER2 and is the only currently approved 
biomarker specific drug for gastric cancer patients, but it is minimally effective and acquired 
resistance happens frequently. To address these issues, other HER2 targeting therapeutics have 
been investigated as potential alternatives. Lapatinib, a tyrosine kinase inhibitor, was shown to be 
effective in trastuzumab-resistant breast cancer but a clinical trial in gastric cancer patients did not 
show the same efficacy199–201. Afatinib, an irreversible TKI that binds to EGFR, HER2 and HER4, 
was approved as a therapy for non-small cell lung cancer and early studies in HER2+ gastric cancer 
cell lines and PDX models indicate that afatinib has better anti-tumor and anti-metastatic activity 








































Figure 3.20 Target genes of S2 cMRs pathway enrichment.  
(A) Network plot of genes downstream of S2 cMRs. Nodes are the Reactome pathways as 









 Work done by our collaborators in the Bass laboratory has been ongoing to better 
characterize the mechanisms and therapeutic potential of afatinib in HER2+ gastroesophageal 
cancer samples. Interestingly, in their studies they have found that while afatinib is effective in 
two HER2+ cell lines, NCI-N87 and OE19, its effect is markedly decreased when these cell lines 
are grown in three-dimensional scaffolding (Alvetex). Notably, this is not the case in a HER2+ 
breast cancer cell line, BT474. Joint delivery with belinostat, an HDAC inhibitor, is able to rescue 
the effect of afatinib, through it is not effective when used alone, implying some level of synergy 
at play. As based on these observations and to test some of my hypotheses from the MOMA 
pipeline, I performed MR analysis on samples from a drug screen across these three cell lines. 
 
3.2.5.2 Experimental Design and Brief Summary of Results 
The three cell lines of interest, OE19, NCI-N87 and BT474, were grown in both 2D and 3D cell 
culture. Alvetex was used for the scaffolding structure in the 3D experiments, which allowed for 
the same growth media conditions to be used for both. The three drug conditions tested were 
afatinib alone, belinostat alone and combined afatinib and belinostat. DMSO, the vehicle for 
delivery of these drugs, was used for the control condition. The cells were treated for both 6 hours 
and 48 hours in order to assess both short- and long-term effects of the drugs. All conditions were 








Table 3.3 Experimental Design and Results of HER2+ Drug Screen 
 Dimension   Drug BT474  OE19  N87  
2D  Afatinib  Yes  Yes  Yes  
Belinostat  -------- Yes Yes 
Combined  -------- Yes Yes 
3D  Afatinib  Yes  No ~60% cells 
remaining 
No ~20% cells 
remaining 
Belinostat   ------- No No 
Combined   ------- Yes  Yes 
 
 
3.2.5.3 Using an MR-Based Classifier to Predict Drivers of Drug Resistance 
Raw fastq files were acquired after the samples were sequenced by the Broad Institute. Read counts 
were then calculated using Kallisto and transformed using variance stabilizing transformation from 
the DESeq2 package (refs). I performed an initial principal component analysis in order to confirm 
that all triplicates were reliably similar. In doing so I found two outlier samples (a BT474 3D 
sample treated with Afatinib for 6 hours and an OE19 3D sample treated with Belinostat for 48 
hours). These were removed from further downstream analyses.  
In order to generate VIPER predicted protein activity scores, I paired each experimental 
condition sample with the corresponding set of DMSO controls in that cell line at that time point 
in the same condition, ie to generate a signature for OE19 3D samples treated with Afatinib for 6 
hours, I used OE19 3D samples treated with DMSO for 6 hours. This was done to adjust for any 
contributions that may have arisen because of the conditions themselves and to optimize detection 
of drug specific MRs. After generating these signatures, I then performed single sample VIPER 
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analysis on each experimental sample using the STES interactome from the MOMA analyses for 
the gastric cell lines and an interactome built on TCGA BRCA samples for the BT474 samples. 
Hierarchical clustering inclusive of all tested TRs showed that cell line and time were still the most 
significant drivers of similarity, not drug sensitivity (Figure 3.21).  
Based on this observation, I decided to build a multi-step classifier to determine which TRs 
were predicted to be key regulators of drug sensitivity across multiple conditions. To do this I 
selected two sets of condition pairs in the gastric cancer lines that were most informative for 
interrogating the regulators of the sensitivity: 1) 2D afatinib treatment (sensitive) vs 3D afatinib 
treatment (resistant) and 2) a combination of all sensitive conditions (2D afatinib, 2D afatinib with 
belinostat and 3D afatinib with belinostat) vs 3D afatinib (resistant). For each cell line I performed  
 
Figure 3.21 Heatmap of VIPER activity across all cell lines show that dominant drivers of 
difference are cell line and time.  
Hierarchical clustering of resulting VIPER profiles for each cell line. Rows are TRs and columns 
are cell lines. Top annotation describes attributes of each cell line. See legend for colors. 




linear discriminant analysis across each TR to determine which ones were able to discriminate 
between the two conditions with 100% accuracy. Examination of the overlap between both cell 
lines and across both condition pairs revealed 12 TRs. Filtering these 12 TRs down to the ones that 
shifted in the same direction activity-wise between sensitive and resistant, resulted in 9 candidate 
MRs (p = 0.0001 after fitting a null distribution to 106 random TRs selected to as classifiers after 
shuffling sample labels). See Figure 3.22 for the number of TRs identified at each step. For this 
analysis I only considered samples from the 6-hour incubation time point as principal component 
analysis showed that all the 48-hour time point samples had a very strong separate signal of activity 
seemingly unrelated to drug their drug resistance status. I also reasoned that the 6-hour time point 
was a better reflection of the immediate transcriptional response to treatment of the drugs. 
 The 9 final MRs fell into two groups in terms of biological mechanism: histone 3 lysine 
(H3K) methylation regulation (ASH2L, SNAI2, and JARID2) and cell differentiation and 
proliferation (CDCA7, MYB, WNT5, ESX1, KLF7 and HOXA10). ASH2L is a methyltransferase 
that methylates H3K4 depending on its H3K9 methylation status. It’s been shown to interact with 
the TAF family of proteins as well as MYC in certain contexts. SNAI2 has been shown to work 
with KDM1A, a histone demethylase, to decrease dimethylated H3K4 and repress transcription, 
in addition to being involved in the induction of epithelial to mesenchymal transition. JARID2 is 
a repressor that recruits the PRC2/EZH2 histone methyltransferase complex and contributes to 
gene regulation in embryonic stem cells. In terms of the other group of MRs, MYB (an oncogene), 
CDCA7, and KLF7 are all involved in pathways regulating cell proliferation and differentiation. 
WNT5A is involved in regulating the Wnt signaling cascade, depending on the context, and 
HOXA10 is known to interact with PTPN6, EGFR and STAT3/STAT1 during oncogenic 
transformation processes. ESX1 seems to be involved in spermatogenesis but also is broadly 
124 
 
associated with the GATA family of genes. Finding both of these signals, methylation regulation 
and cell proliferation is consistent with the fact that belinostat is an HDAC inhibitor, which has 
 
Figure 3.22 Schematic of multi-step classifier and resulting top TRs.  
(A) Venn diagram of TRs selected as classifiers per cell line per comparison. (B) Heatmap of 
resulting top classifier TRs split by cell line.  
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been shown to have effects across multiple types of histone modifications and chromatin structure, 
and because the drugs are aimed at blocking proliferation of the cancer cells. Work is ongoing to 
understand more about the role of these 9 candidate MRs, as will be discussed later. 
 
3.2.5.4 Using Condition Paired VIPER Analysis to Predict Drivers of Drug Resistance 
In order to cast a wider discovery net to understand the biology underpinning this resistance, and 
to select TRs to test in a corresponding CRISPR screen, I performed a second set of analyses on 
this data using a different methodology to prioritize candidate MRs. Rather than using a classifier 
to identify individual TRs capable of differentiating between drug resistant and sensitive, I instead 
set up several paired VIPER analyses that allowed me isolate and interrogate the drug specific 
phenotypes. More specifically, I first generated a gene signature between samples reflecting the 
change in drug sensitivity, ie between samples treated with afatinib in 3D (resistant) vs 2D 
(sensitive), then used VIPER to generate a ranked list of regulators. I then also generated a gene 
signature of the “background,” meaning the aspect of the previous signature not related to the drug 
activity, but rather related to the cell type and conditions. For example, for the afatinib in 3D vs 
2D VIPER analysis, I generated a background signature and VIPER profile using samples with 
only DMSO delivered in 3D vs 2D. I then took the ranked list of TRs and their relative activity 
scores from the main condition and subtracted the activity scores inferred from the background 
condition to generate an adjusted set of VIPER scores for each TR now having accounted for 
biological changes not related to the drug sensitivity (Figure ***). In addition to the above 
condition pair I also generated adjusted VIPER profiles for the combination drug condition 
(afatinib and belinostat) in 3D culture with adjusted backgrounds for both afatinib and belinostat 
alone. Separately paired analyses were done for each cell line and time point and top TRs that were 
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statistically significant across multiple conditions were selected as candidates (p < 0.05 after FDR 
correction).  
 Gene set enrichment analyses of the candidate MRs that came up in at least one third of 
the pairs showed that the top most enriched Reactome pathways were Chromatin modifying 
enzymes and organization, Transcriptional regulation by TP53, HATs acetylate histones and 
Regulation of lipid metabolism by peroxisome proliferator-activated receptor alpha (PPARalpha). 
The high enrichment of chromatin modification related TRs is consistent with the fact that 
belinostat is an HDAC inhibitor and aligns with the predictions from my first classifier, where 3/9  
 
Figure 3.23 Paired VIPER Analysis to select candidate MRs.  
(A) Schematic of work flow. (B) Gene set enrichment of TRs that came up as significant in at least 




1. Get Master Regulators of main question. 
Ex. Afatinib activity in 3D vs 2D
2.   Get Master Regulators of “background”. 
Ex. MRs in 3D vs 2D in DMSO









predicted MRs were related to histone methylation. Notably SUMOylation of transcription 
cofactors also came up in the top 25 most enriched pathways in part because of SUMO1 and BMI1, 
which I also identified as cMRs in my MOMA analysis. This gives further credence to the potential 
importance of these TRs and the role of SUMOylation in this condition. To further validate these 
predictions all TRs that were significant in at least 2 or more conditions were selected to be tested 
in a follow up CRISPR screen. That screen is currently underway so the results were not available 
at this time. 
3.2.6 Cell Line Matching to MOMA Inferred Subtypes  
To further analyze the biological importance of the cMRs, I looked for enrichment of cMRs as 
relatively essential genes from the Achilles analysis in cell lines that were high quality matches 
for the different subtypes of interest. To test for patient similarity, all cell lines from the CCLE 
that were annotated as being derived from either the esophagus, stomach or upper aerodigestive 
tract were selected as candidates (101 cell lines in total). An internal gene signature was generated 
across this pool of samples in order to amply the differences among them and to mirror the internal 
signature used for the MOMA analysis. VIPER analysis was then applied to transform the 
signature into inferred protein activity scores for each cell line using the STES interactome. 
 Two methods were used to assess similarity between patients and cell lines. In one, I 
matched each patient to each cell line in a pairwise manner using viperSimilarity to test for 
enrichment of the top and bottom 25 MRs, as was done in the previously described Achilles 
analysis. Cell lines were considered matches if the enrichment was significant at a threshold of p 
< 0.01 after multiple hypothesis correction. The second method used to assess similarity was to 
first create a single representative profile for each subtype before doing the similarity enrichment 
analysis. To do this I first applied Stouffer’s Integration across the TRs of the samples in each 
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subtype, then subsequently used this integrated profile to generate a subtype match score with each 
cell line as previously described. For this analysis I focused on the cell lines that optimally matched 
S1 and S8 as they had a higher enrichment of HER2 and GS samples respectively. 
These two methodologies produced mostly congruent results (Figure 3.24). Many of the top most 
predicted cell lines for S1 using the two different methods were derived from esophageal squamous 
cell carcinomas. This made them less desirable based on their cellular origin but does open up the 
possibility of biological similarity at the transcriptional level. The 7th best match using the second 
method was SNU16 a cell line derived from a gastric carcinoma which also broadly matched a 
number of patients in subtypes 4, 5 and 6 in addition to S1. GSEA analysis of S1 cMRs on the 
Achilles CRISPR based essentiality scores for SNU16 showed significant enrichment of these 
cMRs (p = 0.010), further confirming the importance of these as key regulators. The 2nd best match 
for S8 using both methodologies was HS746T, a cell line derived from a gastric adenocarcinoma.  
Repeating the same analysis using the S8 cMRs also showed significant enrichment of these MRs 
as being likely essential in HS746T (p = 0.021) (Figure 3.25).  
 Using these matching methodologies also revealed that while NCI-N87 and OE19 were 
good matches for HER2+ patients, they did not match the non-HER2+ patients in S1 and S2 
particularly well. This suggests that there may be some limits to the broader usability of some of 
the insights from the drug screen analyses previously mentioned. Additionally, a second CRISPR 






Figure 3.24 Top matching cluster specific cell lines.   
(A) S1 and (B) S8. Patients are columns and cell lines are rows. For clarity only significant matches 
are colored (p < 0.01 after multiple hypothesis correction). Top annotations are the same as 
previous plots. 
Similarity scores for cell lines optimally matching S1A




Figure 3.25 GSEA Enrichment of cMRs in Achilles scores for matching cell lines.  
(A) Enrichment of S1 cMRs on ranked Achilles scores for SNU16 (negative indicating a gene is 
more likely to be essential). (B) Enrichment of S8 cMRs on HS746T Achilles scores. 
 
3.2.7 Validation in External Cohort  
With any classification system built on a single dataset, the risk of overfitting specifically to that 
data is high. In order to determine whether or not my new methodology and system was more 
generally applicable to gastroesophageal adenocarcinoma biology, I used the data from the Asian 
Cancer Research Group (ACRG) as a validation set. As mentioned previously in the introduction, 
this research group has also developed their own gastric cancer classification system as based on 
a cohort of 300 patient samples acquired at the Samsung Medical Center192–194. Their classifier is 
based on gene expression and delineated four subtypes: microsatellite unstable, mesenchymal-like 
(EMT), TP53 active, and TP53 inactive. The first two subtypes approximately align to the MSI 
and GS subtypes, respectively, from the TCGA analysis (which they confirmed in their work) but 
the TP53 based subtypes were less closely aligned with any particular subtype.  
 To begin this analysis, microarray data from the GEO database (GSE62254) was 
downloaded and transformed to VIPER inferred protein activity values using the STES 
interactome. To match the STES analysis the differential signature was generated using an internal 
reference (comparing the samples to one another) so as to highlight the intra-cohort differences. 




Principal component analysis of the resulting ACRG VIPER profiles along with the STES samples 
showed that the VIPER transformation was able to almost entirely mitigate batch effects (Figure 
3.26). Applying the Global MOMA weights across the TRs of each of the cohorts (as was done 
prior to the clustering step in the STES analysis) resulted in even better concordance between the 
two.  
In order to understand how well their classification labels corresponded to the subtypes 
identified by the MOMA analysis, I built a random forest classifier to predict the different ACRG 
labels using VIPER protein activity values as features. After selecting 75% of the samples for the  
 
Figure 3.26 PCA plots of patient’s VIPER profiles from each cohort.  
(A) Unadjusted VIPER profiles used for each patient. (B) VIPER profiles after weighting with 
STES global MOMA scores. 
 
training, I did fivefold cross validation for ten iterations, and then applied the resulting model to 
the test group. When considering all the regulators as features I found that the overall accuracy 
ranged from 45.5% to 87.5%, with a median of 66.7%. Closer inspection revealed that the EMT 
and microsatellite unstable labels were being accurately predicted close to 100% of the time but 
the accuracies for the TP53 active and inactive labels were quite low. To try and improve the 
overall model accuracy I utilized the Boruta algorithm to prioritize selection of the most 
A B
Viper Scores of ACRG and STES Samples
Viper Scores of ACRG and STES 
Samples with MOMA Weights
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statistically significant relevant features204. Boruta is an all-relevant feature selection method that 
generates a set of randomly permuted shadow features and includes them in the training step of 
the random forest. These serve as a null to compare to the actual features and from this it is possible 
to delineate which features performed statistically better than the randomly permuted ones. Using 
this method refined my list of features down to 121 TRs from the original pool of 2445. I then built 
another random forest model only including these TRs as features and this resulted in accuracies 
ranging from 55.7% to 79.2%, with a median accuracy of 68.2%. Attempts at using other classifier 
methods did not lead to improvements in accuracy so I selected the random forest model based on  
 
Figure 3.27 Subtype annotation plot of STES samples with ACRG labels applied. 
 
the Boruta selected features. Applying this model to the STES samples resulted in concordance 
of the two expected pairs of subtypes, EMT with GS in S8 and S11, and microsatellite unstable 
with MSI in S6, S7 and S13 (Figure 3.27).  
To further understand whether or not the MOMA and iterative clustering methodology 
could be validated in this cohort I applied it to the VIPER profiles of the ACRG cohort. Using the 
same global MOMA weights from the STES analysis to first weigh the TR features in the ACRG 
cohort I then proceeded with iterative clustering using the same parameters as described 
previously. The ACRG samples stabilized at 11 clusters with EMT samples almost entirely 





represented in one cluster and the microsatellite unstable distributed across three clusters. All of 
these clusters had high activity of the expected cMRs as identified in the MOMA analysis, and 
overall had the same global patterns of cMR activity (Figure 3.28). Though fewer overall subtypes 
were found by the iterative clustering method this is likely due to overall differences in the cohort 
make up, and suggests that the TCGA cohort has a wider breadth of patient types. 
 
Figure 3.28 Results of iterative clustering applied to ACRG Samples.  
Row are the MOMA cMRS inferred from the STES cohort. Columns are ACRG patients. Top 
annotations are the ARCG patient labels.  
 
3.2.8 MOMA Identification of Global Regulators of Gastroesophageal Cancer 
Though most of the analyses I performed utilized VIPER inferred values from a gene signature 
generated internal to the STES cohort, this minimized the ability to find likely global drivers of 
the tumors as it was designed to accentuate intracohort differences. In order to interrogate the 
broader biology present across these samples I generated a gene signature using all of the tumor 















Figure 3.29 Clustering Results using TCGA reference VIPER activities.  
(A) Clustering results comparing average cluster reliability scores for each clustering solution 
using k = 2 to k = 15. Panels show clustering using gene expression, unweighted viper scores and 
MOMA weighted VIPER scores respectively. (B) Heatmap of 6 cluster solution based on TCGA 






in the original MOMA analysis. In doing so I was able to capture not only the differences among 
the samples but also which TRs are likely to be key MRs for gastroesophageal cancer as a whole.  
 After generating this TCGA-reference signature I again transformed the values to generate 
VIPER inferred protein activities for all of the TRs using the STES interactome. MOMA analysis 
was then performed as previously described in order to generate a ranked list of MOMA scores for  
each TR and then I proceeded with clustering using these weights. A comparison of cluster 
reliability scores (see previous chapter’s methods for description of this metric) showed improved 
average cluster similarity scores when using VIPER as compared to gene expression and were 
even better when using MOMA weighted VIPER values (Figure 3.29). This analysis showed that 
2 and 6 clusters were statistically equivalent so I selected the 6-cluster solution as it showed 
substantial enrichment of the 3 subtypes of interest, HER2+, MSI and GS, in clusters 1, 2 and 5 
respectively (see Table 4).  
Table 4: Enrichments of TCGA subtypes in 6 cluster solution using TCGA reference. 







CIN HM-SNV MSI GS EBV HER2 
1 192 0.891 1.6e-16 0.96 1 1 1  1.0e-09 
2 53 0.506 0.69 0.96 1 1 1 1 
3 85 0.542 1 0.96 1.1e-13 1 1 1 
4 38 0.598 1 0.96 0.21 1 0.0016 1 
5 71 0.936 1 1 1 5e-20 1 1 
6 23 0.412 0.76 0.96 1 1 0.16 1 
 
Analysis of the resulting cMRs across these 6 subtypes revealed that approximately a 
quarter of them (25/90) had uniformly high predicted activity across all of the patients. Of these 
25, 5 of them are known to be associated with gastrointestinal development (HNF4G, HNF1B, 
HOXA13, FOXA2 and ERN2) and 9 have been identified as gastroesophageal cancer biomarkers 
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(HNF4A, CDX2, HNF1B, HOXA13, FOXA2, MACC1, MYB, HOXB9, and SOX9). 
Identification of these known associated regulators further confirms that this analysis is identifying 
true biological signals. Additionally, it suggests that these and the other cMRs identified as being 
highly dysregulated across these samples could be potential therapeutic targets.  
 
3.2.9 Using Precision Oncology Algorithms to Predict Novel Therapeutics 
In order to prioritize drugs that target these global dependencies, I first performed cell line 
matching analyses as described previously. VIPER activity signature for gastroesophageal cell 
lines from the CCLE were computed from gene signatures that compared them to all other 
available cell lines. This was done to optimize comparability to the TCGA reference STES profiles 
as described above. Matches between a patient and a cell line were determined at a threshold of p 
< 10-10 after Bonferroni correction, Table 5 shows the resulting best cell lines by overall percentage 
match to patients, and Figure 3.30 shows the top 6 based on per cluster matching percentage. NCI-
N87 was selected for screening as it matched a substantial number of patients (78.1%) based on 
this analysis, and it would be possible to couple it with the other analyses done to investigate HER2 
amplification.  
Table 5: Best cell line matches across the STES cohort. 
Rank Cell Line Patient Coverage 
1 X2313287 85.1% 
2 TGBC11TKB 83.1% 
3 KATOIII 81.8% 
4 NCIN87 78.1% 
5 KE39 77.5% 
6 NUGC4 77.3% 
7 AGS 76.0% 
8 GSU 75.8% 
9 SNU719 75.8% 




Using the precision oncology pipeline OncoTreat developed in the Califano lab, NCI-N87 
cells were perturbed with 336 different FDA Phase I/II approved compounds at sublethal doses for  
 
Figure 3.30 Prioritizing drugs based on global STES cMRs.  
(A) Percent coverage of matching cell lines for each subtype. (B) OncoTreat results of 6 highly 































Regulators ranked by activity 







24 hours and then subsequently sequenced130. The resulting RNAseq profiles were then 
transformed to VIPER activity scores for each drug condition, reflecting the regulatory changes 
that occurred in response to exposure to the drug. With this information I then determined which 
drugs most significantly inverted NCI-N87’s VIPER activity profile by calculating the enrichment  
of its top 25 positive and 25 negative regulators that were then inactivated and activated by each 
compound treatment, respectively. A select set of the top 20 drugs predicted by this analysis are 
plotted in Figure 3.30 along with the ranks of the top 25 MRs that were identified as being highly 
dysregulated across all patients. A number of the top most drugs – Daunorubicin, and its analog 
Idarubicin, Teniposide, Irinotecan and Doxorubicin – are known to interfere with topoisomerase 
activity and Irinotecan in particular is already part of treatment regimens for patients with 
metastatic colorectal carcinomas. Daunorubicin has been plotted as a representative drug for this 
class. Other top predicted drugs included OTX015, a bromodomain inhibitor, LY2603618, a 
selective CHK1 inhibitor, and Ponatinib, a multi-target kinase inhibitor. Aminoglutethimide, an 
aromatase inhibitor sometimes used to treat breast cancer, was at the top of the list in terms of 
inverting NCI-N87’s VIPER signature, but was the worst of these in terms of specifically inverting 
the 25 MRs of interest. This highlights the value of looking not only at the effect on the cell lines 
but also prioritizing for inversion of the key MRs of interest. Notably none of these drugs are 
currently used for treatment of gastric cancer so could all be further pursued as novel therapeutic 
options. Work is also underway to screen a second cell line that matches S8 patients (GS enriched 






Gastroesophageal cancer is one of the most commonly diagnosed malignancies worldwide. 
Despite this much is still unknown about the etiology and development of these heterogenous 
tumors, thus stymying development of precise and effective therapies. Over the years several 
groups have developed genetics-based classifications for identifying different subtypes of these 
tumors but they have not yet led to effective changes in the clinical landscape.  
 This work utilized the Master Regulator framework as developed in the Califano lab in 
order to identify and interrogate the key transcriptional dependencies driving different subtypes of 
gastroesophageal cancer. Building upon the multi-omic methodology as elucidated in the first 
MOMA paper, I sought to characterize not just the master regulators themselves but also to identify 
the key genomic drivers leading to their aberrant activity. In doing so, I aimed to capture a fuller 
picture of the complex biology driving the oncotecture of these tumors, which has been yet to be 
comprehensively done. 
 Using a refined version of the MOMA framework along with an iterative clustering 
methodology identified 15 different subtypes. Though generated in an unsupervised manner these 
subtypes aligned with previously described biological phenotypes, giving credence to this 
method’s ability to both capture established patterns as well as discover new ones. Analyses of 
checkpoint MRs, i.e. those able to canalize a high proportion of the likely driver genes across a 
particular subtype, showed a statistically significant enrichment for relatively essential genes, 
suggesting that these cMRs do represent key potentially targetable “Achilles heels” of these tumor 
subtypes.  
 Exploration of the resulting subtypes revealed complex webs of biology at play. In the case 
of the MSI dominant subtypes, S6, S7, and S13, driver mutations in genes related to extracellular 
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matrix organization and connectivity, along with a higher degree of predicted stemness suggest 
that the mutations in these tumors facilitated progression through epithelial-mesenchymal 
transition. The cMRs of these subtypes were overall very similar and controlled cell pathways 
related to cell replication and DNA synthesis, as well as pathways implicated in response to HIV 
infection, possibly due to the abundance of neo-antigens in these hypermutated tumors.  
 The GS enriched subtypes, S8 and S11, exhibited minimal driver mutations, as was to be 
expected. Key genomic events in S8, including ARFGAP1 (amplification), CDH1 (mutation) and 
CLDN18-ARHGAP26 (fusion), occurred in a largely orthogonal manner indicating that a number 
of these patients had aberrancies in different pathways but still converged to similar transcriptional 
profiles. This is a key benefit of the MOMA framework as it is harder to identify these similarities 
when looking only on a gene by gene basis, particularly when very few mutations are present. S8 
had a strong signal of immune infiltration, opening up the possibility of effectively targeting these 
patient types with combination immune checkpoint inhibitor therapies. Part of the signal seemed 
to be driven by T-regs which may complicate this therapeutic strategy as they have been implicated 
in acquired resistance to these therapies, so a more complex regimen may be required (Saleh 2019). 
S11 on the other hand had a higher percent infiltration of leukocytes but did not have pronounced 
dysregulation of T-reg cMRs, suggesting they may be more susceptible to standard immune 
checkpoint inhibitor therapies. 
 Analysis of the two HER2+ enriched subtypes revealed that many of the samples without 
HER2 amplifications instead harbored mutations elsewhere in the HER2 pathway, likely leading 
to their transcriptional similarity. Because of the high frequency of chromosomal aberrancies 
across these samples, the DIGGIT/CINDY component of the MOMA framework was particularly 
crucial for prioritizing candidate drivers within these regions. Enrichment of genes in the 
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SUMOylation pathway occurred across the pool of upstream genomic drivers as well as in the set 
of genes under the control of the cMRs, suggesting increased dependence on this intracellular 
signaling mechanism.  Further analysis of drug resistance to Trastuzumab in HER2 cell lines 
suggested that this process may be driven by chromatin and DNA modifying regulators, 
particularly histone demethylases, but the results of a follow up CRISPR screen for validation are 
not yet complete. Preliminary results from a different screen done in the lab, in which a panel of 
key TRs were knocked out and subsequently sequenced to interrogate the expression of their 
targets, suggests that a number of the key cMRs for S1 may coordinate each other’s activities as a 
hyperconnected module.  
 Combining pan-cohort MR predictions with the OncoTreat drug prediction algorithm, 
identified a number of novel drug classes that significantly inverted activity of these key regulators, 
providing clinically pursuable avenues for treatment of these tumors. A follow up screen in a 
second cell line as well as in patient derived organoids is underway in order to further refine and 
prioritize these candidate therapies.  
In addition to corresponding with subtypes identified by our collaborators at the Broad 
institute, the subtypes predicted by the MOMA analysis also aligned well with the biological 
classifications identified by ACRG189,194. Validating my predictions in this external dataset 
provides strong evidence that the biological patterns MOMA identified are not purely a result of 
over fitting to the primary dataset. Though this is promising, further work still needs to be done to 
build true a MR based classifier on the STES subtypes. This will be crucial for both further 
validating its applicability to other datasets as well as confirming its ability to be used as a tool for 
new patient classification. Additionally, repeating this analysis on the NUS cohort will serve as 
further validation of this new classification system. 
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 While this analysis provided a number of insights into the regulatory logic of 
gastroesophageal cancers, this study also had a number of limitations. Currently the multi-omic 
framework of the MOMA analysis only incorporates mutations, copy number variants and fusions 
as candidate genomic driver events, and in doing so misses out on other potential driving disrupters 
of the regulatory logic, particularly epigenetic modifications. Efforts were made to make the 
algorithm more flexible to additional omic information but they were not successful at improving 
the identification of key biological patterns. Further work will need to be done to fully achieve this 
goal.  
 Additionally, though incorporating the iterative clustering methodology revealed 
interesting and biologically meaningful subtypes, in certain cases it seems to have over stratified 
the samples resulting in subtypes that are more similar than they are different. This seemed to be 
the case for the MSI enriched subtypes suggesting that for clinical classification it may be more 
useful to recombine them into one group. That said, a number of non-MSI samples were 
categorized as having similar regulatory patterns, something that would have been missed if the 
initial analysis had not been agnostic to these labels. Moreover, while a handful of these subtypes 
were selected for deeper analysis a more comprehensive examination of all the subtypes may 
reveal even more actionable insights as well as other instances of over stratification.  
 As mentioned previously, a striking part of this analysis was its ability to recapture many 
previously identified biological phenomena in a completely unbiased manner. More follow up 





4.1 General Conclusions 
The advent of modern sequencing technologies undoubtedly revolutionized the field of cancer 
genomics and brought upon the early ages of the precision medicine era. Despite early successes 
with a few biomarkers, translating the biology of many tumor types into actionable and effective 
therapies has remained elusive.  One of the issues stalling progress has been the focus on the 
oncogene addiction theory of cancer, a model that while true in some cases of tumorigenesis has 
not turned out to be the prevailing mechanism for a large percentage of tumors.  
 Models from the world of network biology have helped to reframe the lens by which the 
field interrogated the complexity of cancer. Much work has been done in an attempt to reverse 
engineer the dynamic, multi-layered array of interactions driving cancer cell biology. Instead of 
looking for singular drivers, modules of genes were instead evaluated for their role in driving 
cancer phenotypes. Through this lens, insights have been gleaned not only about the convergence 
of mutations in biologically similar pathways but also about the key role that regulatory factors 
play as nodes within these cellular networks.  
Indeed as more data from sources like the TCGA and others has become available it’s been 
found that in contrast to the vast genetic heterogeneity observed across cancers, the transcriptional 
states are remarkably similar and stable43,44. This suggests that subsets of tumors may accrue 
different genomic events but ultimately converge to the same dysregulated but homeostatic state. 
 These transcriptional states can be characterized by the key transcription factors, or Master 
Regulators, that coordinate the expression of the genes that are aberrantly expressed in the tumor 
state. In several individual contexts using this Master Regulator framework has been shown to be 
more effective for both classifying tumor subtypes as well as identifying the key regulatory factors 
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that are both sufficient and necessary for maintaining a particular cancer state. Prior to the work 
outlined in Chapter 2 of this thesis, a comprehensive pancancer Master Regulator analysis had not 
been done. 
We developed and applied MOMA, as described in Chapter 2, a methodology built to 
effectively integrate together several types of omics data to better characterize the complex 
genomic landscapes driving these dysregulated transcriptional states. The broad goals of this 
analysis were two-fold: one, to test the Oncotecture Hypothesis and to determine whether tumor 
checkpoints could be identified on a sample by sample basis, which would integrate the genetic 
alterations in that sample to implement its transcriptional state, and two, to assess whether, even 
within tumor checkpoints, MR proteins may form smaller, highly recurrent modular structures. 
Using the MOMA framework, we identified 112 subtypes across 20 cohorts of the TCGA, nearly 
all of which had identifiable MR checkpoints linked to sample specific upstream genomic 
alterations. Subtypes across 19/20 cohorts showed significant survival separation, something that 
had not been previously achievable for certain cohorts using gene expression based clustering 
alone. Analysis of the most recurrent of these checkpoint MRs revealed a highly degree of 
modularity across them, thus confirming both parts of the Oncotecture Hypothesis. Further probing 
the biology of these MR-Blocks revealed functional alignment with a number of the classical 
Hallmarks of Cancer, two of which were validated experimentally. 
In Chapter 3 of this thesis I further expanded on this MOMA framework by directly 
applying it to a cohort of gastroesophageal adenocarcinomas. Though one of the most prevalent 
and lethal tumor types, very few specialized treatments exist, largely due to the high heterogeneity 
of these tumors.  Using an updated version of the MOMA framework in conjunction with iterative 
clustering revealed 15 different subtypes across the cohort that closely aligned with subtypes as 
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previously identified across the field, though they were identified in an unbiased manner. 
Moreover, this new framework captured the upstream variants across this tumor type much better 
than the first MOMA analysis, thus showing the value of applying MOMA to both large and small 
cohorts.  
Analysis of clusters enriched in three of the major previously defined phenotypes—
Microsatellite Instable (MSI), Genomically Stable (GS) and HER2 amplified—revealed a number 
of insights about the complex genetic architecture underpinning the transcriptional states of these 
tumor types. The MSI subtypes (S6, S7 and S13), as predicted, had the highest frequency of 
genomic events, particularly point mutations, in addition to amplifications across chromosome 8. 
The predicted driver genes were enriched in genes related to cell membrane structure and ECM 
connectivity indicating a potential EMT progression, further bolstered by 2/3 subtypes higher 
degree of stemness. The GS subtypes (S8 and S11) on the other hand had far fewer driver events, 
though most occurred in a mutually exclusive manner across the samples within each subtype, 
indicating that different “recipes” of genomic events led to the same transcriptional state. Notably 
S8 had significant leukocyte enrichment and its cMRs controlled a number of immune related 
pathways potentially indicating the possibility of targeting these patients with some form of 
immunotherapy. Across the HER2+ subtypes (S1 and S2), nearly all the samples without HER2 
amplification instead had predicted driver events in other genes in the HER2 signaling pathway, 
specifically PLCG1, SRC, AKT2, AKT1 and RHOA. This explains the similarity in transcriptional 
profiles of the non-HER2 samples within these subtypes. Further work to better characterize and 
validate predicted MRs driving drug resistance to Trastuzumab, a HER2 monoclonal antibody-
based therapy, are ongoing. In addition to these biological insights, applying the Califano lab’s 
recently developed precision oncology pipeline, OncoTreat, to one of the representative cell lines 
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predicted a number of drugs that effectively inverted key global MRs and could be further pursued 
for clinical use.  
 
4.2 Future Directions 
The results of the MOMA framework provide a number of novel avenues to explore moving 
forwards. A database containing all ~ 2 million interactions between the regulators and predicted 
driver events has been made publicly available and can serve as a jumping off point to pursue 
newly predicted connections via experimental validation. This is similarly the case for the MR-
Blocks as we only validated 2 of the 24. A deeper exploration of the biology of these MR-blocks, 
particularly their combinatorial nature within individual checkpoints could reveal not only novel 
biological insights but also pathways for new MR-block specific cancer therapeutics. Additionally, 
an R-package containing the MOMA pipeline has also been publicly available and can thus be 
applied any cohort for which matched expression and mutational data is available. We hope that 
the field will find this useful both in the context of cancer as well as other disease types. 
Though MOMA provided a number of novel insights both from a pancancer lens as well 
as in a more fine-grain analysis on gastroesophageal tumors, there are certainly limitations and 
areas of improvement. As with other high-throughput methods, both experimental and 
computational, it is reasonable to expect that MOMA will also produce false positive and negative 
predictions. Further experimental validation of some of these predictions would need to be done 
to confirm the degree to which this is the case. Known issues with some of the high false negative 
rates in some of the underlying algorithms are currently being addressed by improving the 
statistical models to improve sensitivity. 
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 MOMA could be further augmented to more flexibly integrate other omics into its 
framework. Attempts were made to do this for application to the STES cohort, but more work still 
needs to be done to best capture the underlying distributions of the various omics data in order to 
ensure that they are integrated in a biologically and statistically robust way. 
 With regards to the analyses of the gastroesophageal tumors, while many novel insights 
were predicted, the experimental validation for a number of them is still pending. Once acquired 
these will hopefully lead to actionable insights that can be used to help provide these patients with 
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Appendix A: Supplement for “A modular master regulator 
landscape controls cancer transcriptional identity” 
 
(Note: Only supplementary figures from the paper are provided. Due to their size and complexity 
supplementary table files were not included but they can be downloaded from the online version 




Figure S2.1 Detailed Conceptual Flowchart of MOMA.  
(A) Input data for the MOMA pipeline. Data types are coded by color consistently throughout 
the manuscript. (B) (i) VIPER inference of protein activity from Gene Expression Profile data for 
each sample. Tumor-specific ARACNe networks are used for the analysis. (ii) CINDy modulator 
predictions based on conditional mutual information analysis from gene expression profiles. (iii) 
Selection of functional SCNA (fSCNA) by measuring the statistical independence of gene copy 
number and expression, thus removing the vast majority of candidate SCNA genes. (C) Statistical 
significance from CINDy (i.e., prediction of genes upstream of one or more MR proteins), aQTL 
analysis (i.e., prediction of genes whose genetic alteration is associated with differential MR 
activity), and PrePPI (i.e., genes encoding for proteins that physically interact with one or more 
MRs) is integrated using Fisher’s method. This produces a tumor cohort-specific MOMA score 
and rank for each candidate MR protein that integrates both gene expression and mutational 
profile information. The analysis also associates each candidate MR with a specific set of recurrent 
genomic alterations in its upstream pathways, the “event network.” Finally, (D) for each cohort, 
VIPER-inferred protein activity vectors, weighted by the corresponding MOMA score vectors, 
are clustered to identify molecularly distinct tumor subtypes. This is followed by genomic 
saturation analysis on a per-subtype/per-sample basis to refine the MR repertoire comprising 
each subtype’s Tumor Checkpoint. (E) Finally, cluster analysis of recurrent Tumor Checkpoint 
MRs is performed to reveal highly recurrent sub-modular MR structures (MR-Blocks/MRBs), 
each one regulating a unique set of Cancer Hallmarks. 
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Figure S2.2 Functional validation of MOMA subtypes and survival segregation. 
(A) Kaplan-Meyer survival plots for the best and worst-outcome subtype, for each of the 20 
TCGA cohorts. Survival time in days and survival probability are shown on the x- and y-axes, 
respectively. P-values for the COX proportional hazard model test between subtypes are reported 
in each plot, with non-significant ones (i.e., COAD) shown in red. Subtype Ids are shown in the 
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subtypes—Luminal A, Luminal B, Basal, and HER2+. As shown, S1 and S3 are highly enriched in 
Luminal A samples, S2 in Luminal B samples, and S4 in Basal samples. (C) VIPER-inferred protein 
activity heatmap for STAT3, CEBPd and CEBPb in subtype S2 (mesenchymal) vs. S3 (proneural) 
of the GBM cohort. Consistent with previous publications, showing their role as synergistic MRs 
of the mesenchymal subtype of GBM64, these proteins are aberrantly co-activated in S2 but not in 
S3. (D – E) An 8-cluster solution in BRCA splits the triple negative tumors into two smaller 





Figure S2.3 Checkpoint proteins are highly recurrent and downstream of driver genomic 
events  
(A) The statistical significance of MR recurrence in ≥ k subtypes was assessed using a null 
hypothesis based on 100 random selections of an identical number of proteins, for each Tumor 
Checkpoint, from all possible regulatory proteins (N = 2,506) (black curve). From this analysis k ≥ 
4 (vertical dotted line) emerged as an appropriate threshold for statistical significance (p < 0.05). 
The actual distribution of MOMA-inferred MR recurrence in k Tumor Checkpoints is shown as a 
red curve. The difference between the real and null-hypothesis distributions is highly statistically 
significantly (p < 2.2×10-16, by non-parametric Kolmogorov–Smirnov test), indicating that 
MOMA-inferred MRs are highly recurrent across multiple tumor subtypes. (B) Statistical 
significance of genomic driver gene enrichment upstream of predicted Tumor Checkpoint MRs, 
in each tumor cohort—including single nucleotide somatic variants detected by CHASM and 
focal copy number variants detected by GISTIC 2.0. -Log10 p-values are shown as bar plots, with 
a horizontal dashed line representing the statistical significance threshold (p = 0.05). (C) Violin 
plots represent the enrichment ratio probability densities for CHASM/GISTIC2.0 events vs. all 
mutational events, upstream of predicted Tumor Checkpoint MRs, for each tissue type, on a 
sample by sample basis. This suggests mutations identified upstream of Tumor Checkpoint MRs 
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Figure S2.4 Recurrent MRs are predicted to be hyperconnected and modular.  
Probability density plots of the mean shortest path distance between all predicted MR pairs, in 
each Tumor Checkpoint (blue), compared with pairwise distances between random regulatory 
protein pairs, in (A) the HumanNet network (B) the Multinet network, and (C) the PrePPI protein-
protein interaction network. 
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Figure S2.5 MR-Block (MRB) cluster analysis, Cancer Hallmark enrichment analysis, and 
Achilles’ essentiality analysis  
(A) The analytical clustering score for the 407 recurrent MR proteins, across all tissue types, for 
k = 2 to 100 clusters, was used to identify k = 24 as the optimal MRB number (green line). (B) 
Relative score representing the enrichment specificity of the 24 MRBs in tumor hallmarks proteins 
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(y-axis) as an additional k MRs are added to each MRB by the fuzzy-clustering analysis (x-axis). 
The blue curve represents the Eigen-trace of the covariance matrix of all hallmark enrichments 
for all MRBs (MRB specificity), while the dashed black line represents the delta enrichment (i.e., 
increase or decrease) with respect to the k - 1 solution. We selected k = 6 (dotted red line) as the 
optimal fuzzy-clustering expansion index as it represents the smallest absolute maximum with 
one of the highest specificity increase. (C) Violin plots of the Jaccard concordance index (MR 
overlap) for each of the 24 MRBs with the most similar MRB identified by every other clustering 
solution (k = 2 to 100, excluding k = 24). MRBs are sorted left to right, from the most conserved 
across all clustering solutions (MRB:2) to the one most unique to the k = 24 optimal solution 
(MRB:16). The latter is still consistent with MRBs in >25% of the clustering solutions, confirming 
the analysis robustness. (D) Enrichment of MRB MR target genes in KEGG and Reactome gene 
sets (FDR < 0.05). Given the much larger set of gene sets in these databases, only the top 3 most 
significant for each MRB are shown. More than 3 may be shown when statistical ties are 
determined for 1st, 2nd or 3rd place.  (E) Conceptual representation of the cross-comparison 
between MOMA-inferred MRs and Achilles-based essential genes. For each MOMA subtype the 
cell lines that best recapitulate its MR activity signature are identified comparison of VIPER 
inferred protein activity profiles (p < 0.01, Bonferroni corrected, see STAR Methods). This is based 
on the enrichment of subtype checkpoint MRs in proteins that are differentially active in each cell 
line. The Achilles’s K.O. score of matching cell lines is then averaged to assess overall MR 
essentiality. Finally, MRB Enrichment in essential MRs is computed by Fisher’s Exact Test. (F) 
MR protein overlap with Achilles’s significantly essential genes (Bonferroni corrected p ≤ 10-5) 
across all MOMA-inferred checkpoint MRs (n = 141, blue vertical line), compared with the 
probability density generated by 106 random selections of the same number regulatory proteins 
for each subtype and fitted to a normal distribution to asses statistical significance (black curve) 
(p < 7.1×10-6). This is highly conservative as many checkpoint MRs control phenotypes such as 





Figure S2.6 Survival stratification by MRB activity  
(A) The statistical significance of single-variable Cox regression models for patient survival in 
each TCGA cohort (rows) is shown for each MRB (columns). Each colored bar represents the -
Log10(p) significance of the MRB-based predictor. Bars are truncated at -Log10(p) = 5 to improve 
visualization; non-statistically significant values are omitted. Dashed lines represent the 
statistical significance threshold (p = 0.05). (B) Survival plots of all 20 TCGA cohorts using a 
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of an MRB is computed as the average activity of its MRs. The statistical significance of each cox 
regression model (coefficient), which can include multiple MRBs, is below each plot, with the 
non-significant cohorts colored in red. Censored marks are shown along each curve. (C) Analysis 
of the 7 MRBs contributing to survival stratification of TCGA BRCA samples in the METABRIC 
breast cancer dataset (Figure 2.5C). Differential survival is shown for METABRIC samples with 
positive (red) vs. negative (blue) activity of MRB MRs. MRs lacking an ARACNe regulon in the 
METABRIC analysis were omitted. Survival stratification was most significant for MRB:2, 3, 7, 
16, and 21 (p2 = 1.9×10-8, p3 = 2.0×10-8, p7 = 3.5×10-8, p16 = 3.1×10-8, p21 = 9.1×10-7, MRB:11 not shown 





Figure S2.7 MRB:2 and MRB:14 Validation  
(A) Results of wound healing assays following shRNA mediated silencing of genes harboring the 
top 5 mutations upstream of MRB:2, for each of two distinct hairpins per gene, see Figure 2.7C,D 
for integrated results. (B) Results of Boyden Chamber assays following shRNA-mediated 
silencing of genes harboring the top 5 mutations upstream of MRB:2, for each of two distinct 
hairpins per gene, see Figure 2.7E for integrated results. (C) Western blot assays of LNCaP, DU145 
and PC-3 prostate cancer cells confirmed that MRB:14 activity tracks with AR signals. Key MR 
proteins—SPDEF, GRHL2, CDH1 and γ-catenin—were expressed in LNCaP cells (AR sensitive) 
and suppressed in AR-independent cells (PC3 and DU145). (D) This was further confirmed by 
Differential Gene Expression (DGE) analysis of MRB:14 MRs in LNCaP cells grown in the 
presence of androgen (DHT) and treated with or without enzalutamide (GEO accession 
GSE130534). Top panel shows differential expression heatmap of select canonical AR gene targets 
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(Benjamini-Hochberg FDR ≤ 0.05; fold-change FC ≥ 1.5). Lower panel shows genes encoding for 
MRB:14 proteins that passed cutoff (FDR ≤ 0.1; FC ≥ 1.2). (E) Segregation of normal prostate 
luminal and basal compartments based on MRB:14 protein activity as inferred by VIPER. The 
heatmap shows hierarchical clustering of VIPER-inferred activity of MRB:14 MRs, across 
prostate-derived purified luminal and basal epithelial cells, in triplicate, based on RNA-Seq 
profile analysis (GEO dataset accession GSE067070).  Inconsistent differential expression vs. 
activity behavior for AGRN, MAPK15, and TCEA3 is consistent with the reported 20% – 30% rate 
of MR-activity inversion by VIPER where absolute level of activity is correctly computed but the 
sign (i.e., positive vs. negative MR) is inverted due to autoregulatory loops (F) MRB:14 activity 
tracks with luminal vs. basal classification—based on PAM-50 gene signature analysis—in breast 
(BRCA) and bladder (BLCA) TCGA cohorts.  (G) MRB:14 MR activity is inverted in patients 
undergoing androgen deprivation therapy (ADT), as shown by VIPER-based analysis of RNA-
Seq data from 7 TRUSS patient-matched biopsy pairs, pre- and post-ADT (GEO accession 
GSE48403). Hierarchical clustering using MRB:14 proteins activity provides complete segregation 
of the two phenotypes. 
